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General Introduction and 
Aims of the thesis 
Chapter 1 
General introduction 
The neural crest is a transient and multipotent embryonic structure in vertebrates 
that gives rise to most of the peripheral nervous system and to several non-neural cell 
types, including smooth muscle cells of the cardiovascular system, pigment cells in the 
skin, craniofacial bones, cartilage and endocrine, paraendocrine, and connective 
tissues (Le Douarin, 1999). Although neural crest cells undergo developmental 
restrictions with time, at least some of these cells have the capacity to self-renew and 
display a developmental potential nearly only topped by embryonic stem cells. 
Intriguingly, such neural crest-derived stem cells {NCSCs) are not only present in the 
embryonic neural crest, but also in various neural crest-derived tissues in the foetal 
and even adult organism (Shakhova and Sommer, 2010). 
Several neural crest-related disorders have been reported. Due to their 
nature, they are called neurocristopathies and they can be caused by genetic 
abnormalities in specific genes. 
Hirschsprung disease (HSCR) and Multiple endocrine neoplasia type 2 (MEN2) 
are two of these neurocristopathies. HSCR is a developmental disorder characterized 
by the absence of enteric ganglia in the intestinal tract (Parisi and Kapur, 2000), 
whereas MEN2 is a dominantly inherited cancer syndrome affecting neuroendocrine 
organs (Hansford and Mulligan, 2000). HSCR and MEN2 have distinct properties and in 
each case different tissues are affected, however they can both be caused by genetic 
abnormalities in a specific proto-oncogene: the REarranged during Transfection (RETI 
gene. 
In this thesis, we focus on HSCR and MEN2 and we combine genetic and 
functional approaches in an attempt to understand the protein networks involved in 
the development of these disorders. 
RET gene and encoded protein 
RET was first described in 1985 during transfection of NIH-3T3 cells with human 
lymphoma DNA {Takahashi et al., 1985). In the transformed cells, two unlinked human 
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DNA segments were recombined resulting in a chimaeric gene. As this chimaeric gene 
was not present in the transfected DNA, the recombination step must have taken 
place during the transfection experiment and it was therefore called REarranged 
during Transfection (RET) (Takahashi et al., 1985). 
RET is located on the long arm of chromosome 10 (10q11.2), has a length of 
55 Kb and contains 21 exons (Pasini et al., 1995). It encodes a receptor tyrosine 
kinase, which is expressed in neural 
crest-derived cell lineages and is 
essential for the early development 
of the kidney, spermatogenesis, and 
the sympathetic, parasympathetic 
and enteric nervous systems 
(Pachnis et al., 1993; Schuchardt et 
al., 1994). 
By alternative splicing, 
three different RET isoforms are 
formed and they can be 
distinguished from each other by 
the length of their C-terminus: 9 
(RET9), 43 (RET43) and 51 (RET51) 
amino acids (Fig. 1). This results in 
Cadherin Domain 








Figure 1 - Schematic representation of the RET receptor. 
RET proteins of 1072, 1106 and 1114 amino acids in length, respectively. Several 
observations suggested that different isoforms have distinct tissue-specific effects 
during embryogenesis, with RET 51 and RET 9 being the most prevalent isoforms in 
vivo (Myers et al., 1995; de Graaff et al., 2001). 
Like other receptor tyrosine kinases, RET contains an extracellular region, a 
transmembrane region and an intracellular tyrosine kinase region (Fig. 1). The 
extracellular region is composed of a cadherin-like domain that induces and stabilizes 
conformational changes needed for interaction with ligands and co-receptors 
13 
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(Schneider, 1992), and by a cysteine-rich domain located in proximity to the plasma 
membrane. This domain plays a critical role in the establishment of intramolecular 
disulphide bonds which are important for the tertiary structure of RET (Hansford and 
Mulligan, 2000). Moreover, the extracellular region also contains several glycosylation 
sites necessary for membrane anchoring (Takahashi et al., 1991). Based on the 
glycosylation state, RET localization alternates between the cell membrane, cytoplasm 
and endoplasmatic reticulum. When RET is totally glycosylated, it is in its mature form 
and is present in the cell membrane. When RET is not glycosylated and therefore in its 
immature form, it is present only in the endoplasmatic reticulum and the cytoplasm 
(Takahashi et al., 1993). The intracellular region contains two tyrosine kinase 
subdomains that are involved in numerous intracellular signal transduction pathways 
initiated by phosphorylation on one of the tyrosine residues (Fig. 1). 
RET activation and downstream signalling pathways 
RET plays a central role in several intracellular signalling cascades that regulate cell 
survival, differentiation, proliferation, migration, and chemotaxis (de Groot et al., 
2006). These cascades are initiated upon RET activation, a process that is unique 
among receptor tyrosine kinases as it requires a multi-protein complex instead of 
common direct receptor/ligand activation (Plaza-Menacho et al., 2006). The RET 
activation complex includes a soluble ligand of the Glial cell-line-derived neurotrophic 
factor (GDNF) family, a glycosyl-phosphatidylinositol membrane anchored co-receptor 
of the GDNF family receptor (GFRa 1-4), and RET itself {Manie at al., 2001). The 
activation process starts when GDNF or one of its homologues, neurturin, artemin or 
persephin, binds to GFRa (Jing et al., 1996; Airaksinen et al., 1999). After the ligand 
and co-receptor have bound to each other, this complex binds to RET, which by then 
has been recruited to the lipid rafts. By association of two RET molecules to the 
ligand-co-receptor complex, RET becomes activated (Manie et al., 2001; de Groot et 
al., 2006; Plaza-Menacho et al., 2006). 
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Once activated, specific tyrosine residues of the RET tyrosine kinase domain 
become phosphorylated and initiate specific downstream signalling pathways. The 
phosphorylated residues act as docking sites for adaptor proteins that link receptor 
activation to the main signal transduction pathways. Several phosphorylation sites 
have been identified in RET and these include: tyrosine 687 (Y687), serine 696 (S696), 
Y752, Y791, Y806, Y809, Y826, Y864, Y900, Y905, Y928, Y952, Y981, Y1015, Y1029, 
Y1062, Y1090 and Y196. The last two sites are only present in the long RET isoform, 
RET51 (Manie et al., 2001; Liu et al., 1996; Santoro et al., 2004; lchihara et al., 2004). 
Phosphorylation of S696 is necessary for activating the RAC1-guanine 
nucleotide exchange factor (GEF) and for lamellipodia formation. Interestingly, 
activation of Y687 induces the opposite effect on lamellipodia formation. These 
cytoskeletal rearrangements are regulated via cyclic AMP/protein kinase A (PKA)­
dependent signalling (Fukuda et al., 2002). 
RET Y752 and Y928 activate a latent transcription factor involved in several 
types of cancer when aberrantly activated, called signal transducer and activator of 
transcription 3 {STAT3) {Schuringa et al., 2001; Fukuda et al., 2002). 
Phosphorylation of Y905 stabilizes the active conformation of the kinase and 
thus facilitates auto-phosphorylation of tyrosine residues located on the C-terminus 
(Iwashita et al., 1996). Furthermore, it interacts with the growth factor receptor­
bound (GRB) docking proteins 7 /10. Tyrosines Y806, Y809 and Y900 were described as 
complementing the function of Y905 and thus also interact with GRB7 /10 {Kawamoto 
et al., 2004). 
Phosphotyrosine residue Y981 was described as the major binding site for the 
chicken Rous sarcoma virus oncogene (Src), and is therefore the responsible residue 
for Src activation. Src is known to play a role in neuronal survival, but has also been 
described as part of the oncogenic RET signalling by mediating signalling between RET 
and focal adhesion kinase (FAK). FAK is an important regulator of tumour formation 
and cell migration and it was reported to be necessary for the invasion and metastatic 
behaviour of cancer cells (Encinas et al., 2004; Panta et al., 2004; Mclean et al., 2005). 
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Y1015 is the binding site for phospholipase C-y (PLC-y), which triggers protein 
kinase C (PKC) activation. PKC is know to exert a double effect on RET: it can stimulate 
RET phosphorylation, but it can also downregulate RET and its downstream signalling 
pathways exerting a negative feedback loop that controls RET activity (Borrello et al., 
1996). Furthermore, PLC-y is involved in the release of Ca2+ via generation of inositol­
triphosphate (IP3) (Andreozzi et al., 2003). Ca2+ ions are known to play a decisive role 
in RET transport to the cell membrane and in facilitating binding of RET ligands for 
receptor activation, however the exact role of Ca2+ influx triggered by RET is not yet 
clear (van Weering et al., 1998; Nozaki et al., 1998). 
Y1062 is known to be the docking site of several adaptor proteins namely, Src 
homolog collagen (She), Src homology 2 domain-containing transforming protein C 
(ShcC), insulin receptor substrate (IRS) 1/2, fibroblast growth factor receptor 
substrate 2 (FRS2), downstream of kinase (DOK) 1/4/5, enigma extracellular signal 
regulated kinase 5 (ERKS), mitogen activated protein kinase (MAPK), 
phosphoinositide-dependent kinase 1 (PDK1), cyclin-dependent kinase 5 (CDKS), SH3 
(a protein-protein interaction domain), multiple ankyrin repeat domains 3 (Shank3) 
and PKC isoforms. In general, the signalling pathways activated by phosphorylation of 
Y1062 include: the phosphatidylinositol 3-kinase/protein kinase B (Pl3/Akt) pathway 
initiated via recruitment of She, ShcC, IRSl/2 or Shank3; the MAPK and the rat 
sarcoma oncogene (RAS)/ERK pathways triggered by binding of Shank3, DOK 4/5 and 
She or FRS2 to the Grb2/ son of sevenless multi-protein scaffold (SOS) complex; and 
the c-Jun N-terminal kinase (JNK) pathway initiated by binding of DOK1 (Segouffin­
Cariou and Billaud, 2000; Pelicci et al., 2002; Mellilo et al., 2001; Schuetz et al., 2004; 
Kurokawa et al., 2001; Mellilo et al., 2001; Grimm et al., 2001; Xia and Karin, 2004; 
Kennedy and Davis, 2003). The Pl3K/Akt pathway is involved in cell survival, enhanced 
cell-cycle progression and RET-mediated transformation (Segouffin-Cariou and 
Billaud, 2000; Murakami et al., 1999). The RAS/ERK and MAPK pathways are 
responsible for cellular differentiation and proliferation (Watanabe et al., 2002), and 
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the JNK pathway plays a role in cell proliferation, cell survival, cell death, DNA repair 
and metabolism (Xia and Karin, 2004; Kennedy and Davis, 2003). 
Y1096, only present in the RETSl isoform, serves as a docking site for GRB2 
which activates the RAS/ERk and Pl3K pathways (Lorenzo et al., 1997). 
Finally, the activated downstream signalling pathways initiated by 
phosphorylation of the residues Y791, Y826, Y864, Y952, Y1029 and Y1091 still need 
to be delineated (Kawamoto et al., 2004; Liu et a/.,1996). An overview of all the 
proteins involved in activation of the different signalling pathways initiated via RET 
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Figure 2 - Overview of signalling pathways triggered by phosphorylation of specific RET tyrosin kinase residues 
(Adapted from de Groot et al., 2006). 
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RET associated syndromes 
Several disease-causing germline mutations have been found in RET. Roughly these 
mutations can be classified into two types: inactivating and activating 
mutations/rearrangements. Inactivating mutations, result in a loss of RET function and 
have been found to be associated with a developmental disorder called Hirschsprung 
disease (Parisi and Kapur, 2000). The activating mutations/rearrangements on the 
other hand, lead to a constitutively active RET receptor and, as a consequence, are 
involved in the development of the cancer syndrome Multiple Endocrine Neoplasia 
type 2 and Papillary Thyroid Cancer (Hansford and Mullingan, 2000; Takahashi et al., 
1985). These disorders will be discussed in more detail in the next section. 
Hirschsprung disease (HSCR) 
HSCR is an abnormality of the enteric nervous system characterized by the absence of 
enteric neurons along a variable length of the gut. It is a developmental disorder that 
is caused by a failure in the migration of neural crest stem cells (NCSCs) into the 
intestinal tract or due to a failure in the survival, proliferation, or correct development 
of NCSCs once they reach the gut (Heanue and Pachnis 2007). In either case, an 
aganglionic segment occurs in which peristalsis is absent (Fig. 3). 
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Figure 3 - Hirschsprung disease (Adapted from 2003 Nucleus Communications). 
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Based on the length of the aganglionic segment, three forms of HSCR can be 
distinguished. In 80% of the cases the aganglionic segment does not extend beyond 
the upper sigmoid and this is called short-segment HSCR (SS-HSCR). In 15% of the 
cases aganglionosis extends proximal to the sigmoid and is called long-segment HSCR 
(LS-HSCR). When the absence of NCSCs affects the whole bowel, total intestinal 
aganglionosis (TIA) is observed. This is a rare form of HSCR accounting for only 5% of 
the cases (Passarge, 1967; Holschneider, 1982; Garver et al., 1985; Chakravarti and 
Lyonett, 2001) (Fig. 4). 
Normal 
Short segment HSCR 
Long segment HSCR 
Total intestinal aganglionosis 
.- -- ) 
-:.:..:.- 7 / r r  
Figure 4 - Representation of the three types of HSCR classified based on the length of aganglionic segment 
(Adapted from Heanue and Pachnis, 2007). 
HSCR is a relatively common disorder with an occurrence of approximately 1:5000 live 
births and is thereby the main cause of intestinal obstruction (Passarge, 1967; 
Goldberg, 1984; Spouge and Baird, 1985; Garver et al., 1985; Russell et al., 1994; 
Ikeda and Goto, 1984). However, there is significant racial variation in the incidence of 
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this disease. Among all ethnic groups, HSCR is most often found in Asians (2.8 per 
10,000 life births), whereas Hispanics show the lowest incidence of this disease (1.0 in 
10,000 life births) (Torfs, 1998). HSCR also shows a low, sex-dependent penetrance 
and is seen more frequently in males than in females (4:1) (Badner et al., 1990). 
Interestingly, the male:female ratio is significantly higher for S-HSCR (4.2-4.4) than for 
L-HSCR (1.2-1.9) (Torf, 1998; Badner et al., 1990; Amiel and Lyonnet, 2001). 
HSCR can be a Mendelian (heterogeneous) disease but, in most cases, it is a 
complex non-Mendelian disorder. For both situations several genes have been 
identified but RET is the most important one. Several RET mutations have been 
identified in HSCR patients including large deletions, micro-deletions and insertions, 
nonsense, missense and splicing mutations (Edery et al., 1994; Romeo et al. 1994). 
These findings, together with mice studies showing that inhibition of RET expression 
resulted in a HSCR phenotype, confirmed RET as a major gene involved in HSCR 
(Schuchardt et al., 1995; Uesaka et al., 2008). However, mutations in the coding 
region (CDS) of this gene are only identified in 50% of familial and 15% of sporadic 
HSCR cases (Angrist et al., 1995; Attie et al., 1995, Hofstra et al., 2000). Nevertheless, 
linkage studies performed in sib-pairs and multi-generational HSCR families showed 
that in the majority of patients, association to the RET locus was found, even when 
CDS mutations in RET had not been identified (Attie et al., 1995; Bolk et al., 2000, 
Gabriel et al., 2002). Based on this result, it is clear that non-coding RfTvariants could 
also play a major role in HSCR development. 
Several studies performed by different groups identified the presence of a 
common disease associated haplotype in the 5' region of the RET locus in patients of 
European, American and Asian descent, confirming the idea that non-coding RET 
variants do play an important role in disease development (Borrego et al., 2003, Fitze 
et al., 2003, Sancandi et al., 2003; Burzynski et al., 2004; Pelet et al., 2005). This 
haplotype spans approximately 27 Kb and includes 4Kb of the 5' UTR, exon 1, intron 1 
and exon 2, which pointed to the presence of possible mutations in either the 
promoter region or intron 1. In total, four presumed pathogenic single nucleotide 
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polymorphisms (SNPs) were identified in this region. Two of these SNPs (rs10900296 
and rs10900297) were located in the promoter region just upstream of the RET 
transcription starting site (Fitze et al., 2003), and were shown to reduce the binding 
affinity of the transcription factor TTF-1 (Thyroid Transcription Factor 1) (Garcia­
Barcelo et al., 2005). They were also shown to reduce promoter activity in luciferase 
reporter assays, but this effect was found to be cell-line-dependent (Griseri et al., 
2005). The two other SNPs are located in intron 1. They have been considered as 
disease-causing variants based on association studies, comparative genomics and 
functional assays: rs2435357 and rs2506004 (Burzynski et al., 2005; Emison et al., 
2005; Emison et al., 2010; Sribudiani et al., unpublished data). Both these SNPs are in 
close proximity to each other and are located in highly conserved regions among 
different mammalian species. Mutant alleles of these SNPs showed the highest values 
for association in HSCR patients and the region containing both SNPs showed reduced 
promoter activity in luciferase assays (Emison et al. , 2005). Additional studies 
performed by Grice et al., and Fisher et al., in mice and zebrafish respectively, 
confirmed the relevance of this region in regulating RET expression (Grice et al., 2005; 
Fisher et al., 2006). Several transcription factors were predicted to bind to these two 
regulatory regions, however no functional data was available to support these 
predictions. Recently, however, two independent studies were able to identify the 
binding of two transcription factors to these regulatory regions. SOXlO binding was 
reported to be disturbed by SNP rs2435357 (Emison et al., 2010), and the 
heterodimer NXF2/ARNT was shown to bind to the regulatory region where SNP 
rs2506004 is located (Sribudiani et al., unpublished data). Furthermore, both these 
SNPs were shown to reduce RET activation, confirming the importance of these two 
regulatory regions in HSCR development. Taken together, these data show that, in 
almost all HSCR cases, RET plays a minor or major role in disease development. 
Besides RET, ten other genes have been implicated in the development of 
HSCR: GDNF, NTN, EDNRB, EDN3, SOXlO, ECE-1, ZFHX1B, PHOX2B, KIAA1279/KBP and 
NRGl (Angrist et al., 1996; Salomon et al., 1996; Doray et al., 1998; Puffenberger et 
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al., 1994; Hofstra et al. ,  1996; Edery et al., 1996; Pingault et al., 1998; Hosftra et al., 
1999; Cacheux et al., 2001; Amie! et al., 2003; Brooks et al., 2005; Garcia-Barcelo et 
al., 2009). 
GDNF and NTN encode for the RET ligands, GDNF and Neurturin (NTN), which 
are necessary for receptor phosphorylation and activation of downstream signalling 
pathways. EDNR, EDN3 and ECE-1, encode for the endothelin receptor type B, 
endothelin 3 and endothelin-converting enzyme 1, respectively, and they are part of 
the endothelin signalling pathway. SOX10, ZFHXlB and PHOX28 encode for 
transcription factors involved in RET and/or EDNRB activation. KIAA1279/KBP encodes 
for the kinesin-binding protein which has recently been involved in neuronal 
differentiation (Alves et al., 2010). Finally, NRGl, recently identified (Garcia-Barcelo et 
al. , 2009), encodes for a receptor protein that belongs to the Erb B family of tyrosine 
kinase. 
Despite the fact that all these genes have been identified as playing a role in 
HSCR disease, they only account for 20% of all the cases, with most of them being 
associated to syndromic forms of HSCR (Amiel et al., 2008). This suggests that other, 
unidentified genes or loci are likely to be involved in the development of this disease. 
Syndromic HSCR 
In 70% of the cases HSCR occurs as an isolated trait, while 30% of the cases are 
associated with other congenital malformations (Amiel and Lyonnet, 2001). 
Chromosomal abnormalities are found in 12% of cases, trisomy 21 being the most 
frequent (90%), while congenital anomalies are found in 18% of HSCR patients (Amiel 
et al. ,  2008). Among the eleven genes described as playing a role in HSCR, seven have 
been directly associated to the development of congenital malformations: EDNRB, 
EDN3, ECE-1, SOX10, PHOX28, ZFXHl and KIAA1279/KBP. 
Mutations in EDNRB and EDN3 are involved in an autosomal recessive form of 
Waardenburg-Shah syndrome (WSS). WSS is characterized by sensorial deafness, 
pigmentary abnormalities of the skin, eyes and hair, and by HSCR disease (Omenn and 
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McKusick, 1979; Shah et al., 1981). A dominant form of WSS has also been identified 
in some cases where additional neurological features are present. However, in this 
dominant form, mutations in SOXlO are responsible for the phenotype (Pingault et al., 
1998). 
An ECEl mutation was identified in a single patient with HSCR, craniofacial 
and cardiac defects (Hofstra et al., 1999). 
Congenital Central Hypoventilation syndrome (CCHS), also called Ondine's 
curse, is a life-threatening disorder characterized by failure of the autonomic control 
of breathing, especially during sleep (Weese-Mayer et al. ,  2005). HSCR is variable 
feature and is present in approximately 20% of CCHS cases. The association of HSCR 
with CCHS is called Haddad syndrome (Trochet et al., 2005; Haddad et al., 1978; 
Verloes et al., 1993). PHOXZB was identified as the disease-causing gene with de novo 
heterozygous mutations, and a mutation in this gene has been identified in more than 
300 CCHS patients (Amiel et al., 2003; Weese-Mayer et al., 2003; Matera et al., 2004; 
Trang et al., 2005). 
Mutations in ZFXHl are involved in Mowat-Wilson syndrome (MWS), a 
multiple congenital anomaly characterized by microcephaly, epilepsy, a facial gestalt 
and severe mental retardation (Mowat et al., 1998). HSCR is a variable feature and is 
present in 40-70% of the cases (Zweier et al., 2005). Heterozygous de novo deletions 
encompassing ZFHXl or truncating mutations within this gene have been found in 
over 100 cases (Wakamatsu et al., 2001; Cacheux et al., 2001; Amiel et al., 2001). 
Additionally, rare splicing and missense mutations have also been reported (de 
Pontual et al., 2007). 
Goldberg-Sprintzen syndrome (GOSHS) is an autosomal recessive disorder 
characterized by polymicrogyria, microcephaly, facial dysmorphic features, mental 
retardation and HSCR (Goldberg and Shprintzen, 1981). Homozygous nonsense 
mutations in KIAA1Z79/KBP were identified as being the disease-causing factor 
(Brooks et al., 2005). 
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Multiple Endocrine Neoplasia type 2 (MEN2) 
MEN2 is a dominantly inherited cancer syndrome that accounts for approximately 
25% of all the medullary thyroid carcinoma (MTC) cases. MEN2 can be divided into 
three subtypes: MEN2A, MEN2B and Familial Medullary Thyroid Carcinoma (FMTC), 
based on the clinical description and tissues affected (Hansford and Mulligan, 2000). 
All subtypes are characterized by the presence of medullary thyroid carcinoma (MTC), 
a tumour of the parafollicular C-Cells, which are responsible for the secretion of 
calcitonin by the thyroid gland (Sipple, 1961). However, each MEN2 subtype also has 
its own characteristic features. In MEN2A, pheochromocytoma (PC) is observed in 
50% of the cases and hyper-parathyroidism (HPT) in 15-30% of the cases (Sipple, 
1961). MEN2B patients also develop PC (in approximately 50% of the cases), but 
instead of HPT, these patients develop a more complex clinical phenotype that 
includes ganglioneuromas on the tongue, lips and eyelids, intestinal ganglioneuromas, 
thickened corneal nerves as well as a marfanoid habitus. It is the most aggressive 
form of MEN2 with the earliest age of onset (Carney et al., 1976; de Groot et al., 
2006). FMTC is characterized by the development of MTC as the only clinical 
manifestation and normally several family members are affected. In general, patients 
with FMTC tend to develop detectable tumours at a later age than patients with 
MEN2A and MEN2B and they also tend to have a more favourable prognosis (Yip et 
al., 2003). Activating mutations can occur in specific domains of the RET protein and, 
depending on their location, they are associated with either MEN2A, MEN2B or FMTC 
(Fig. 5). 
RET mutations associated to MEN2 result in a ligand-independent activation 
of the encoded RET protein, which leads to a constitutive phosphorylated receptor 
and consequently to uncontrolled activation of downstream signalling pathways. 
Mutations located in the cysteine-rich domain of the extracellular region of RET 
(codons 609, 611, 618, 620, 630 and 634), are generally involved in the development 
of MEN2A. These mutations result in the replacement of a critical cysteine residue by 
another amino acid leading to the loss of an intramolecular disulphide bond. As a 
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consequence, a "free" cysteine residue becomes available for the formation of an 
intermolecular disulphide bond (with another mutated RET monomer), resulting in a 
constitutively activated receptor (Plaza-Menacho et al., 2006). 
Mutations located in the intracellular tysosine kinase domain are associated 
with the development of either MEN2B (codons 883 and 918) or of FMTC (codons 
768, 790, 791, 804 and 891). The way these mutations affect RET activation is 
completely different from MEN2A mutations as they signal independently of GDNF as 
monomeric oncoproteins. However, it has been shown that GDNF can further 
enhance MEN2B activity (Plaza-Menacho et al., 2005; Plaza-Menacho et al., 2006). 
Independent of the type and location of the mutation, the end result is 
always the same: continuous RET phosphorylation that leads to a constant activation 
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Papillary Thyroid Carcinoma {PTC) 
PTC is the most common cause of thyroid cancer, representing approximately 80% of 
all thyroid cancer cases. PTC occurs in the follicular epithelial cells of the thyroid and 
exposure to radiation is a major risk factor for its development (Sherman, 2000). 
Several genetic alterations have been reported to be associated with PTC, including 
oncogenic activation of RAS (Fagin, 2002), v-RAF murine sarcoma viral oncogene 
homolog B1 (BRAF) (Xing, 2005), hepatocyte growth factor receptor (MEn (Wasenius 
et al., 2005), and chromosomal alterations that affect NTRK1 and RET (Pierotti et al., 
1998). Specific rearranged forms of RET, among which is the same rearrangement 
originally found by Takahashi et al. (Takhashi et al., 1985), were detected in PTC and 
account for a small percentage (S-30%) of cases, with the majority being caused by 
exposure to external radiation. In these rearrangements, the intracellular kinase 
domain of RET is recombined with the N-terminus of a gene normally expressed in the 
follicular epithelial cells that is capable of ligand-independent dimerization. The 
RET/PTC proteins do not have a transmembrane domain, and thus are not integral 
membrane proteins, but RET is constitutively active. Several genes have been 
described as being rearranged with RET forming different hybrid oncogenes. The most 
prevalent variants are RET/PTC1 and RET/PTC3, which result from the rearrangement 
of RET with H4 and Elel, respectively (Nikiforov, 2002). 
Signalling pathways involved in HSCR and MEN2 
HSCR associated signalling pathways 
Several genes have been implicated in HSCR development. Although a first look at the 
proteins encoded by these genes shows no apparent connection between them, the 
majority of these genes can be divided into three groups: those involved in RET 
activation pathways (RET, GDNF, NTN), those involved in EDNRB pathways (EDNRB, 
EDN3, ECE-1), and transcription factors that can affect both RET and/or EDNRB 
pathways (SOX10, ZFXH1B, PHOX2B). 
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Effect of RET s ignalling on NCSCs 
Besides RET itself, mutations have also been identified in the coding sequences of 
GDNF (Angrist et al. ,  1996; Salomon et al., 1996) and NTN (Doray et al., 1998), both 
encoding for RET ligands necessary for receptor activation. 
One of the main purposes of the RET signalling pathway is to promote 
migration of NCSC precursors into the foregut (Pachnis et al., 1998; Young et al., 
2001). For that, GDNF works as a chemoattractant promoting migration of RET­
positive NCSCs into the foregut. In the earliest stages of gut colonization (E9.0), high 
levels of GDNF are observed in the stomach ahead of the migrating front of NCSCs. 
Through time, GDNF expression shifts from the migration front to the streams of 
migrating cells, probably exerting a proliferative and survival effect rather than a 
migratory effect (Natarajan et al., 2002). Gdnr1- mice showed an approximately 50% 
reduction in the number of NCSCs, which was probably due to reduced NCSC 
proliferation and delayed NCSC migration (Gianino et al., 2003; Shen et al., 2002; 
Flynn et al., 2007). Furthermore, equivalent aganglionosis phenotypes were observed 
in mice and zebrafish in the absence of Ret, Gdnf or Gfral, supporting the importance 
of this pathway for gut colonization (Schuchardt et al., 1994; Shepherd et al., 2004; 
Sanchez et al., 1996; Pichel et al., 1996; Moore et al., 1996; Cacalano et al., 1998; 
Shepherd et al., 2001). 
Effect of EDNRB signalling on NCSCs 
Mutations in EDNRB, EDN3 and ECE-1 have been identified and these genes encode 
for components of the EDNRB pathway. EDNRB is a G-protein coupled receptor that is 
activated by endothelins such as EDN3. However, for this activation to take place, 
EDN3 needs to be first cleaved in an active peptide and this is done by the endothelin 
converting enzyme 1 (ECE-1). Ednrb is expressed primarily in migrating NCSCs, 
whereas Edn3 is expressed in the midgut and hindgut during early phases of NCSCs 
migration, and at high levels in the caecum and proximal colon as NCSCs colonize the 
terminal gut regions (Barlow et al., 2003; Leibl et al., 1999). This pattern of expression 
27 
Chapter 1 
suggests that EDN3-EDNRB signalling is involved in regulating the normal migration of 
NCSC. Consistent with this model, Edn3 and Ednrb mutant mice exhibit delays in NCSC 
migration (Barlow et al., 2003; Lee et al., 2003; Ro et al., 2006). Furthermore, several 
studies have suggested an additional role for EDN3-EDNRB signalling in maintaining 
enteric progenitors in a proliferative state, because NCSC numbers are reduced in 
Edn3 mutant mice (Barlow et al., 2003; Bondurand et al., 2006), and NCSC 
differentiation is inhibited in the presence of EDN3 (Bondurand et al., 2006; Nagy and 
Goldstein, 2006; Wu et al., 1999). These data implicate EDN3-EDNRB signalling in 
several aspects of the Enteric Nervous System (ENS) development, as well as in 
coordinating normal colonization of the gut by NCSCs. 
RET and EDNRB interaction 
Interaction between the RET and EDNRB signalling pathways were described first in a 
genetic study and afterwards using an animal model. A genome-wide association 
study using 43 trios from a genetically isolated Mennonite population reported the 
joint associations between the inheritance of an EDNRB mutation and a certain RET 
allele in patients with HSCR (although no RET mutations were identified), suggesting 
epistasis between RET and EDNRB (Carrasquillo et al., 2002). This idea was supported 
using animal models: mice homozygous for the recessive hypomorphic allele of Ednrb 
(EdnrbS or Piebald, which only rarely exhibit aganglionosis) and heterozygous for a Ret 
null mutation (Ret1-) showed high frequencies of aganglionosis (Carrasquillo et al., 
2002; Mccallion et al., 2003). Similar genetic studies showed that, whereas Ref1151 
and Edn315115 (lethal spotting) mice display colonic aganglionosis, combinations of these 
mutant alleles led to almost complete intestinal aganglionosis (Barlow et al. , 2003). 
Together, these studies suggest a genetic interaction between the RET and EDNRB 
signalling pathways. Since the effects of EDN3 on both proliferation and 
chemoattraction could be mimicked by PKA inhibitors, it was suggested that PKA 
might serve as a connection link between RET and EDNRB signalling (Barlow et al. ,  
2003). Furthermore, a critical role for PKA was also suggested by the NCSC migration 
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defects and aganglionosis phenotypes observed when the putative PKA binding site of 
RET, serine 697, was mutated (Asai et al., 2006). However, it is unclear whether these 
phenotypes are related to a role of PKA in mediating RET or EDNRB signalling. 
Parallel to these findings, GDNF and EDN3 were seen to have opposite effects 
during the development of the ENS. While GDNF promoted the proliferation of 
migratory NCSCs and encouraged differentiation (Hearn et al., 1998; Barlow et al., 
2003), EDN3 was shown to modulate GDNF activity to inhibit differentiation (Hearn et 
al., 1998; Wu et al., 1999). These results led to a model in which EDN3 acts to balance 
the effect of GDNF to prevent premature differentiation of NCSCs and maintain these 
cells in a proliferative state, thus generating appropriate numbers of NCSCs to fully 
colonize the gut (Hearn et al., 1998; Wu et al., 1999). However, how the balance 
between RET and EDNRB signalling is achieved is still unknown. 
Transcription factors 
In the third group of genes implicated in HSCR development, those encoding 
transcription factors were described as mutated in HSCR patients: SOXlO, PHOX2B 
and ZFXH18. Interestingly, mutations in these genes were never found in patients 
presenting with HSCR as an isolated trait, but they are always associated with other 
congenital anomalies involved in rare recessive syndromes. 
SOXlO encodes a transcription factor that can regulate expression of both 
RET and EDNRB (Pattyn et al., 1999; Zhu et al., 2004). Indeed, regulatory binding 
regions have been found in RET and EDNRB that, once mutated, led to an impairment 
in SOXl0 binding and, as a consequence, to a decrease of RET expression (Heanue and 
Pachnis, 2007; Emison et al., 2010). 
PHOX2B is also a transcription factor that is expressed in several classes of 
differentiating neurons of both the peripheral and central nervous systems. Mice with 
a homozygous disruption of Phox2b showed no enteric ganglia and no RET expression 
which suggests that PHOX2B might play a regulatory role in RET expression {Pattyn et 
al., 1999; Brunet and Pattyn, 2002). 
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Finally, ZFXH1 encodes for a transcriptional repressor which interacts with 
several members of the SMAD family. Expression of ZFXHl was detected in early 
neuronal development in Xenopus and homozygous mutant Zfxhl mice showed a 
complete lack of NCSC precursors (Van de Putte et al., 2003). However, the exact role 
of ZFXHl in HSCR development is unknown. 
Oncogenic RET signalling 
The observation that different RET mutations result in different disease phenotypes 
might be explained by signalling through diverse downstream pathways triggered via 
differential activation of the mutated RET receptors. However, not much is known 
about these specific signalling pathways initiated by oncogenic RET receptor. There 
might be subtle differences in protein conformation when RET is activated by either 
ligand-binding or MEN2 mutations that can lead to the initiation of different signalling 
pathways. Furthermore, studies have shown that wild-type RET and mutated RET 
receptors display differences in phosphorylation of docking sites, and are thus likely to 
activate downstream pathways specific for a disease phenotype (Liu et al., 1996; 
Arighi et al., 2004; Chiariello et al., 1998). This indeed seems to be the case. 
Mutations associated to MEN2A and MEN2B have been described as having a 
marked impact on downstream Akt activation when compared to the wild-type 
receptor (Freche et al., 2005). Akt is part of the Pl3 kinase/Akt pathway which is 
responsible for cell survival, enhanced cell-cycle progression, and RET-mediated 
transformation. Interestingly, this pathway seems to be more active in MEN2B than in 
MEN2A (Segouffin-Cariou and Billaud, 2000; Murakami et al., 1999), a difference that 
might be due to enhanced phosphorylation at tyrosine 1062 (Y1062) by MEN2B 
mutations. Since Y1062 is the docking site for Shank3, an adaptor protein involved in 
activating of not only the Pl3 kinase pathway but also the Ras/MAP kinase pathway, 
this difference in phosphorylation levels probably contributes to the differences 
between the MEN2A and MEN2B phenotypes (Salvatore et al., 2001). 
Further evidence for the differences in oncogenic signalling triggered by the 
various mutation types is provided by a strong association of the JNK pathway with 
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RET/MEN2B. Just like the Pl3K/AKT and RAS/MAPK pathways, Y1062 is also the 
phosphorylation site involved in JNK signalling activation. Thus, higher 
phosphorylation levels of RET on Yl062 seen in MEN2B mutants lead to an activation 
of the JNK pathway (Murakami et al., 2002; Grimm et al., 2001). 
STATs are a family of latent transcription factors involved in activating many 
genes induced by cytokines and growth factors (Schindler et al., 1995). However, 
STATs can also contribute to cancer development when aberrantly activated 
(Schindler et al., 1995). In particular, STAT3 has been reported to play a role in many 
types of cancer, including MTC. The MEN2A mutant RET C634R has been reported to 
enhance oncogenic activation of STAT3 via a process independent of Janus tyrosine 
kinases (JAKs) and c-Src (Schuringa et al., 2000). In contrast, FMTC mutants, RET Y791F 
and S891A, need the involvement of c-Src and JAKs to constitutively activate STAT3 
(Plaza-Menacho et al., 2005). These data suggest that STAT3 activation by MEN2A­
and FMTC-associated mutations is triggered via different signalling routes. 
Not all RET mutant receptors are sensitive to GDNF stimulation and this 
characteristic may also influence oncogenic signalling. MEN2A mutations such as RET 
C634R are responsive to GDNF, while MEN2A/HSCR and FMTC/HSCR mutations, such 
as RET C620R, do not respond to the same stimulation (Arighi et al., 2004). A similar 
influence of GDNF was seen for MEN2B-associated mutations, such as RET M918T, 
since they are highly responsive to GNDF stimulations (Plaza-Menacho et al., 2005). 
These findings agree with the idea that differences in signalling pathways 
activated by different RET mutations, combined with differences in GDNF 
responsiveness of these receptors, could be the explanation for the different 
phenotypes (Jhiang, 2003). 
HSCR and MEN2 
HSCR-associated RET mutations are inactivating mutations, disabling expression and 
activation of this receptor (Pasini et al., 1995), while MEN2 mutations result in a 
constitutively activation of RET (Santoro et al., 1995). Nevertheless, HSCR can be 
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found in association with MEN2A and FMTC in patients with a mutation in codons 
609, 611, 618 and 620 (Takahashi et al., 1999; Sijmons et al., 1998). These mutations 
seem to have a dual effect on RET: they can constitutively activate RET by the 
formation of covalent dimers, but they can also result in a drastic reduction of RET 
expression at the plasma membrane. As a consequence, uncontrolled proliferation of 
the C-cells of the thyroid occurs in MEN2, and apoptosis of enteric neurons is 
detected in HSCR. This double effect is likely to be due to differences in sensitivity to 
GDNF. MEN2A and FMTC mutations, such as RET C634R, are normally responsive to 
GDNF stimulation, but HSCR-MEN2A mutations such as RET C620R are not (Arighi et 
al., 2004). Considering that insensitivity to GDNF makes cells more prone to apoptosis, 
it might explain the features seen in all HSCR-associated RET mutations (Mograbi et 
al., 2001). Furthermore, as GDNF functions as a chemoattractor for the NCSCs, the 
lack of mutant RET receptors at the membrane might also be implicated in this 
process. Further studies are needed to confirm this hypothesis. 
Based on this dual effect of RET, it is tempting to suggest that understanding 
the protein network involved in MEN2 migth bring new insights into HSCR and vice 
versa. Previous studies have shown that, indeed, this could be the case. Homozygous 
mutations on leucine 1061 of RET were involved in HSCR development due to 
disruption of the docking site of She on tyrosine 1062 (Geneste et al., 1999). She is an 
adaptor protein involved in activating the MAP kinase pathway. Since this pathway is 
known to be involved in cell proliferation and differentiation, it is not surprising that it 
plays a role during enteric neurogenesis. However, it is also not surprising that it is 
involved in oncogenic RET signalling (Schuringa et al., 2000, Plaza-Menacho et al., 
2007). 
These observations suggest that the signalling pathways involved in MEN2 
and HSCR triggered by RET activation should be combined and seen as a whole. In this 
way, a full picture of the RET protein network will become available and might help in 
identifying new players involved in the development of HSCR and MEN2. 
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Aims and outline of this thesis 
The aim of the work described in this thesis was to obtain a better understanding of 
the protein network involved in the development of Hirschsprung disease (HSCR) and 
Multiple Endocrine Neoplasia type 2 (MEN2). Thus, this thesis conveniently divides 
into two parts. 
In the first part we focus on HSCR, a complex inherited disorder for which 
several genes have been identified. However, since these known genes explain no 
more than 30% of all HSCR cases, it is likely that other genes are involved in the 
development of this disease. Giving that HSCR is frequently associated with congenital 
malformations present in rare recessive syndromes, studying the genes involved in 
these syndromes may reveal new insights into the HSCR-related protein network and 
help in identifying new candidate genes. 
In chapter 2 we studied the function of the protein encoded by 
KIAA1279/KBP, the gene involved in Goldberg-Sphrintzen syndrome, a rare autosomal 
recessive syndrome characterized by HSCR, among other features. We found that KBP 
interacts with SCGlO, a stathmin-like protein, and is involved in neuronal 
differentiation. Because SCGlO was identified as a susceptibility gene for HSCR 
development in a mouse model, we decided to investigate the occurrence of SCGlO 
mutations in a group of HSCR patients. The results of this study are reported in 
chapter 3. To conclude the first part of the thesis, we have reviewed what is known 
about HSCR in chapter 4. We describe the aetiology of HSCR, its genetic 
heterogeneity, and the polygenic nature of this disease. Moreover, we discuss 
challenges and expectations from technological advances in the quest to better 
understand the protein networks involved in HSCR development and hope these will 
help identify candidate genes involved in the polygenic inheritance of this disorder. 
In the second part of this thesis, we focus on MEN2. In chapter 5 we aimed 
to gain more insights into the signalling pathways associated with different types of 
MEN2: MEN2A, MEN2B and FMTC. Kinome profile analysis of the most common 
mutations associated with each type of MEN2 were performed in an attempt to 
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identify specific signalling pathways triggered by MEN2A, MEN2B and FMTC 
mutations. 
In chapter 6 the effect of four different tyrosine kinase inhibitors in the 
treatment of medullary and papillary thyroid carcinoma was assessed, in an attempt 
to find more effective therapeutic options for patients with a MEN2A or a MEN2B 
mutation, and with a RET/PTC rearrangement. 
Finally, in chapter seven, the results described in the previous chapters are 
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Abstract 
Goldberg-Shprintzen syndrome is a rare clinical disorder characterized by central 
and enteric nervous system defects. This syndrome is caused by inactivating 
mutations in the Kinesin Binding Protein (KBP) gene, which encodes a protein of 
which the precise function is largely unclear. We show that KBP expression is up­
regulated during neuronal development in mouse cortical neurons. Moreover, 
KBP-depleted PC12 cells were defective in NGF-induced differentiation and 
neurite outgrowth, suggesting KBP is required for cell differentiation and neurite 
development. To identify KBP interacting proteins, we performed a yeast two­
hybrid screen and found that KBP binds almost exclusively to microtubule­
associated or related proteins, specifically SCGlO and several kinesins. We 
confirmed these results by validating KBP interaction with one of these proteins: 
SCGlO, a microtubule destabilizing protein. Zebrafish studies further 
demonstrated an epistatic interaction between KBP and SCGlO in vivo. To 
investigate the possibility of direct interaction between KBP and microtubules, 
we undertook co-localization and in vitro binding assays, but found no evidence 
of direct binding. 
Thus, our data indicates that KBP is involved in neuronal differentiation and that 
the central and enteric nervous system defects seen in Goldberg-Shprintzen 
syndrome are likely caused by microtubule-related defects. 
Keywords: KBP, SCGlO, kinesins, microtubules, neuronal development, axonal 
growth. 
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Introduction 
Goldberg-Shprintzen syndrome (GOSHS) is an autosomal recessive disorder 
characterized by polymicrogyria, mental retardation, microcephaly, facial 
dysmorphisms and, in most cases, by Hirschsprung disease (Goldberg and Shprintzen, 
1981; Brooks et al. , 2005). Homozygosity mapping studies showed linkage to 
chromosome 10 and subsequent sequence analysis of all 35 genes in this region led to 
the identification of truncating mutations in the KIAA1279 gene (Brooks et al., 2005). 
KIAA1279 encodes a protein with two tetratrico peptide repeats whose function is still 
uncertain. Based on the GOSHS clinical phenotype, it is clear that mutations in 
KIAA1279 are associated with both central and enteric nervous system defects. 
Subsequent studies by Wozniak and co-workers led to KIAA1279 being named Kinesin 
Binding Protein (KBP) due to its interaction with the motor domain of two related 
kinesin-like proteins, K IFlC and K IF1Ba. (Wozniak et al., 2005). The interaction with 
KIF1Ba. suggested that KBP plays a role in mitochondria localization and distribution 
(Wozniak et al. , 2005). More recently, KBP has been implicated in the regulation of 
neuronal microtubules organization, and in axonal growth and maintenance (Lyons et 
al., 2008). This finding stemmed from the characterization of a kbp mutant zebrafish, 
the first animal model to be described for GOSHS (Lyons et al. , 2008). However, the 
mechanism by which KBP exerts its effect on microtubules is still unknown. 
Microtubules are dynamic structures that provide mechanical support for the 
shape of cells, and a track along which molecular motors, kinesins and dyneins move 
organelles from one part of the cell to another (Howard and Hyman, 2003). To 
perform these functions, a cell must carefully control the assembly and orientation of 
its microtubule cytoskeleton. Several proteins have been described that modulate 
microtubule dynamics and they can be divided into two groups: microtubule 
stabilizing proteins (MAPs) and microtubule destabilizing proteins (Andersen, 2000). 
Although much is known about the role of MAPs, relatively little is known about the 
molecular machinery that controls the microtubule destabilizing family of proteins, 
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especially with respect to neuronal development and regulation (Duncan and 
Goldstein, 2006). 
Here we describe the identification of several KBP-interacting proteins, all of 
which are implicated in microtubule transport and microtubule dynamics, and show 
that KBP is necessary for proper neuronal differentiation and neuronal development. 
Materials and Methods 
Constructs 
mKBP and hKBP constructs: pCMV-mKBP is an image clone ordered from Geneservice 
(5350638) with the full length mouse cDNA cloned into pCMVSport 6.1. The pCMV­
hKBPkiaa is derived from the human image clone (Geneservice - 455085), which was 
recloned into the pOTB7 vector. hKBP was cloned into pCMVsport6.1 using EcoRI-Xhol 
restriction sites. pGBKT7-mKBP construct was generated by Notl-Sa/1 digestion of 
pCMV-mKBP, followed by ligation with pGBKT7 vector. 
pCDNA-HA-mKBP was generated by EcoRI-Notl digestion of pGBKT7-mKBP 
followed by ligation with pDNA3-HA. pCDNA-HA-hKBP construct was generated by 
EcoRI-Xhol digestion of pCMV-hKBP followed by ligation with pCDNA3-HA. pEGFP-Nl­
hKBP construct was generated by hKBP PCR amplification from pCDNA-HA-hKBP using 
the primers KBP forward {5'-CGTGATGTGTACAGTATGGCGAACGTTCCG-3') and KBP 
reverse {5'-CGTGACGTCTAGAGGATTAAGTCAGGGCCATCTTG-3'). BsrGI-Xbal restriction 
sites included respectively in KBP forward and KBP reverse primers, were used to 
clone hKBP into pEGFP-Nl vector. 
pcDNA3-Myc-SCG10 construct: mSCGlO cDNA was obtained from the yeast 
two-hybrid screen and amplified using the primers SCGlO forward {5'­
CGCGGAATTCACAATGGCTAAAACAGCAATGGC-3') and SCGl0 reverse (5'­
CATGGCGGCCGCTGCTTCAGC CAGAC- 3'). EcoRI-Notl restriction sites, included 
respectively in the SCGlO forward and SCGl0 reverse primers (underlined sequences), 
were used to clone mSCGlO into pCDNA3-Myc vector. 
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pSUPER-shKBP construct: The target sequence used for designing the shRNA 
was based on the rat KBP sequence: GCTCACGCTTACTATGACA. Two oligos were 
designed containing the target sequence in its sense and antisense form (bold) 
separated by the hairpin loop sequence and flanked by BamHI, and Hindl l l ,  overhangs 
at the S'and 3'ends respectively (underlined). Forward sequence (5'­
GATCCCC GCTCACGCTTACTATGACA CTTCCTGTCA TGTCATAGTAAGCGTGAGC 
TTTTTGGA�-3') and reverse sequence (5' -AGCTTTTCCAAAAA 
GCTCACGCTTACTATGACA TGACAGGAAG TGTCATAGTAAGCGTGAGC GG§_ -3'). BamHI­
Hindl l l  restriction sites were used to clone the sh RNA into pSuper vector. 
Cell culture and transfections 
HEK293, NIH-3T3, Hela and NlE/115 cells were cultured in DMEM high medium 
containing 4.5 g/L of glucose, L-glutamine and pyruvate {Gibco), supplemented with 
10% fetal calf serum (BioWhittaker) or with 10% newborn calf serum (Gibco) (for NIH-
3T3), and 1% penicillin/streptomycin (Gibco), at 37°C and 5% CO2. 
For transient transfections, 300.000 cells of HEK293, Hela, 3T3 and NlE/115 
were seeded in 6-well plates. Transfections were performed 24 hours after seeding 
using jetPei (Promega). 
Culture of primary cortical neurons 
Primary cortical neurons were prepared from embryonic brains (ElS-16) of C57Bl/6J 
mice. After mechanical dissociation, neurons were plated on 6-well plates previously 
coated with poly-D-lysine (2 µg/ml). Neurobasal medium (GIBCO) supplemented with 
827-supplement (GIBCO), 0.5 mM glutamine (BioWhittaker), 1% 
penicillin/streptomycin (Gibco) and 2.5 µg/ml amphotericin B (Sigma-Aldrich), was 
used as culture medium. After 48 h, cells were treated with 10 µM cytosine 




Yeast two-hybrid screen 
The yeast two-hybrid screen was performed using the Matchmaker 3 System 
(ClonTech) according to the manufacturer's instructions. Briefly, pGBKT7-mKBP was 
transformed into AH109 Saccharomyces cerevisiae yeast strain, which was then 
mated with the Y187 strain pre-transformed with an eleven days old mouse library 
(ClonTech). Clones that survived the quadrupole selection (-His, -Ade, -Leu, -Trp) and 
that stained positive for �-galactosidase activity were isolated. The DNA of these 
clones was recovered and after electroporation into KC8 cells, was subsequently 
analyzed by digestion with Hindlll. Clones that showed the expected two bands after 
digestion were used for repeating mating experiments with Y187 yeast strain 
transformed with empty pGBKT7 and pGBKT7 mKBP to eliminate false-positives. 
Clones able to grow in a triple dropout medium (-Leu/-Trp/-His) only in the presence 
of mKBP were subsequently transformed into JM101 cells. The DNA isolated from this 
strain was sequenced and the results were blasted for matches. 
Cell lysates, co-immunoprecipitation assays and Western blot analysis 
Cell lysates were prepared as followed: cells were washed with ice cold PBS and 
incubated with lysis buffer (200 mM NaCl, 20mM Tris-HCI pH 7.8, 1% Triton X-100 and 
protease inhibitors) for 30 min on ice. Cell lysates were collected by scraping and 
cleared by centrifugation at 14000 rpm for 10 min in a pre-cooled (4°C) centrifuge. 
Supernatants were stored at -80°C before they were processed further for SDS-PAGE 
followed by Western blot analysis. For immunoprecipitation, lysates were incubated 
with HA-coupled sepharose beads (Roche) ON at 4°C. Precipitates were washed with 
lysis buffer and protein was eluted in loading buffer. For western blot analysis the 
following antibodies were used: KBP (affinity purified rabbit polyclonal directed 
against a peptide encompassing amino-acids 24-38 of mKBP, Eurogentec), SCGlO 
(rabbit polyclonal kindly provided by Ellen Coffey, Turku Centre for Biotechnology, 
Finland), HA (3F10; Roche), tubulin (B-5-1-2, Sigma), actin (C4, MP Biomedicals). 
Secondary antibodies used for immunodetection were goat anti-rabbit lgG-HRP (Santa 
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Cruz Biotechnology), rabbit anti-rat lgG-HRP (DakoCytomatin), and goat anti-mouse 
lgG-HRP (Bio-Rad). 
Microscopy and image analysis 
For immunofluorescence analysis NlE/115, 3T3 and Hela cells were cultured on poly­
D-lysine coated cover slips. 2% PFA was used as fixative agent for NlE/115 and Hela 
cells and 3T3 cells were fixed in ice cold methanol for 3 min at -20°C. Cells were made 
permeable with 1% BSA and 0,1% Triton X-100 in PBS. Endogenous SCGl0 was 
detected using a a-SCGlO antibody (clone LS/1, Antibodies Incorporated) followed by 
a goat a-mouse Cy3 secondary antibody (Zymed). HA-KBP was detected using a a-HA 
antibody (3Fl0; Roche) followed by goat a- rabbit Alexa-fluor 488 secondary antibody 
(Molecular probes). The Golgi protein giantin was detected using a a-giantin antibody 
(Abeam) followed by a goat a- rabbit Alexa-fluor 488 secondary antibody (Molecular 
probes) or a goat a- rabbit Cy3 secondary antibody (Jackson lmmunoResearch). 
Mitochondria staining was detected using MitoTracker (lnvitrogen). 
For microtubule staining, 3T3 cells were cultured on poly-D-lysine coated 
cover slips and fixed in ice cold methanol for 3 min at -20°C. Cells were permeabilized 
with 0.1% Triton X-100 and 1% BSA in PBS. Endogenous tubulin was detected using a­
tubulin antibody (B-5-1-2, Sigma), fol lowed by an anti-mouse lgG conjugated 
antibody. Fluorescent images were made using a Leica TCS SP2 (AOBS) microscope. 
In vitro polymerization of microtubules and high-speed fractionation 
NIH-3T3 cells were lysed in tubulin buffer (Cytoskeleton) containing 0.1% Triton X-
100. Lysates were centrifuged at 100,000 X g for 1 h in an Optima TM MAX-E- Beckman 
Coulter ultracentrifuge. Supernatant fractions were incubated for 30 min at 37°C with 
purified, taxol-stabilized microtubules, which were generated according to the 
manufacturer's indications (Cytoskeleton ™). Microtubules were pelleted down by 
centrifugation (100,000 X g for 1 hour) and both supernatant and pellet fractions were 
checked by Western blotting. 
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PC12 culture, differentiation and transfection 
PC12 cells were cultured in RPMI 1640 (Gibco) supplemented with 10% horse serum 
(Gibco), 5% fetal calf serum (Gibco) and 1% penicillin/streptomycin (Gibco), at 37°C 
and 5% CO2. 
For transient transfections, 50,000 PC12 cells were seeded in 12-wel l  cu lture 
plates coated with laminin (Millipore). 24h after, cells were transfected with pEGFP­
Nl vector alone or in combination with pSuper-shKBP vector using lipofectamine 2000 
(lnvitrogen). 24 h after transfection, cells were cu ltured in low serum concentration 
for 12 h at 37°C and 5% CO2. P-NGF (R&D systems) was then added to the culture 
medium and 48 h after green cells were counted and analyzed for the presence of 
neurites. 
Fish and embryos 
Zebrafish were kept and bred under standard conditions at 28.5°C (Westerfield, 
2000). Embryos were staged and fixed at specific hours post-fertilization (hpf) as 
described elsewhere (Kimmel et al., 1995). To better visualize in situ hybridization 
results, embryos were grown in 0.2 mM 1-phenyl-2-thiourea (Sigma) to inhibit 
pigment formation (Westerfield, 2000). 
Antisense oligonucleotide (Morpholinos) injections 
Splice blocking scg10a, scg10b and kbp morpholinos (SBMO) were designed to 
complement the sequences corresponding to the splice donor site at the predicted 
exon2/exon3 junction for scg10a, exonl/exon2 for scg10b and exon3/exon4 for kbp. 
scglOa SBMO: S'TTTCATTTCCTACCTTCAAACTCGC3', scglOb SBMO: 
5'TTCTCCCACTTACCTTCAAACTCAC3', kbp SBMO: 
5' AAGAGAGGGATGTTACCTTCTAATC3'. 
The MOs (Table Sl) were diluted in sterile filtered water over a 
concentrations range of 1-5 µg/µI. Approximately 1 nl of diluted MO was injected at 
the 1-2 cell stage using a gas-driven microinjection apparatus to determine the effects 
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of knocking down single genes or combinations of them. The standard control MO 
from Gene Tools was injected as a negative control for the MO experiments. A p53 
MO (5'GCGCCATTGCTTTGCAAGAATTG3') was injected in combination with other MOs 
to eliminate potential apoptotic side effects of MOs injections (Plaster et al., 2006). 
Whole mount in situ hybridization and double-labeling immunohistochemistry in 
zebrafish 
Digoxigenin labeled riboprobes that complement scglOa, scglOb and kbp mRNAs 
were generated by linearization of pCR TOPO II vectors that contained partial ORFs of 
the genes. SCGlOa and SCGl0b plasmids were linearized with EcoRV (New England 
Biolabs) and subsequently transcribed with SP6 polymerase (Promega). KBP plasmid 
was linearized with Sall (New England Biolabs) and transcribed with T7 polymerase 
(Promega). Embryos were collected and processed for whole-mount in situ 
hybridization as previously described (Thisse et al., 1993). Digoxigenin-labeled probes 
were detected using a standard NBT/BCIP staining reaction. 
For immunohistochemistry, FoxD3-GFP transgenic embryos (Gilmour et al., 
2002; Lister et al., 2006) were fixed in 4% PFA. To obtain frozen sections, tissues were 
cryoprotected overnight in a 20% sucrose/PBS solution and placed for lh at 37°C in a 
20% sucrose/5% gelatin solution. Afterwards, tissues were rapidly frozen in 
isopentane pre-cooled in liquid nitrogen to -60°C. Frozen sections were cut at 14 µm, 
collected on Superfrost Plus microscope slides (BDH Laboratories), air dried, and 
stored at -20°C. Prior to labeling, sections were placed in warmed PBS (37°C) for 15 
min in order to remove the sucrose/gelatine, and then rinsed in PBS (2X 5 min). 
Histochemical staining was done using a polyclonal rabbit anti-GFP antibody 
(Molecular Probes) as previously described (Delalande et al., 2008). Sections were 
then stained with DAPI (5 min). In order to observe any co-localization of KBP RNA 
and FoxD3-GFP, bright field in situ images were converted into grayscale, inverted and 
then inserted into the red channel before being overlaid with FITC images using 




1) KBP plays a role in neuronal development and neuronal differentiation 
Goldberg-Shprintzen syndrome is a developmental disorder in which both the central 
and enteric nervous systems are affected. To determine KBP expression levels in 
neuronal cells, we isolated ElS mouse cortical neurons and cultured them for 6 days. 
Cells were lysed each day from the second day of the experiment onwards, and 
protein levels were analyzed by Western blotting (Fig. lA). Our data shows that there 
is an up-regulation of KBP expression levels in primary cortical neurons that seems to 
go hand-in-hand with neuronal differentiation. 
In situ hybridization performed in zebrafish confirmed expression of KBP both 
in the central and enteric nervous system (Fig. 1B). A detailed examination of the 
expression pattern in the developing gut revealed that KBP is only expressed at low 
levels in migrating ENCSCs during the initial period of gut colonization (Fig. lC). Taken 
together, these mouse and zebrafish results suggest that KBP plays a role during the 
development of the central and enteric nervous systems. 
To determine if KBP is required for neuronal maturation, we reduced KBP 
expression in PC12 cells using a sh RNA expressing vector (Fig. 2A). We used PC12 cells 
because they have the ability to differentiate into neuronal-like cells in the presence 
of nerve growth factor (�·NGF) (Greene and Tischler, 1982). After co-transfection of 
PC12 cells with shRNA expressing vector targeting KBP mRNA and a GFP expressing 
plasmid to monitor the transfected cells, GFP expressing cells were counted (approx. 
4,000 cells/condition) and morphologically analyzed for the presence of neurites (Fig. 
2B). We consider any extension that could be seen from the cellular body a neurite 
and the presence of one small extension was enough to consider the cell as 
differentiated. Our results show that the number of PC12 cells that differentiate and 
produce neurites when KBP expression was impaired was significantly lower (p< 0.05) 
than for the control (Fig. 2C). These data indicate that KBP strongly contributes to the 
NGF-induced neuronal differentiation of PC12 cells. 
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Figure 1 - KBP expression during neuronal development and neuronal maturation. (A) Western blot analysis of 
mouse primary cortical neurons cultured for 6 days showed that KBP expression levels increase during neuronal 
development. (B) Whole-mount in situ hybridization of KBP in zebrafish. At 20-somite stage KBP is expressed 
ubiquitously (B'). At 24 hpf KBP expression is restricted to the anterior central nervous system (CNS) and to the 
anterior gut (B"). This pattern of expression is maintained at 48 hpf with cranial ganglia (cg) also expressing KBP 
(B"'). (C) KBP expression in the hindbrain, cranial ganglia and the gut. Transverse sections of whole-mount KBP in 
situ hybridization/GFP immunohistochemistry performed in Tg(foxd3:gfp) zebrafish at 48 hpf showed a strong 
KBP expression in the ventral neural tube (nt), the posterior lateral line ganglia (pllg), the developing liver (L) and 
gut (g) (Cl, Cl'). A magnified view of the gut shows that GFP/Foxd3 positive enteric neural crest cells (encc) 






• p < 0,05 
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Figure 2 - KBP is required for PC12 differentiation. (A) Western blot analysis of KBP expression in PC12 cells 
transfected with GFP alone or in combination with a shRNA expression vector targeting KBP mRNA. (B) 
Morphology of �-NGF treated PC12 cells expressing a GFP vector alone or in combination with the shKBP vector 
was analysed using a fluorescence microscope. (C) The number of green differentiated cells was counted in the 
absence and in the presence of the shKBP and showed to be significantly lower when KBP expression was 
reduced (p<0.05). Scale bars 15 µm. 
2) Yeast two-hybrid interactions of KBP 
KBP contains two tetratricopeptide repeats which mediate protein-protein 
interactions (Blatch and Lassie, 1999), suggesting that KBP likely binds to other 
proteins. To identify KBP interacting partners, a pre-transformed Ell mouse cDNA 
library was screened using a yeast two-hybrid screen. The Ell mouse library was used 
as this is a critical stage in brain development and coincides with the stage at which 
the colon is being colonized by neural crest cells. 
From our yeast two-hybrid screen we selected 69 positive clones which we 
isolated and sequenced. 19 of these 69 clones encoded for the same protein, SCGlO, 
a stathmin-like protein. In addition, 6 kinesins were found among these inserts, 
namely KIFSB, KIFSC, KIF7, KIF2C, KIF3A and also, KIFCl. A blast search using the cDNA 
of the kinesins found revealed that they all interact with KBP via their motor domain. 
None of the kinesins previously described to interact with KBP (Wozniak et al. , 2005), 
KIFlC and KIFlBa, were found in our screen. Additional ly, three of these 69 clones 
encoded for tubulin, the main constituent of microtubules (Table 1) . 
Taken together, these results strongly suggest a role for KBP in microtubule 
organization and stability. Moreover, the fact that all these kinesins were obtained in 
this screen reinforced the idea that KBP is involved in kinesin-mediated microtubular 
transport and is indeed a kinesin binding protein. 
Since the majority of clones obtained encoded for microtubule associated or 
microtubule interacting proteins, we conclude that KBP might be involved in 
microtubule-related events. In order to confirm the validity of this result, we decided 
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6 clones 
3 clones 
19 clones Superior cervical ganglia, neural specific 10 - SCG10 
Table 1. Yeast two-hybrid results for the Kines in binding protein (KBP) 
3) KBP interacts with SCG10 
SCG10 is a member of the stathmin family of proteins, all of which bind to tubulin to 
act as a sequestering agent and promote microtubule disassembly (Bondallaz et al., 
2006). SCG10 is a membrane associated neuronal protein that is largely expressed 
during development and whose expression correlates with neurite outgrowth 
(Bondallaz et al., 2006). It possesses a unique N-terminal domain that is critical for 
membrane binding, is responsible for SCG10 localization to the Golgi complex and is 
important in the targeting of SCG10 to the growth cones (N ixon et al., 2002; Di Paolo 
et al. , 1997). 
To confirm the specificity of the KBP interaction with SCG10 we performed a 
co-immunoprecipitation assay. HA-KBP was expressed in Human Embryonic Kidney 
cells (HEK293) alone or in combination with Myc-tagged SCG10. Expression of 
exogenous Myc-SCG10 was necessary as HEK293 cells do not endogenously express 
SCG10. Precipitation of Myc-SCG10 was only observed in the presence of HA-KBP ( Fig. 
3A), confirming an interaction between KBP and SCG10. This interaction was further 
supported by co-localization studies in a mouse neuroblastoma cell l ine, NlE-115. This 
cell line was chosen due to its ability to differentiate in neuronal l ike cells when 
incubated in the presence of low serum concentrations. Using this cell line we 
evaluated GFP-KBP and SCG10 cellular d istribution in the cell. SCG10 is enriched in the 
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Golgi complex and in the growth cones as expected (Di Paolo et al., 1997), while KBP 
shows a cytoplasmic distribution in the cell that overlaps with SCGlO specifically in the 
Golgi complex (Fig. 3B). To confirm KBP and SCGl0 co-localization in the Golgi 
complex we used a specific antibody against a Golgi protein, giantin (Linstedt and 
Hauri, 1993), as a Golgi marker (Fig. 3B). 
These results support our yeast two-hybrid data and confirm the cellular 
interaction between KBP and SCGl0. 
4) Epistatic interaction between KBP and SCGlO in Zebrafish 
To further validate KBP-SCGlO interaction, distribution of the mRNA transcripts for 
both these proteins was evaluated and epistasis was determined using a zebrafish 
model. 
The zebrafish genome contains one KBP gene and two SCG10 orthologs 
(Lyons et al., 2008; Burzynski et al., 2009). To determine the spatial expression 
pattern of the zebrafish scglOa, scglOb and to compare it to kbp orthologs during 
embryogenesis, matched whole-mount in situ hybridizations were performed using 
riboprobes for all three genes. Discrete patterns of expression were detectable as 
early as 16 hours post-fertilization (hpf). At this stage, expression of both scglOa and 
scglOb genes is restricted to the posterior lateral line (PLL) ganglia and Rohan-Beard 
sensory neurons in the spinal cord (Fig. 4A). By contrast, expression of kbp is initially 
rather diffused and ubiquitous in the whole embryo (Fig. lB'). From 24 hpf kbp's 
expression becomes predominantly restricted to the anterior CNS and this pattern of 
expression persists throughout all the stages examined in the present study. kbp 
transcript is present in all brain regions, as well as in the anterior and posterior lateral 
line (ALL and PLL) ganglia (Fig. lC, 4A). SCGlO expression at 24 hpf can be detected 
within the anterior CNS regions including ventral telencephalon and diencephalon, all 
hindbrain rhombomeres, the ALL and PLL and primary sensory neurons of the spinal 
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Figure 3 - KBP interacts with SCGlO. (A) HA pulldown performed in  HEK293 cells co-expressing HA-KBP alone or 
in combination with Myc-SCGlO showed that Myc-SCGlO precipitates only in the presence of HA-KBP. (I-input, 
FT- flow through, PD- pull down). (B) Confocal images of NlE/115 cells showed that GFP-KBP co-localizes with 
SCGlO in the Golgi complex and in the neurites. Giantin staining was performed to confirm KBP and SCGlO co­
localization in the Golgi complex. Scale bars 20 µm. 
At 48 hpf, expression of the SCGlO genes becomes more abundant but like the 
pattern of kbp expression, they are primarily restricted to the anterior CNS and cranial 
ganglia. Further in development (72 and 96 hpf) SCGlO transcripts remain expressed 
in the same CNS regions and are also expressed in the enteric neurons (Burzynski et 
al. , 2009). The pattern of expression of both SCGlO orthologs in zebrafish is very 
similar, although scglOa transcript is much more abundant (Burzynski et al. , 2009). At 
48 hpf expression of scglOa, scglOb and kbp overlap in the forebrain region, retina, 
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optic tectum, trigeminal, vagal ganglia, ALL and PLL ganglia, and in the hindbrain (Fig. 
4A). 
To determine if there is an epistatic interaction between KBP and SCGlO, 1-2 
cell stage zebrafish embryos were injected with splice blocking morpholinos (SBMO) 
targeted against scg10a, scg10b and kbp transcripts (Draper et al. , 2001). Injections 
were carried out either separately or in combination. In addition, combined injections 
were performed with a p53 morpholino (MO) to exclude potential cytotoxic side 
effects of MOs used (Robu et al. , 2007). The concentration of scglO and kbp MOs 
were titrated to the sub-threshold doses so that when injected separately they 
resulted in no apparent phenotype (Fig. 48). By contrast, when the MOs were injected 
in combination, perturbation in development became apparent. In the case of scglOa 
and scg10b double injections, morphants displayed a general delay in development, 
smaller heads and eyes and axial defects (Fig. 48). This result suggests that the scg10 
genes are functionally redundant and this is consistent with their almost identical 
patterns of expression. Injections of scglOa, scglOb and kbp MOs together resulted in 
a much more severe phenotype. Triple morphants were significantly smaller with 
severely malformed body axis, very small head and eyes, necrotic areas in the brain 
and heart edema. Injections with p53 MO reduced the cel l death in the retina and 
optic tectum areas but did not change the general morphology of the morphants, 
confi rming that the observed morphant phenotype is not the result of offsite effects 
of the MOs (Fig. 48) (Robu et al., 2007). These results strongly suggest an epistatic 
interaction between kbp and scglO genes and support the results of the yeast two­
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Figure 4 - Epistatic interaction of KBP with SCG10. (A) Whole-mount in situ hybridizations performed in zebrafish 
at 24 and 48 hpf show expression patterns of scglOa, scg10b and kbp orthologues. (B) Splice blocking 
morpholinos (SBMO) targeted against scglOa, scg10b and kbp transcripts were injected in zebrafish embryos at 
1-2 cell stage. When injected individually hardly any phenotype was seen. scg10a and scglOb double injections, 
lead to a general delay in development. However, when kbp SBMO was injected in combination with scglOa and 
scglOb, morphants showed a severe phenotype with malformed body axis, very small head and eyes, necrotic 
areas in the brain and heart edema. A p53 morpholino was combined to exclude potential cytotoxic side effects 
of the morpholinos used. 
5) KBP interaction with microtubules 
Based on the yeast two-hybrid results and on the direct interaction between KBP and 
SCGlO, a microtubule destabilizing protein, we hypothesize that KBP plays a role in 
microtubule organization or microtubule stability and dynamics. Furthermore, the 
recent study characterizing a kbp mutant zebrafish showed that the loss of KBP 
function leads to a disorganization of axonal microtubules and to an improper 
orientation of microtubules along the axonal axis (Lyons et al., 2008). In an attempt to 
further explain this microtubule effect, we investigated whether there is a direct 
interaction between KBP and microtubules by determining the co-localization of GFP­
KBP with tubulin in mouse fibroblast cells (N IH-3T3). We detected no co-localization 
between KBP and tubulin ( Fig. SA). To rule out the possibility that the interaction of 
KBP with microtubules is very transient and thus difficult to detect in co-localization 
studies, in vitro microtubule binding assays were performed. Taxol-stabilized 
microtubules were purified and mixed with cytosolic cell extracts of N IH-3T3 cells 
expressing KBP. Microtubules were pelleted by high speed centrifugation and the 
binding of KBP to the microtubules was determined by co-sedimentation. We found 
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that KBP remains in the supernatant both in the absence and presence of 
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Figure 5 · KBP association with microtubules. (A) Confocal images of N IH-3T3 cells expressing GFP-KBP and 
stained with an anti-tubulin antibody showed that KBP does not co-localize with microtubules. (B) Microtubule in 
vitro binding assay showed that KBP does not precipitate with Taxol-stabilized microtubules when subjected to 
high speed centrifugation (P- pellet, SP- supernatant). Scale bars 20 µm. 
6} KBP has a cytoplasmic localization 
During the co-localization studies performed we noticed that KBP was distributed 
throughout the cytoplasm. Previous studies performed in NIH-3T3 cells reported that 
KBP co-localizes with mitochondria and that it plays a role in mitochondria 
distribution by interaction with KIFlBa. (Wozniak et al., 2005). To reassure ourselves 
that the GFP tag was not influencing KBP localization in the cell, we expressed HA­
human KBP in Hela cells. Using an anti-HA antibody and a specific marker for 
mitochondria {MitoTracker), we repeatedly observed that KBP is distributed 
throughout the cytoplasm and is not specifically localized to mitochondria {Fig. GA). To 
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further support this observation, we co-expressed a modified Bicaudal D2 (BICD2-N) 
construct in Hela cells with the HA-human KBP construct (Fig. 6B). BICD2 is a motor­
adaptor protein involved in the transport of various cargoes by dynein-mediated 
transport in Drosophila and mammals. Previous studies have shown that in the 
absence of its C-terminal, BICD2-N-terminal strongly binds to dynein and impairs its 
normal function leading to disruption of the retrograde distribution of membranous 
organelles (Hoogenraad et al., 2001). When we over-expressed BICD2-N in Hela cells 
mitochondria became aggregated, however, we saw no change in KBP loca lization 
(Fig. 6B). Since NIH-3T3 cells were also used by us with no change in the diffuse 
localization of KBP in the cell (Fig. SA), maybe a difference in the experimental 
procedure used could explain the differences in co-localization seen by us and by the 
previous study (Wozniak et al. , 2005). However, based on our results, we conclude 
that KBP has a cytoplasmic localization and does not co-localize with mitochondria. 
A) 
B) 
Figure 6 - KBP has a cytoplasmic localization. (A) Confocal images of Hela cells expressing HA-hKBP and stained 
with a mitochondrial marker (Mitotracker) showed that KBP has a cytoplasmic distribution and does not co­
localize with mitochondria. (B) Co-expression of HA-hKBP and BicD2-N constructs in Hela cells confirms KBP 




Homozygous nonsense mutations in the KIAA1279/KBP gene encod ing the Kinesin 
Binding Protein (KBP) lead to Goldberg-Shprintzen syndrome (GOSHS). Affected 
patients have undetectable levels of KBP and show both central and enteric nervous 
system defects (Brooks et al., 2005). Based on the clinical phenotype, KBP is required 
for normal neuronal development, but its precise function is largely unclear. 
Subsequent to our initial identificat ion of KBP mutations underlying the GOSHS 
phenotype, two independent studies have investigated the function of the KBP 
protein. The first study showed that KBP has a mitochondrial localization and that it 
interacts with the a isoform of KIFlB, increasing its motility. The same study showed 
that a reduction in the expression levels of KBP led to mitochondrial aggregation, 
suggesting that KBP regulates mitochondria distribution in the cell by controlling 
KIFlBa activity (Wozniak et al., 2005). The second study characterized a zebrafish kbp 
mutant, which had reduced axonal growth and disruption of axonal microtubules 
(Lyons et al. , 2008). Axonal degeneration and mislocalization of mitochondria were 
also observed in the neurons at later stages of development, suggesting that KBP is a 
regulator of the neuronal cytoskeleton (Lyons et al. , 2008). Although both studies 
shed some light on KBP function, they only partially expla in the role of KBP in GOSHS. 
Our results show that KBP plays a role in neuronal development and is 
necessary for neurona l differentiation. Using zebrafish as a vertebrate model, we 
clearly show that KBP is strongly expressed in the central nervous system (CNS) during 
embryonic development. KBP is also expressed in some periphera l  nervous system 
(PNS) structures, such as the cranial ganglia, although its expression is low in the 
migrating enteric precursors. Our study also shows that KBP interacts with severa l 
microtubule related proteins, including the stathmin SCGlO, a microtubule 
destabilizing protein. Based on this interaction, we suggest that KBP potentially 
modulates the proper organization of microtubules. We also show that KBP interacts 
with several kinesins, as previously described (Wozniak et al., 2005), further 
confirming that KBP is indeed a kinesin bind ing protein and suggesting that KBP may 
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regulate multiple aspects of intracellular transport along microtubules. Furthermore, 
we can not exclude the possibility that KBP may be involved in signalling pathways 
mediated by primary cilium especially because one of the kinesins that we found in 
our yeast two hybrid screen, KIF7, was shown to be a cilia-associated protein (Liem et 
al., 2009). 
Taken together, these results provide further insights into the cellular 
mechanisms that are perturbed in GOSHS patients and that underlie the clinical 
phenotype. 
KBP, SCG10 and microtubules 
Microtubules are dynamic structures composed of a and � tubulin dimers. These 
structures are necessary for many processes in the cell, including transport and 
maintenance of neuritic processes (Tanaka et al., 1991; Rochlin et al., 1996; Dent and 
Gertler, 2003; Manna et al., 2007). Microtubule dynamics are characterized by stages 
of catastrophe alternated with stages of polymerization; this process is called dynamic 
instability. Although dynamic instability occurs both at the plus and minus ends of 
purified microtubules in vitro, it is more pronounced at the plus ends (Manna et al., 
2007). 
Several proteins are known to regulate microtubule dynamics, including KBP 
(Lyons et al., 2008). Our results show that KBP interacts with SCGlO, a stathmin-like 
protein previously reported to be involved in microtubule dynamics (Di Paolo et al., 
1997; Grenningloh et al., 2004). Moreover, during differentiation SCGl0 enhances 
neurite outgrowth, a phenomenon that is believed to depend on microtubule 
dynamics (Grenningloh et al. 2004; Riederer et al., 1997). 
Our results strongly suggest that KBP's role in microtubule 
organization/dynamics is not a result of its direct interaction/association with 
microtubules but is instead due to its interaction with SCGlO. As KBP interacts with 
several kinesins, a possible function for KBP would be as an adaptor molecule for the 
transport of SCGl0 to the growth cones via kinesin related transport. However, our 
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yeast two-hybrid screen showed that KBP's interaction with the kinesins is via the 
kinesin motor domain. Knowing that the motor domain is responsible for the docking 
of kinesins to the microtubules, it is very unlikely that KBP is directly involved in the 
transport of SCGlO to the growth cones. However, KBP might be involved in the 
process that precedes the transport of SCGl0 to the growth cones. Additionally, KBP 
might regulate SCGlO activity, leading to a change in its microtubule destabilizing 
properties and may thus be involved in the maintenance of microtubule dynamics. 
Another possibility is that KBP might mediate SCGlO interaction with tubulin. 
Consistent with this, we observed an interaction between KBP and tubulin in our 
yeast two-hybrid study. Potentially, KBP could control the levels of free tubulin 
available for microtubule polymerization. If either of these mechanisms is correct, KBP 
will affect neurite extension and axonal growth, and this is in line with our data and 
the analysis of the zebrafish kbp mutant (Lyons et al., 2008). Furthermore, as the 
expression pattern of SCGlO is restricted to neuronal tissue, any perturbation of the 
KBP-SCGl0-tubulin interaction will potentially result in neuronal development defects 
consistent with the GOSHS clinical phenotype. 
Finally, our observation that KBP is required for neuronal maturation of PC12 
cells is consistent with our biochemical studies that showed an interaction between 
KBP and SCGlO. 
KBP implications in GOSHS and HSCR 
GOSHS is a rare but severe genetic disorder characterized by central and enteric 
nervous system defects. Based on our results, we propose that the GOSHS phenotype 
is caused by a reduction in neuronal differentiation and perturbed microtubule 
dynamics due to a deregulation of SCGlO activity. The data we now present supports 
previous findings ( Lyons et al. , 2008). 
Since GOSHS patients frequently have Hirschsprung disease (HSCR), KBP interacting 
proteins could bring some new insights about HSCR development. Currently, the 
genetic basis of this condition can only be explained in approximately 20% of all the 
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cases, with RET being the major gene involved (Amiel et al., 2008). SCGlO has been 
previously identified as a down-regulated gene in a RET mouse model for HSCR 
(Heanue and Pachnis, 2007) and we have shown that SCGlO interacts with KBP in vitro 
and in vivo. Both these facts suggest that SCGlO might also play a role in HSCR 
development, but it is still not clear what mechanism is involved. SCGlO activity is 
known to be controlled by two post-translational modifications: palmitoylation and 
phosphorylation (Antonsson et al., 1998; Lutjens et al., 2000). The former is 
responsible for growth cones targeting of SCGlO and the latter is responsible for 
controlling SCGl0 activity. As RET modulates several signalling pathways, it is possible 
that RET, via one of its downstream pathways, controls SCGlO activity, linking this 
gene directly to HSCR. Further studies are required to determine if there is any 
association between RET and SCGlO and a possible involvement of SCGl0 in HSCR. 
Conclusions 
Our study shows that KBP is necessary for neuronal development and neuronal 
maturation. Furthermore, we show that KBP interacts with several microtubule­
associated and microtubule-related proteins in vitro and in vivo, being l ikely involved 
in microtubule organization/stability. Our results provide new insights into perturbed 
cellular mechanisms that lead to GOSHS and suggest that KBP has an important role in 
modulating SCGlO function during neuronal development. 
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Mutations in SCG10 are not involved in 
Hirschsprung disease 
Maria M. Alves, Jan Osinga, Joke B.G.M. Verheij, Marco 




Hirschsprung disease (HSCR) is a congenital malformation characterized by the 
absence of enteric neurons in the distal part of the colon. Several genes have been 
implicated in the development of this disease that together account for 20% of all 
cases, implying that other genes are involved. Since HSCR is frequently associated 
with other congenital malformations, the functional characterization of the proteins 
encoded by the genes involved in these syndromes can provide insights into the 
protein-network involved in HSCR development. Recently, we found that KBP, 
encoded by the gene involved in a HSCR-associated syndrome called Goldberg­
Shprintzen syndrome, interacts with SCGlO, a stathmin-like protein. To determine if 
SCGlO is involved in the ethiology of HSCR, we determined SCGlO expression levels 
during development and screened 85 HSCR patients for SCGlO mutations. We showed 
that SCGlO expression increases during development but no germline mutation was 
found in any of these patients. In conclusion, this study shows that SCGlO is not 
directly implicated in HSCR development. However, an indirect involvement of SCG10 
cannot be ruled out as this can be due to a secondary effect caused by its direct 
interactors. 
Keywords: SCGlO, Hirschsprung disease, mutation, screening. 
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Introduction 
Hirschsprung disease (HSCR) is an abnormality of the enteric nervous system 
characterised by the lack of ganglia along a variable length of the gut. It is a 
developmental disorder that arises due to failure in migration of enteric neural crest 
cells into the intestinal tract or due to a failure in survival, proliferation, or correct 
development of enteric neurons once they reach the gut (Heanue and Pachnis, 2007). 
In either case an aganglionic segment occurs in which contraction and relaxation is 
absent. The length of the aganglionic segment can vary and HSCR patients are 
classified into short segment (S-HSCR, 80%), long segment (L-HSCR, 15%), or total 
colonic aganglionosis (TCA, 5%) (Chakravarti and Lyonnet, 2001). HSCR is a common 
genetic disorder with an estimated incidence of 1:5000 live births and is more 
frequent in males than in females (4:1), a difference most prominent in S-HSCR 
(Badner et al., 1990). 
Several genes have been implicated in the development of this disease, being RETthe 
most important one (Edery et al., 1994). RET (REarranged during Transfection) 
encodes a receptor tyrosine kinase which is expressed in neural crest derived 
lineages, playing a pivotal role during development of the enteric nervous system 
(Heanue and Pachnis, 2007). Mutations in the coding region of RET are responsible for 
50% of familial HSCR cases and 15% of sporadic ones (Sancandi et al., 2000). However, 
they only account for 20% of HSCR cases, suggesting that other genes are involved. 
Since HSCR is frequently associated with other congenital malformations present in 
rare recessive syndromes, the study of the proteins involved in these syndromes can 
bring new insights about HSCR development. Such syndrome, in which HSCR is 
frequently observed, is Goldberg-Shprintzen syndrome (GOSHS), a rare autosomal 
recessive disorder. The gene responsible for this syndrome is KBP and recently we 
identified the Superior Cervical Ganglia Neural Specific-10 or SCGlO as the major 
interacting protein of KBP (Brooks et al., 2005; Alves et al., 2010). SCGlO is a stathmin­
like protein involved in microtubule dynamics (Grenningloh et al., 2004). But unlike 
other stathmins, SCGlO acts in two ways to promote microtubule dynamics: it 
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stabilizes microtubules at their plus end and promotes microtubule catastrophe at 
their minus end (Manna et al., 2007). Moreover, SCGlO is known to play an important 
role in neuronal differentiation by enhancing neurite outgrowth, a phenomenon that 
is believed to be dependent on microtubule dynamics (Grenningloh et al., 2004). Also, 
SCG10 has been previously identified as a down-regulated gene in a RET mouse model 
for HSCR (Heanue and Pachnis, 2006) and we have shown that SCGlO interacts with 
KBP in vitro and in vivo (Alves et al., 2010). All together these facts suggest that SCGlO 
might also play a role in HSCR development. 
In this paper we evaluate the role of SCG10 in HSCR development by 
determining SCGlO expression levels during the process of gut colonization and by 
screening a set of isolated non-syndromic HSCR patients without RET mutations for 
the presence of SCG10 mutations. 
Material and Methods 
Culture of enteric neural crest stem cells (ENCSCs) 
ENCSCs were prepared from embryonic gut (jejunum to rectum) of C57BL/6 mice 
El0.5, 11.5, 12.5, 13.5, 14.5 and 15.5. The gut was mechanically dissected and then 
tissues were incubated in collagenase/dispase enzyme solution (collagenase XI [750 
U/ml; Sigma-Aldrich] and dispase II [250 µg/ml; Roche] in PBS for approximately 5 
minutes at 37°C. Digested tissue was triturated until a homogenous cell suspension 
was created. Cell suspensions were washed and seeded on 35-mm petri dishes 
previously coated with fibronectin (2 µg/cm2, Sigma-Aldrich). DMEM-F12 medium 
(PAA) supplemented with N2 supplement (lnvitrogen), B27-supplement (lnvitrogen), 
1% penicillin/streptomycin (PAA), 20 ng/ml fibroblast growth factor (FGF, Peprotech) 
and 20 ng/ml epidermal growth factor (EGF, Peprotech), was used as culture medium. 
Every two days half of the medium was replaced with new medium containing freshly 
added FGF and EGF. The enteric neural crest-derived cells were kept in culture as 
neurospheres-like bodies (NLBs) for 14 days. 
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RNA extraction and RT-PCR 
After 14 days in culture, NLBs were collected and washed with PBS. RNA extraction 
was performed using the RNeasy mini kit0 (Qiagen). First strand cDNA was originated 
from 2ug of RNA using the Ready-To-Go You-Prime First-Strand Beads0 kit (GE 
Healthcare) and pdN(6) as first-strand primer. First-strand cDNA generated by this 
method was directly used for RT-PC. The primers used for amplification were SCGlO 
forward (S'-ACAATGGCTAAAACAGCAATGGC-3') and SCGlO reverse (S'­
TGCTTCAGCCAGAC-3'), Actin forward (S'-ATATCGCTGCGCTGGTCGTC-3') and Actin 
reverse (S' -AGGATGGCGTGAGGGAGAGC -3'). 
Patients 
All patients included in this study were diagnosed with HSCR disease and showed no 
mutations in the RET gene. All patients gave their written informed consent for the 
study. In total, 85 patients were screened. From these 85 patients 43 were S-HSCR, 11 
were L-HSCR and for 31 cases the length of the segment affected was unknown. 
Mutation screening of SCGlO 
Genomic DNA was isolated from peripheral blood lymphocytes by use of standard 
methods. Sequencing of exons 1-5 of SCG10 was performed using 5 sets of primers 
(for primers and PCR conditions see table 1). DNA amplification was performed using 
song of genomic DNA in 30µ1 PCR reactions containing: lOX reaction buffer, lOµM 
primer pair mix, 25mM dNTPs and 1 unit Taq Polymerase (Amersham). PCR products 
were amplified and purified (ExoSap it - GE Healthcare). Direct sequencing of exons 1-
5 was performed using the 3730 DNA Analyser (Applied Biosystems). Using the 
software Mutation Surveyor (Version 3.23, SoftGenetics LLC) sequences were aligned 
and compared with consensus sequences. 
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Primer Sequences bp Size(bp) Tm °C PCR Seq.prim 
SCGl0 lF TCTAGCACGGTCCCACTCTG 20 
20 174 58 lF SCG10 1R AGGTAGAGCCGACGGAGAAC 
SCGl0 2F ACCTGGCAATATTCACTCTG 20 
20 
340 58 2F 
SCGl0 2R TAGACACGGCAAGTCAATAG 
SCGl0 3F CTCCCGGAATAACAACGCTAC 21 
19 
444 58 3F 
SCGlO 3R ACATGTTGGCATGGCACAG 
SCGlO 4F CCGTTATTCTGCTAGGTTTG 20 
20 
327 58 4F 
SCGlO 4R TCAGGCATATGGAAGTTCAC 
SCGl0 SF TAGACACCAAACTGGGTTAC 17 
20 
236 58 SF 
SCGlO SR ATCCTGATATCGCATGATCC 
Table 1: PCR conditions. 
Results 
Expression of SCGlO in ENCSCs 
To determine SCGlO involvement in the development of the enteric nervous system, 
SCG10 expression levels were analysed in enteric neural crest stem cells ( ENCSCs). 
Because gut colonization occurs between day 9 and 15.S of mouse development, 
ENCSCs were isolated from El0.5 until ElS.S mouse and maintained for 2 weeks in an 
undifferentiated state. In  these ENCSCs, SCGlO expression was detected in the 
earliest stage analysed, El0.5, and an increase in expression levels was observed in  
the following stages (Fig. 1) .  Our data shows that there is  an up-regulation of  SCG10 
expression levels in ENCSCs. 
10.5 11.5 12.5 13.5 14.S 15.5 B ----� SCGlO 
Actin 
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Figure 1 - SCGlO expression levels during the development of the enteric nervous system. Expression studies in 
mouse enteric neural crest cells show that RNA levels of SCGlO are upregulated in the initial stage of gut 
colonization (11.S) and remain constant until the whole process is finished by ElS.5. 
Mutation screening of SCGlO 
To further evaluate the involvement of SCGlO in HSCR development, we screened 
blood DNA from 85 patients diagnosed with isolated, non-syndromic HSCR. No 
germline mutation was detected in SCGl0. 
Discussion 
Hirschsprung disease (HSCR) is a developmental disorder in which the process of gut 
colonization is disturbed. To date, 11 genes have been reported to be involved in 
HSCR development: RET, GDNF, NTN, EDNRB, EDN3, SOXlO, ECE-1, ZFHXlB, PHOX2B, 
KBP and NRGl (Edery et al., 1994; Brooks et al., 2005; Angrist et al., 1996; Doray et 
al., 1998; Puffenberger et al., 1994; Hofstra et al., 1996; Pingault et al., 1998; Hofstra 
et al., 1999; Cacheux et al., 2001; Amiel et al., 2003; Garcia-Barcelo et al., 2009). 
However, a l l  together, they only explain approximately 20% of all HSCR cases. To 
better understand HSCR development, the study of rare syndromes that are 
characterized by the presence of HSCR can be of major importance, as determining 
the protein network connected to the mutated proteins can help identifying 
candidate genes. In this study we focus on such a candidate gene, SCGl0, encoding a 
microtubule destabilizing protein, recently described to interact with KBP and 
believed to be important in the development of Goldberg-Shprintzen syndrome and 
consequently, in HSCR (Alves et al., 2010). Furthermore, SCGlO has been previously 
identified as a downregulated gene in a RET mouse model for HSCR (Heanue and 
Pachnis, 2006) reinforcing the idea that SCGlO might also play a role in HSCR 
development. Our results showed that SCGlO expression is clearly up-regulated 
during the process of gut colonisation, which suggests that SCGlO migth play a role in 
the development of the enteric nervous system. However, SCGlO screening in a set of 
85 patients diagnosed with isolated, non-syndromic HSCR showed that no mutation 
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was present. Taken together, these results suggest that although SCGlO seems 
necessary for the development of the enteric nervous system, it is not directly 
implicated in HSCR. A possible explanation for this result is that SCGlO involvement in 
HSCR can be a consequence of a disruption in the normal protein network necessary 
for proper development. SCGlO activity is known to be controlled by two post­
translational modifications: palmitoylation and phosphorylation (Lutjens et al., 2000). 
The first one is responsible for growth cone targeting of SCGlO and the second one is 
responsible for controlling SCGlO activity. As RET is a tyrosine kinase receptor known 
to be involved in several signalling pathways, it is possible that RET, via one of its 
downstream pathways, controls SCGlO activity, linking this gene directly to HSCR. 
Further studies are required to determine if there is any association between RET and 
SCGlO and a possible involvement of SCGlO in HSCR development. 
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Hirschsprung disease as a model of complex 
disorders 
Maria M. Alves, Bart J . L. Eggen, Gerard J. 




Genome-wide association studies (GWAS) have tried to identify the inherited risk 
factors contributing to the development of complex diseases. Although many disease­
associated variants have been found, only a small fraction of the total genetic risk for 
these diseases can be explained. The unexplained heritability is due partly to the 
diseases' multifactorial origin, and partly to a lack of power to identify associations 
with high frequency genetic variation. Rare and stronger mutations may also play a 
role in specific diseases, such as Hirschsprung (HSCR) disease. In this review, we focus 
on HSCR disease as an example of a complex disorder. We discuss what is known 
about HSCR disease, how new technological advances can be used to support the 
hypothesis of a risk contribution from rare penetrant mutations and how these 
advances can contribute to their identification. 
Keywords: Hirschsprung disease, genes, GWA studies, next generation sequencing, 
gene-networks, systems biology 
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Introduction 
Complex diseases are common and a major contributor to disability and death 
worldwide. They are thought to arise from multiple predisposing factors, both genetic 
and non-genetic, and the joint effects of these factors are thought to be of key 
importance in the disease development (Lander and Schork, 1994; Kiberstis and 
Roberts, 2002). 
Understanding genetically complex (polygenic) diseases has become a major 
topic in the field of human genetics, since finding mutations that, in concert give rise 
to a disease has proven to be extremely difficult. Most of the attention has been given 
to large-scale association studies and in particular, to the progress made in the 
Human Genome Project and the HapMap project, which have made genome-wide 
association studies (GWAS) feasible (Witkowski, 2010). It is now possible to scan the 
entire genomes of patients and controls for more than 1 million DNA markers (i.e. 
single nucleotide polymorphisms or SNPs) and test these for genetic association. SNPs 
showing a considerable difference between cohorts of affected and non-affected 
individuals and those that are independently replicated can be considered genetic risk 
factors for the disease under study. This hypothesis-free approach has led to the 
identification of many novel, disease-susceptibility loci for a large number of 
multifactorial diseases. All these studies claim to have found new loci or genes and 
many results have already been replicated in independent populations. However, it is 
important to realize that GWAS use SNPs that have high heterozygosity and are less 
sensitive to find effects of low frequency variation. The results are therefore biased 
towards loci or variants that are common (occur frequently), meaning that the specific 
loci or variants do occur at high frequencies. Furthermore, all the recent studies make 
it clear that the common variants identified do not explain more than 20% on average 
of the total attributable risk for these complex diseases (i.e. they have low odd ratios 
(OR) of 1.2-1.5), which is substantially less than the heritability in fact observed for 
most diseases. Yang and colleagues (Yang et al., 2010) have put forward arguments 
that the missing heritability can be explained as a consequence of associations that 
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are too small to be detectable and the bias due to the SNP composition of the 
genotyping arrays ( Ioannidis et al., 2006). In addition to the valid arguments raised by 
Yang et al, we propose an additional explanation:  besides many common weak 
mutations, complex diseases a re also caused by rare, and stronger, mutations. I n  this 
review, we focus on Hirschsprung disease (HSCR) as an example of a complex disorder 
and we discuss what is known about HSCR, and what is expected from technological 
advances in detecting rare causative mutations. Furthermore, we discuss how these 
technologies can be used to find new candidate genes and rare mutations. 
Box 1. HSCR - the d isease 
HSCR is a congenital d isorder characterized ( pathologica l ly) by an absence of enteric 
neurons in the d ista l  part of the gut. This absence leads to tonic contraction of the 
affected segment, i ntestina l  obstruction that results in a fa i lure to pass the first stool 
within 48 hours after birth, vomiting, and massive distension of the proximal bowel (a lso 
cal led megaco lon) or neonatal en terocolit is. Patients a re diagnosed with one of three 
forms: the short-segment form {S-HSCR, approximately 80% of cases) when the 
agangl ionic segment does not extend beyond the upper sigmoid; the long-segment form 
( L-HSCR) when aganglionosis extends proximal to the sigmoid (Amiel et al., 2008); or 
total colonic aganglionosis or even total intestina l  HSCR, which occur in a smal l  m inority 
of patients or (Amiel et al., 2008). One in th ree affected chi ldren a lso has other 
congenital anomal ies, a l though a syndrome d iagnosis is only establ ished in a minority of 
these cases (Brooks et al., 2005) .  
The enteric neurons that form the enteric nervous system (ENS) originate main ly 
from vagal neura l  crest cells that invade the foregu t  and migrate in a rostral to caudal 
d i rection to colonize the entire foregut, midgut, caecu m, and hindgut. These vaga l neural 
crest cel ls give r ise to most of the enteric nervous system. Sacral neural crest cel ls a lso 
make a contribution but 1t is much sma ller. These sacral cel ls migrate in the opposite 
d i rection, caudal to rostral, to colonize the colon (Burns and Douarin, 1998; Anderson et 
al., 2006). I t  is believed that HSCR can be caused by any fai lure i n  the migration, 
prol iferation, d ifferentiation or surviva l in the intest ina l  wa l l  of the progen itors of the 
enteric neurons, the cells that are cal led entenc neura l  crest-derived cel ls or ENCCs 
(Heanue and Pachnis 2007) .  
HSCR and genetics 
The situation as seen in HSCR, a congenital The situation as seen in HSCR, a congenital 
disorder characterized by an absence of enteric neurons in the distal part of the gut, 
resembles many other complex diseases (for a more detailed description of the 
clinica l features of HSCR see Box 1). We see a small proportion of famil ial  cases, 
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whereas the majority of cases are sporadic. Furthermore, HSCR in a substantial 
proportion of cases is associated with other congenital malformations and a 
syndrome diagnosis can be established in some cases (Moore, 2006; Amiel et al., 
2008). The familial (syndromic) cases show a Mendelian mode of inheritance (both 
dominant and recessive), whereas the sporadic cases are believed to have a complex, 
non-Mendelian mode of inheritance (Badner et al., 1990). Since around 1990, most 
attention has been paid to the rare familial and syndromic cases: linkage analysis was 
performed in large multi-generational HSCR families, sib-pair analysis in smaller 
nuclear families, homozygosity mapping in consanguineous HSCR families, and 
genetically isolated populations were used to search for inherited ancestral alleles or 
shared haplotypes putatively carrying mutations (for a review see Brooks et al., 2005). 
Besides these extended family-based approaches, candidate genes were also 
identified based on natural mouse models, created mouse models and gene 
networks. Although these approaches successfully identified mutations in 11 genes, 
only -20% of the cases were explained by the mutations found (see Box 2 for an 
overview of the genes identified). In the last decade, most studies have focused on 
association, using both a case-control design and a trio design, and almost all 
screening isolated HSCR cases (Borrego et al, 2003; Fitze et al., 2003; Sancandi et al., 
2003; Burzynski et al., 2004; Pelet et al., 2005). The association studies focused mainly 
on the major HSCR gene, RET. Haplotype sharing was found for a region of 
approximately 27 Kb, including 4 Kb of the 5'UTR, exon 1, intron 1 and exon 2 of RET. 
It is believed that one or more SNPs within intron 1 are involved in disease 
development (Emison et al., 2005, 2010; Burzynski et al., 2005). One GWAS was 
recently performed in Chinese cases of sporadic HSCR in an attempt to find additional 
loci that contribute to the development of this disease (Garcia-Barcelo et al., 2009). 
As expected a strong association to RET was found. However, two additional SNPs 
located in intron 1 of Neuregulin-1 gene (NRGl) were also found to be strongly 
associated, pointing to NRGl as a plausible candidate gene. Its involvement was 
corroborated by the identification of coding sequence mutations in NRGl. Under an 
additive model, the authors showed that there was significant association between 
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RET and NRGl with an increase in the OR for the RET risk genotype in the presence of 
a heterozygous mutation in NRGl (Garcia-Barcelo et al., 2009). 
Box 2 .  HSCR-associated genes 
Genetic d issection of HSCR was successful in identify ing 11 genes, with RET as the most 
important  one (Edery et al., 1994; Romeo et al., 1994). RET encodes for a receptor 
tyrosine kinase i nvolved in the activation of several downstream pathways. 
Besides RET, ten other genes have been impl icated in the development of HSCR· 
GDNF, NTN, EDNRB, EDN3, SOX10, ECE-1, ZFHXlB, PHOX28, KIAA1279/KBP and NRGl 
( Puffenberger et al., 1994; Angrist et al., 1996; Salomon et al., 1996; Hofstra et al., 1996; 
Edery et al., 1996; Doray et al., 1998; P ingau lt et al., 1998; Hosftra et al., 1999; Cacheux 
et al., 2001; Amie! et al., 2003; Brooks et al., 2005; Garcia-Barcelo et al., 2009) .  
GDNF and NTN encode for the RET l igands, GDNF  and Neurturi n (NTN), necessary for 
receptor phosphorylation and activation of downstream signall ing pathways. EDNR, 
EDN3 and ECE-1 , encode for the endothel in  receptor type B, endothel in 3, and 
endothelin-converting enzyme 1 respectively and they are part of the endothel in 
signa l l ing pathway. SOXlO, ZFHXlB and PHOX28 encode for transcription factors i nvolved 
in R ET and/or EDNRB activation. KIAA1279/KBP encodes for the kines in-b inding protein 
which has recently been i nvolved in  neurona l  d ifferentiation (Alves et al., 2010). F ina l ly, 
NRGl, recently identified (Garcia-Barcelo et al., 2009), encodes for a receptor protei n  
that belongs to the E rb  B fami ly o f  tyrosine k inases. 
For detailed i nformation about these genes and their encoded proteins, see the 
recent  review by Tam and Garcia-Barcelo (2009) 
Can GWAS find the missing heritability? 
It is hypothesized that complex, late onset diseases are driven by the combined effect 
of many mutations, each of which may have only a small effect (Roopers, 2007). 
Patients are therefore believed to carry large numbers of mutations. If this hypothesis 
is true, it means these mutations must be very common in the general population and 
they must therefore be hundreds - if not thousands - of generations old. Finding only 
a small number of loci could be due to a lack of power in the study, so that enlarging 
the case cohorts should lead to additional loci being found. Many consortia are now 
collecting 10,000 samples or more, in anticipation of finding these loci. In a recent 
study on risk factors for coronary artery disease more than 100,000 samples were 
analysed to find 59 new loci (Teslovich et al., 2010). However, these enlargements are 
not without risk. To achieve a very large case cohort, consortia members need to 
combine their separate cohorts, which might have been diagnosed or ascertained in 
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slightly different ways. Moreover, small genetic variations within or between cohorts 
can have strong effects on outcome and replicating results (Ioannidis et al., 2006). 
Although genotyping is very reliable, a small fraction of the SNPs still produce non­
Mendelian genotypes for known and unknown reasons. Due to the high number of 
SNPs tested, there is a possibility that false signals are being generated that are 
indistinguishable from true signals. Although expanding the cohorts will certainly help, 
the loci that will be identified will have an even lower effect than the ones that have 
been found already. Therefore we think that expanding the cohorts will probably not 
result in the identification of SNPs with a high attributable risk for these complex 
diseases. In addition, it should be recalled that association only suggests causation 
and inferring causality from a statistical association is not straightforward. 
� 









200 400 600 800 1000 0 10 1 00 10 00 
Number ol genorallons SUMval disadvantage in % 






survival disadvantage In ,c. 
Figure 1 - Alleles that are associated with a decreased reproductive fitness will reproduce at a lower rate 
compared to alleles with normal fitness. Once a mutation has occurred, survival is in first instance mainly 
determined by chance, because the probability that a specific allele is retained over many generations is very 
low. Once alleles have drifted to a substantial number, adverse or positive selection comes into play. The number 
of descendants of a specific allele many generations later is highly variable, and follows an exponential 
distribution with the property that the standard deviation is equal to the mean. The probability that an allele that 
confers a reduced fitness survives over longer periods compared to the allele with normal fitness is mainly 
determined by selection, where even a low disadvantage will eliminate an allele over time. Most complex 
diseases lead only to a slight decrease in relative fitness which translates into a survival disadvantage dependent 
on the allele frequency and the disease incidence. An example calculation illustrates the effects to be expected. 
For a complex disease with a 2% incidence associated with a dominant allele with 20% allele frequency, giving a 
relative risk of disease of 1.5 compared to homozygotes for the non-disease allele and a reduced fitness of 90% 
for affected individuals, a survival disadvantage can be calculated. From this the expected number of generations 
where the allele frequency is reduced to 1% of its original value can be computed as 6777 generations. If the 
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fitness is 50% reduced, the expected number of generations for a reduction to 1% of its original frequency is 
1343. If the relative risk is 2.0, this number becomes 773 generations. 
Will epistasis give the answers and is it related to the idea that combinations of 
mutations can influence each other in such a way that they enhance the effect of the 
mutations? Although epistasis exists, the combined effects of rare variants will be 
very difficult to detect and, moreover, cannot contribute strongly to the attributable 
risk because the specific combinations with increased risk over the additive risks will 
be relatively rare compared to the individual alleles. 
Was it realistic, from an evolutionary point of view, to assume that GWAS 
could identify many loci that would explain a large part of the genetic risk, or could 
moderate or strong predispositions be expected in the GWAS? Mutations that only 
have a marginal influence on reproductive success will already be selected against in a 
fairly efficient way. A mutation that has a selective disadvantage of only 1 %, will be 
reduced to 1/e = 36% in 100 generations, and to 12% after 200 generations (Figure 1). 
Taking this selection pressure into account and considering the findings from GWAS in 
complex genetic diseases, it seems inevitable that most of the common loci can only 
contribute marginally to the disease risk. Expecting very strong effects fom common 
loci seems unrealistic, or the mutation should provide the carriers with a selective 
advantage. Of course, one could argue that for late-onset diseases, the selective 
advantage is less important compared to early-onset polygenic diseases. However, 
many late-onset diseases, e.g. multiple sclerosis or dementia, also have early-onset 
forms and thus cannot be considered evolutionarily neutral. If we consider alleles with 
a selective advantage, HSCR provides us with a good example. The previously 
mentioned HSCR-associated allele gives homozygous carriers (50% of patients are 
homozygous for this variant), a 20 times higher chance of developing HSCR. As HSCR is 
a congenital disease, this allele can only exist when it gives carriers a selective 
advantage (Emison et al. , 2005, 2010). The strongest argument for a selective 
advantage for heterozygotes for the RET mutation is that the same mutation is 
present in all the investigated populations. This points towards a very early origin, 
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which is inconsistent with an evolutionary disadvantage. However, most data point 
towards a selective pressure driving the frequency of the mild and strongly associated 
mutations down to the rare variant level. Given these considerations, it seems 
realistic to conclude that GWAS will eventually identify only a small part of the total 
genetic risk. We therefore propose a complementary hypothesis, namely that besides 
many weak mutations, rare and strong mutations must contribute to complex 
diseases. 
Rare variants 
In clinical practice, rare variants are encountered fairly often. These variants are 
observed in genes that are suspected because of their functional properties, possibly 
involved in a causal pathway, or based on previously identified associations. The 
number of rare variants present in a population is very high. Simple arithmetic shows 
that under neutral conditions (no selection pressure) the contribution to the 
mutational load of each breeding generation is the same after the point of 
coalescence, where we have a single ancestor (for most human DNA some 100-500 
generations ago). 
The hypothesis that these commonly occurring rare variants are involved in 
complex diseases has some supporting evidence. Two of the early studies were 
described by Frikke-Schmidt and colleagues (Frikke-Schmidt et al., 2004) and Cohen 
and colleagues (Cohen et al., 2004). They sequenced the ABCAl gene, which is known 
to cause a Mendelian form of low HDL-cholesterol levels (Tangier disease), in 
individuals taken from the lower and upper 1-5% tails in a population-based study. 
Non-synonymous rare sequence variants were found to be significantly more 
common in individuals with low HDL-cholesterol than in those with high HDL­
cholesterol, leading to major phenotypic effects being proved to contribute 
significantly to low plasma HDL-cholesterol levels in the general population. These 




How to identify these rare disease-associated variants 
Next Generation Sequencing 
Over the past few years, large-scale sequencing has been revolutionized by the 
development of several so-called next-generation sequencing (NGS) technologies. The 
major strengths of NGS is the fact that tens of mil lions PCR products can be 
sequenced in parallel, generating several hundreds of megabases to tens of gigabases 
of sequencing data per run and making it possible to sequence entire human 
genomes. Several studies have completed whole human genome sequencing and 
resulted in important scientific findings and new insights into human genetic 
variations (Levy et al., 2007; Wheeler et al., 2008; Mckernan et al., 2009; Pushkarev et 
al., 2009). 
For complex disorders, including HSCR, application of NGS has still not been 
reported. It is definitely a very promising approach to find rare coding or non-coding 
variants in identified and in other, unknown genes. In spite of these advantages, one 
could also argue that since genome-wide sequencing generates a huge amount of 
information, it might be hard - even almost impossible - to extract the relevant 
information. This is especially the case because the specificity is still not optimal, 
although the sensitivity for detecting mutations is very high, because most deviations 
from the reference sequence in humans amount to false-positives (Bloksberg, 2008). 
Undoubtedly this will improve over time as artefacts due to DNA processing are 
better recognized and eliminated. In addition, the effects of variations in non-coding 
regions are still difficult to explain and these regions are more likely to have neutral or 
weak effects on phenotypes, even in well conserved non-coding sequences (Ahituv et 
al., 2007; Chen et al., 2007). An alternative approach is to sequence all protein-coding 
regions, also called exome sequencing. This approach has been successfully applied 
for the detection of recessive (Ng et al., 2009, 2010) and de novo mutations (Hoischen 
et al., 2010). With this alternative approach, only 5% of sequencing results will be 
generated when compared to whole genome sequencing. Furthermore, it detects not 
only changes in protein-coding sequences, but also splice acceptor and donor sites; 
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these represent an additional class of sequences that are enriched for highly 
functional variation and are also targeted by this method (Ng et al., 2010). 
Filtering next generation sequencing data for candidate genes 
If exome sequencing is the method of choice, the number of non-synonymous coding 
and flanking intronic rare variants that wil l  be detected wil l  be very large (thousands 
of such variants can be expected, see for instance Ng et al., 2009, 2010). 
A first step in the selection procedure might be a statistical one. One could 
determine which genes contain more mutations in cases than in controls (for an 
example of such an approach see Johansen et al., 2010). The power to detect an 
excess of rare variants depends on differences in the mutational load of cases and 
controls. We assume that cases and controls are sampled under the null hypothesis 
that they come from the same population. The power of such studies is high. For 
instance, when analysing two groups of 500 people for a stretch of 100,000 bases, and 
a time to coalescence of 1000 generations, we expect the number of mutations seen 
in the controls to be : E(mutations) = mutation rate per generation per base x number 
of generations to coalescence x number of people observed. Being (#) the number of 
people observed and (") the number of cases detected: E(mutations) = 2.5X10-8 # x 
108 x 500 
,, 
= 1250. If we assume that the mutation rate in the descent tree for cases 
for this particular stretch of bases is 10% higher (2.75x10-8),  then we would expect to 
see 1375 mutations in the case group. The excess of 125 mutations is 3.5 X the 
expected standard deviation using a Poisson model and indicates that there is 
substantial power to detect such increases. Variants with a higher relative risk will 
improve the power of such a study, due to the possibility of linking cases through 
haplotype sharing. It would be interesting in such kind of studies to make a 
comparison between the expression levels of the highly mutated genes in cases and 
controls. One would expect to find loss-of-function mutations, which is consistent 
with lower expression of the highly mutated genes (in cases). 
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Another option to reduce the number of variants is to focus on mutations in 
candidate disease genes. As complex diseases are probably caused by mutations in 
genes that participate in specific protein-networks, identification and analysis of the 
gene-networks is essential in understanding the genetic aspects of a complex disease. 
This idea, that disease-associated proteins are interconnected, can be nicely 
illustrated by the proteins involved in HSCR. In Box 3 we show that for HSCR almost all 
the disease-associated proteins interact which each other directly or indirectly. We 
therefore believe that identifying and analyzing these protein-clusters is also essential 
in understanding a complex disease. A systems biology approach, in which protein 
networks or protein interactions are searched for, using a number of a layers of 
information (often 'omics' datasets) might be the best choice to select these 
candidate disease genes. These layers of information could consist of genetic data 
(association or linkage data), expression data, protein-network data, or proteomics 
data. 
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Box 3. I nteractions between the known HSCR p.:ithways 
Several genes have been imp l icated i n  HSCR development ( Box 2 ) .  Although a first look at 
the p rote ins encoded by these genes shows no apparent connect ion between them, the 
majority of these genes can be d ivided ,nto three groups: those involved i n  RET activation 
p.:i thways (RET, GDNF, NTN), t11ose i nvolved in EDNRB  pathways (EDNRB, EDN3, ECE-1), 
and transcription factors that can affect both RET and/or EDNRB pathways (SOXlO, 
ZFXHlB, PHOX2B). There is i ncreasing evidence to show that the proteins encoded by 
these genes are i ntercon nected. A genome-wide association study, us ing 43 trios from a 
geneti cal ly isolated Mennon i te popu lation, reported statisti cal ly s ignificant joint 
transm ission of RET .:ind EDNRB a l leles ( C.:irrasqui l lo et al. ,  2002). Furthermore, mice 
homozygous for the recessive hypomorphic al lele of Ednrb (EdnrbS or Piebald) and 
heterozyr:1ous for a Ret nul l  mutation (Ree ·i showed high frequencies of aganel ionosis. 
These find ings are suggestive of epistasis between EDNRB and RET ( Carrasqu i l lo et al., 
2002), and this idea was fu rther supported by work on RET/EDNRB mouse crosses 
(McCa l l  ion et al. , 2003). S imi lilr  studies showed that, whereas Ret"1;,: a nd  Edn3;,;i·. ( lethal 
spott ing) mice display colonic agangl ionosis, combinations of these mutant  a l leles lead to 
u lmost complete i n test 1nul aga ngl ionosis ( Barlow el al., 2003) .  
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Para l lel to these f ind ings, it was observed that GDNF  and EDN3 have opposite 
effects duri ng the development of the enteric nervous system :  GDNF promotes the 
pro l i fe ra tion of m igril tory NCSCs and encourages d i fferentic1t ion (Hearn et al., 1998; 
Barlow et al., 2003 ), whi le EDN3 has been shown to modulate GDNF  activity to i nh ib it  
d i fferentiation (Hearn et al., 1998; Wu et al., 1999) .  Since the effects of EDN3 on both 
prol iferation and chemoattraction could be m imicked by Protin K inase A ( PKA) inhibitors, 
it was suggested that PKA might serve as u connect ion l ink between RET a nd EDNRB 
signil l l ing (Barlow et al., 2003 ) .  A cri tica l role for PKA was a l so  suggested by the NCSC 
m igration defects and agangl ionosis phenotypes observed when the putative PKA-bind ing 
site of RET, serine 697, was mutated (Asai et al., 2006) .  
The transcription factor SOXlO is i nvolved in  the regu lation of both RET and 
EDNRB expression (Pattyn et al. , 1999; Zhu et al., 2004, Heanue und Pachnis, 2007). 
PHOX28 is a lso a transcription factor that is expressed in several classes of d ifferentiat ing 
neurons of both the peripheral and central nervous systems .  M ice with a homozygous 
d is ruption of PhoxZb showed no enteric ganglia and no RET expression which suggests 
that PHOX2B m ight p lay a regulatory role in RET expression ( Pattyn et al., 1999; Brunet et 
al. , 2002). 
KBP m ight a lso l i nk  to the other prote ins involved in HSCR development due to its 
i nteraction with SCG lO {Alves et al., 2010) .  SCGlO activity can be control led by 
phosphorylation of specific serine res idues by PKA (Togano et al., 2005) .  Possibly PKA is 
not only the miss ing l ink between the RET und the EDNRB pathway, but it m ight a lso 





Figure 2 - Scl1ernatic representation of possible interactions between HSCR-related genes. 
81 
Chapter 4 
A good example of such a systems biology approach has been described for 
Parkinson's disease, as explained in Box 4. A similar systems biology approach might 
provide insights into HSCR disease, pinpointing possible disease-associated genes. In 
such a study for HSCR we could include: four genomic regions, loci identified by sib­
pair analysis, identity-by-descent (IBD) mapping and linkage analysis in 3p21, 4q31.3-
q32.3, 9q31, 16q23 and 19q21 (Bolk et al., 2000; Gabriel et al., 2002; Carrasquillo et 
al., 2002; Brooks et al., 2005; Brooks et al., 2006); many potential loci as identified by 
GWAS (on data of the International HSCR Consortium, Garcia-Barcelo et al., 2009); the 
known protein-networks for RET, EDNRB, KBP, ErbB and the genes whose expression 
is (partly) regulated by the identified transcription factors (see Box 2); and expression 
profiling studies of neural crest stem cells isolated from the gut (Heanue and Pachnis, 
2006 and Iwashita et al., 2003). Further analysis of these expression datasets and 
comparable datasets currently being generated with new bioinformatic tools such as 
the TSR-finder (transcriptional system regulation) might reveal new and as yet 
unknown interactions. TSR-finder, a bioinformatics tool developed in-house 
(Fehrmann et al., 2008) is based on the correlation structure of expression variation in 
over 17,000 published arrays. It can detect clusters of genes and thereby identify 
systematic changes of expression in gene-clusters with a minimal, but consistently, 
low expression. 
How to prove the pathogenic nature of the presumed disease associated rare 
variants? 
When the best candidate genes are selected, one can start analysing the identified 
rare variants in these genes both by in silica methods and by functional assays. In 
silica predictions can be applied in a disease- and gene-independent manner. The 
functional assays, on the other hand, are gene- and disease-dependent. Below we will 
briefly discuss possible approaches to study newly identified, mutant HSCR genes. 
82 
HSCR as a complex disorder 
Box 4. Systems biology helps in understanding Parkinson's d isease 
A successful examp le of this type of approach came from the study of Parkinson's d isease 
(PD) .  P revious studies had reported that genetic variabi l i ty in  the axon guidance pathway 
might be a contributing factor to the cause of PD ( Livesey and H unt, 1997) . Furthermore, 
GWAS had identified the most s ignificantly associated SNP for PD susceptibly i n  SEMA5A 
(Maraganore et al., 2005), a gene known to encode a protein that interacts with several 
other proteins from the axon guidance pathway (Chilton JK, 2006). These two results 
reinforced the idea that the axonal guidance pathway was involved in the development of 
PD. To confirm this result, Lesnick et al., employed bioinformatics methods to ana lyse a 
whole-genome association dataset for SNPs that were within bra in - expressed, axon­
guidance pathway genes ( Lesnick et al., 2007). They identified 128 such genes and found 
1,460 SNPs based on the SNP dataset i n  117 of those genes. By us ing a mu lti-stage 
process to predict PD susceptib i l ity, they found that of the 1,460 SNPs identified, 183 
were ind iv idual ly associated to PD susceptib i lity. Furthermore, by us ing an expression 
profiling dataset they found that 13  of these genes were differentia l ly expressed in at  
least one of the three regions of the bra in affected by PD (eight in the substantia n igra, 
one in the putamen, and fou r  in the caudate) compared to controls ( Lesnick et al., 2007). 
In silica prediction of newly identified rare variants 
To verify the putative pathogenic nature of the identified coding variants (amino acid 
changes), one can start by checking online (locus-specific) databases and by analysing 
these variants by in silico prediction programs such as PolyPhen, Sift or Grantham. As 
coding variants might also disturb or create a splice-site, splice-site prediction 
programs such as Netgene2, Splicesitefinder, and Splicesite predict should be checked. 
For the non-coding variants one might look for the disruption or creation of regulatory 
sequences such as transcription factor binding sites by using, for instance, 
Matslnspector. As non-coding variants might also disrupt or create spice-sites they 
should be analysed by the splice-site prediction programs as well. 
Functional assays for newly identified HSCR mutated genes 
If the in si/ico analysis predicts the coding variant to be possibly pathogenic, the 
variant should be further analysed using functional assays. These assays can be highly 
gene-specific but, in the case of HSCR, one might also try a more general approach, 
such as in vitro differentiation assays using neural crest stem cells (NCSCs), as 
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described by Metzger et al. (2009). It would be even better to determine whether the 
new (mutated) HSCR candidate genes are involved in gut colonization by NCSCs, by for 
instance grafting of NCSCs carrying the mutation on aganglionic explants. All these 
experiments should, of course, be carried out by comparing wild-type and mutant 
gene constructs. 
If the in silica assays predict that a non-coding variant disturbs a transcription 
factor binding site, several assays can be performed to determine the effect of the 
identified variant on gene expression. Promoter studies could be performed to 
determine the effect of the mutation on promotor activity. Electrophoresis mobility 
shift assays could be used to study the potential effect of transcription factor binding, 
complemented by supershift assays if the transcription factor binding to the identified 
sequence element can be predicted. Alternatively, if no functional supershift 
antibodies are available, DNA pull-down assays could be performed. 
If the outcomes are still in favour of an involvement in disease development, 
these assays might be followed by the development of animal models, which would 
give greater insight into how the newly identified genes contribute to the disease's 
development (Telslovich et al., 2010). 
Conclusion 
Unravelling the genetics of complex, polygenic diseases is proving extremely difficult. 
Combinations of common and rare variants probably contribute to disease 
development and the identification of the disease-associated variants is far from easy. 
We have outlined a way to find rare disease-associated variants, making use of a 
statistical selection procedure followed by a systems biology approach, in 
combination with next-generation exome sequencing. To validate the findings, we 
discussed the need for performing functional analysis of the variants in the selected 
genes. 
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RET (REarranged during Transfection) is a proto-oncogene that encodes a receptor 
tyrosine kinase, which is expressed in neural crest-derived cell lineages. Specific RET 
mutations result in a ligand-independent activation of the encoded RET protein and 
cause the inherited cancer syndromes Multiple Endocrine Neoplasia types 2A and 2B 
(MEN2A, MEN2B) and Familial Medullary Thyroid Carcinoma (FMTC). As different RET 
mutations result in different disease phenotypes, we hypothesize that these 
mutations have different effects on downstream signalling pathways. To test this 
hypothesis, HEK293 cell lines stably expressing RET wild type and the most common 
mutations found in MEN2A (RET609, RET620, RET634), MEN2B (RET918) and FMTC 
(RET791, RET891) under control of the Tet-On system, were generated and analysed 
on a peptide array consisting of 1024 different kinase substrates. Our results showed 
that there are significant differences between cells expressing RET mutants and wild­
type RET. All mutants showed activation of the canonical RET signalling pathways via 
Pl3 Kinase/Akt, MAP kinase and the Rae pathways. However, we were also able to 
identify specific alterations for some of these mutants. We saw an increase in FAK 
phosphorylation levels for the RET918 mutant, and detected a decrease in receptor 
internalization for RET891. We also observed that mutations associated with the same 
phenotype exhibit different signalling properties, as small differences in activation 
levels of shared pathways were detected. In conclusion, our results showed that 
differences in the signalling pathways between wild-type RET and different types of 
MEN2 do exist, confirming the hypothesis that different RET mutations have specific 
effects on downstream signalling pathways. Furthermore, it also shows that 
differences in clinical phenotype are not only due to differential activation of 
canonical RET signalling pathways, revealing a hitherto unrecognised role of non­
canonical RET signalling in clinical phenotype. 
Keywords: MEN2, RET, mutations, kinome profile, signalling pathways 
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Introduction 
RET (REarranged during Transfection) is a proto-oncogene that encodes a receptor 
tyrosine kinase which is expressed in neural crest-derived cell lineages (Marcos and 
Pachnis, 1996). RET plays a central role in several intracellular signalling cascades that 
regulate cellular survival, differentiation, proliferation, migration, and chemotaxis (de 
Groot et al., 2006). These cascades are initiated upon RET activation, a process that is 
unique among receptor tyrosine kinases as it requires a multi-protein complex instead 
of common, direct receptor/ligand activation (Plaza-Menacho et al. , 2006). The RET 
activation complex is formed in two steps. The first step starts when a soluble ligand 
of the glial cell-line derived neurotrophic factor (GDNF) family, (GDNF or one of its 
homologues, neurturin, artemin or persephin), binds to a glycosyl­
phosphatidylinositol membrane anchored co-receptor of the GDNF  family receptor 
(GFRa 1-4) (Jing et al., 1996; Airaksinen et al., 1999). The second step consists of 
interaction of this complex with RET, leading to its autophosphorylation on specific 
tyrosine residues (Manie at al., 2001). The complex formation and activation takes 
place in the lipid rafts (Manie et al., 2001). 
Specific mutations in RET result in a ligand-independent activation of the 
encoded RET protein, giving rise to the development of the cancer syndrome Multiple 
Endocrine Neoplasia type 2 (MEN2). MEN2 is a dominantly inherited cancer syndrome 
that can be divided into three subgroups: MEN2A, MEN2B and Familial Medullary 
Thyroid Carcinoma ( FMTC), based on the clinical features and tissues affected 
(Hansford et al., 2000). 
Activating mutations can occur in distinct domains of the RET protein and, 
depending on their location, they are associated with either MEN2A, MEN2B or FMTC. 
Mutations located in the cysteine-rich domain of the extracellular part of RET (codons 
611, 618, 620, 630 and 634), are generally involved in the development of MEN2A. 
Mutations located in the intracellular tyrosine kinase domain are associated with the 




The observation that specific RET mutations result in different disease 
phenotypes, might be explained by alterations in signalling through diverse 
downstream pathways. Moreover, these altered signalling profiles might be shared 
between mutations associated with the same phenotype. If true, identifying the 
specific signalling pathways associated to different RET mutations and consequently 
to different phenotypes, can provide important clues to the design specific kinase 
inhibitors for treating MEN2 subtypes. 
Previous studies have already explored this effect showing that there are 
indeed differences in the downstream signalling via activation of these mutants 
(Iwashita et al., 1999; Schuringa et al., 2001; Plaza-Menacho et al. , 2005; Plaza­
Menacho et al. , 2007). 
To further investigate this hypothesis we looked for protein phosphorylation 
profiles specific for the most common mutations found in MEN2A (RET609, RET620, 
RET634), MEN2B (RET918) and FMTC (RET791, RET891), using a peptide array 
consisting of 1024 different kinase substrates. We have previously shown that the 
kinome profiling is a powerful tool to generate descriptions of cellular signalling and 
to elucidate the pathways involved in different pathogenesis (Parikh et al., 2010; 
Parikh et al., 2009; Diks et al., 2004). With this approach, we aim to find a more 
significant relationship between specific mutations and different MEN2 phenotypes. 
Moreover, we will try to explain these differences based on downstream signalling 
pathways, providing new insights into the RET signalling network. 
Materials and Methods 
Expression vectors 
pTRE2hyg-RETWT was generated by PCR amplification of RETWT from pRC-CMV­
RETWT (Plaza-Menacho et al., 2005) using the primers RETwtF and RETwtR (Table 1). 
fcoRV-Notl restriction sites included respectively in RETwt forward and RETwt reverse 
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primers (underlined sequences), were used to clone RETWT into pTRE2-hyg vector 
(ClonTech). 
pTRE2hyg-RETC609Y, pTRE2hyg-RETC620R, pTRE2hyg-RETC634R, pTRE2hyg­
RETY791F, pTRE2-RETS891A and pTRE2hyg-RETM918T were generated from the 
pTRE2hyg-RETWT vector by site-directed mutagenesis according to the 
manufacturer's instructions (QuickChange site-directed mutagenesis kit, Stratagene) 
using the primers listed in Table 1. Following mutagenesis, the entire RET insert was 
checked by sequencing. 
Primer name Sequence 
RETwtF CATGTAGCGGCCGCATGGCGAAGGCGACGTCCGG 













Table 1. List of primers. 
Cell culture and transfection 
HEK293-Tet-On cells (ClonTech) were cultured in DMEM high medium containing 4.5 
g/L of glucose, L-glutamine and pyruvate (Gibco), supplemented with 10% fetal calf 
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serum (Tet-On system approved FBS, ClonTech), 1% penicillin/streptomycin (Gibco) 
and 100 µg/ml Geneticin (Gibco). 
To generated HEK-Tet-On RET stable cell lines, 1.500.000 HEK293-Tet-On cells 
were seeded in 10 cm dishes (Greiner) and transfected with 5 µg RET wild-type, 
RETC609Y, RETC620R, RETC634R, RETY791F, RETS891A and RETM918T expression 
vectors, using jetPei (Promega). 24 hours after transfection, cells were washed and 
cultured in HEK293-Tet-On medium containing 100 µg/ml of the selection agent, 
hygromycin (Gibco). Massive cell death was observed 5 days after selection and 10 
days after selection, clones were picked and screened for the presence of RET by 
Western blotting. All cells were cultured at 37°C and 5% CO2. 
Stimulations, cell lysates, and Western blot analysis 
Before lysis, cells were incubated for 24 hours with 1 µg/ml doxycicline (ClonTech) 
after which they were stimulated for 20 minutes with GDNF (20 ng/ml, Prepotech) 
and GFRa 1 (100 ng/ml, R&D systems) in serum free medium. Stimulations were 
terminated by an ice-cold phosphate buffered saline wash and cell lysates were 
prepared by incubation with lysis buffer (m-Per, Thermo Scientific) containing 
protease (Thermo Scientific) and phosphatase (Thermo Scientific) inhibitors, for 30 
min on ice. Cell lysates were collected by scraping and cleared by centrifugation at 
14,000 rpm for 10 min in a pre-cooled (4°C) centrifuge. Supernatants were stored at -
80°C before they were processed further for SOS-PAGE followed by Western blot 
analysis. The following antibodies were used: RET (H-300), p-RET (Y1062) (Santa Cruz 
Biotechnology); p-ERK, p-JNK, p-p38, p-mTOR, p-p70S6 kinase, p-PDK1, p-Akt, p-PAK2, 
p-FAK (Cell Signaling); and actin (C4, MP Biomedicals). Secondary antibodies used 
were goat anti-rabbit lgG-HRP and goat anti-mouse lgG-HRP (Bio-Rad). 
Proliferation assays 
HEK-Tet-On RETWT, HEK-Tet-On RET609, HEK-Tet-On RET620, HEK-Tet-On RET634, 
HEK-Tet-On RET791, HEK-Tet-On RET891 and HEK-Tet-On RET918 were seeded in 96-
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well plates (10,000 cells/well) containing complete medium used for culture of HEK­
Tet-On RET cells (previously described). Doxycycline was added 24h after and cells 
were incubated for 48 and 96 hours. Cell proliferation was measured using a cell 
proliferation kit (MTT assay, Roche) according to the manufacturer's instructions. 
Soft agar colony formation assays 
2500 cells of HEK-Tet-On and HEK-Tet-On RET mutants, RET609, RET620, RET634, 
RET918, and RETWT, were mixed with 1.5 ml of 0.7% agarose (Eurogentec) and 1.5 ml 
of DMEM containing 20% FBS, 2 µg/ml doxycycline, 200 ng/ml of GFRa. 1 and 40 
ng/ml of GDNF. 1ml of this mixture was platted in triplicate in 6-well plates previously 
coated with 1 ml of 0.5% agar (Becton, Dickinson (BD)) and DMEM medium containing 
20% FBS. Cells were fed twice a week with 500 µI of culture medium and incubated 
for 25 days in an incubator at 37°C and 5% CO2. Each well was stained with 0.5 ml of 
0.005% Crystal Violet for 2 hours and the cells were analysed in a stereo microscope 
(Leica-MZ75). 
Kinome array analysis 
The protocol of the kinome array is described in detail on the website 
(http://www.pepsca n presto.com/files/PepCh ip%20Kinase%20Lysate%20Protocol_ vs. 
pdf). 
Data acquisition and statistical analysis of the PepChip array 
After drying, the glass slides were exposed to a phosphor-imager plate for 72 hours. 
Acquisition of the peptide array was performed using a phosphor-imager (Storm; GE 
Healthcare). The level of incorporated radioactivity, which corresponds to the 
phosphorylation status, was quantified by array software (ScanAlyze; Eisen Software) 
and as described elsewhere (Diks et al., 2004; Diks et al., 2007; Lowenberg et al. , 
2005; van Baal et al., 2006). Different kinase activities of the lysates from the RET 
wild-type, RET609, RET620, RET634, RET791, RET891 and RET918 cell lines were 
95 
Chapter 5 
determined by significant fold change ratios of the combined values of 
phosphorylated peptides, as previously described (Parikh et al., 2009; Fuhler et al., 
2010). 
Flow cytometry analysis 
After doxycycline incubation and stimulation with GDNF and GFRa 1, HEK293-Tet-On 
cells stably expressing RETWT, RET791 and RET891 were collected by resuspension in 
PBS and transferred to a FACs tube. Cells were washed with PBS containing 1% BSA 
and centrifuged for 5 min at 1000 rpm in a pre-cooled centrifuge. An antibody 
recognizing the extracellular domain of RET (H-300) was added (1:50) and cells were 
incubated for 1 hour at 4°C. Cells were washed twice and incubated for 30 min with a 
goat a- rabbit FITC secondary antibody (Jackson Labs). Cells were washed twice and 
fixed with 4% paraformaldehyde. Flow cytometry was performed using the FACS 
Calibur (BD Biosciences), and data was analysed using Flowjo software. 
Results 
Properties of the different RET mutants 
To study the signalling properties of the different RET mutations, we used a system in 
which RET expression can be induced by doxycycline. As the host cell line, we used 
Human Embryonic K idney cells (HEK293). Since HEK293 does not endogenously 
express RET, the use of this cell line provided us with a clean background to study the 
effect of each mutation on downstream pathways without interference of the 
endogenous protein. Seven double-stable cell lines were created expressing the most 
common MEN2A (RET C609Y, C620R, C634R), MEN2B (RET M918T) and FMTC (RET 
Y791F, S891A) mutations. 
To analyse the levels of RET expression and RET activation of the different 
mutants, cells were incubated with doxycycline in order to induce RET expression. 
After 24 hours, GDNF and GFRa were added and cells were incubated for 20 minutes. 
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This time point was chosen because RET has been reported to reach a peak in 
phosphorylation between 15-30 min after GDNF/GFRa. stimulation (Richardson et al., 
2006). Doxycycline induced RET expression and RET phosphorylation on tyrosine 1062 
in all clones. However, in some clones, RET was expressed in the absence of 
doxycycline (Fig. lA). RET mutants harbouring the same type of mutation with similar 
levels of RET expression differed in their levels of activated RET. For MEN2A mutants, 
RET609 displayed the lowest levels of RET phosphorylation, while RET620 and RET634 
showed similar, high levels of RET phosphorylation. For FMTC mutants, levels of RET 
and phosphorylated RET were equivalent for RET791 and RET891, and they were the 
mutants showing the lower levels of RET expression and RET phosphorylation. For 
MEN2B mutation RET918, RET expression levels were similar to MEN2A mutants, 
however, the level of Y1062 phosphorylation was higher for the MEN2B mutant (Fig. 
lA). 
Next, the effect of mutant RET expression on the cellular proliferation rate 
was determined. After two days of doxycycline induction almost no change was seen 
between the mutants and the wild-type cell lines. However, after four days both the 
MEN2A and the MEN2B mutants showed higher proliferation rates compared to RET 
wild-type (RETWT). For the FMTC mutants, there was almost no increase in 
proliferation after four days' incubation (Fig. 1B). 
To measure the capacity of these cells to proliferate, anchorage-independent, 
soft agar assays were performed. Cells were cultured for 25 days and analysed for the 
presence of foci. Interestingly, the highest number of foci were observed for the most 
aggressive RET mutations (de Groot et al., 2006) (RET609, RET620, RET634 and 
RET918) (Fig. le). For FMTC mutants, although the number of foci was higher that of 
wild-type RET expressing cells, fewer colonies were observed compared to MEN2A or 
MEN2B mutants (Fig. le). 
To summarize, RET mutants harbouring a MEN2B or a MEN2A mutation have 
higher RET phosphorylation levels, increased cell proliferation, and anchorage­
independent growth properties compared to FMTC mutants and wild-type RET. These 
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results are in agreement with the disease phenotype associated with the different 
mutations in which the most aggressive phenotype is observed for MEN2B and 
MEN2A mutations. 
A) MEN2A FMTC MEN2B 
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Figure 1 - Different properties of RET Tet-On stable mutants. A) Western blot analysis of the HEK293-Tet-On RET 
stable cell lines expressing RET wild-type (WT) and six d ifferent RET mutations involved in the development of 
MEN2A (RET609, RET620, RET634), FMTC (RET791, RET891) and MEN2B (RET918) shows that RET is expressed at 
higher levels when doxycycline is present (+). Phosphorylated RET is almost exclusively detected in the presence 
of doxycycline. (B) Cell proliferation of HEK293Tet-On RETWT and the different mutants was analysed after 
stimulation with GDNF, GFRa and doxycycline for two and four days. After two days of culturing almost no 
change in proliferation was seen between the mutants and the WT cell lines. However, after four days both 
MEN2A and MEN2B mutants showed higher proliferation rates compared to the WT. For the FMTC mutants, 
there was almost no increase in proliferation after four days of incubation. C) Soft agar assays performed for the 
different RET expressing cell lines, showed that the MEN2A and the MEN2B mutants are the ones with stronger 
invasive properties in comparison with the FMTC mutants and RETWT. Hek293-Tet-On cells were used as a 
negative control, since they do not endogenously express RET. 
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MEN2A, MEN2B and FMTC RET mutants show distinct kinome profiles that are 
different from the wild-type RET. 
To gain insight into the differences in signal transduction properties of mutant RET 
receptors, the kinome of cells expressing different RET mutations, MEN2A mutants 
(RET609, RET620, RET634), MEN2B mutant (RET918) and FMTC mutants (RET791, 
RET891) was determined. We analysed all cell lines in the presence (+) and absence (-) 
of doxycycline (Fig. lA). Each kinome was compared with cell lines expressing wild­
type RET. All cell lines were activated with GDNF and GFRa. The profiles were 
generated by incubating each cell lysate onto an array exhibiting 1024 different kinase 
substrates spotted in triplicate, with 33P-gamma-ATP. In each experiment, the amount 
of protein incubated in each array was corrected for relative RET expression based on 
the Western blotting analysis (Fig. lA), in such a way that the amount of RET protein 
used for the arrays was nearly the same for all the different cell lines. The arrays 
incorporated substantial amounts of radioactivity and in figure 2A, a representative 
phosphor-imager scan of the generated kinome profiles for RET918 in the presence 
and absence of doxycycline is shown. Kinome profiles were generated in duplicate, 
with the average Pearson product moment correlation coefficient between the 
replicates greater than 0.85 in all experimental groups. 
From qualitative comparison of the four experimental groups, it appeared 
that the profiles of the mutants were substantially different from wild-type RET 
expressing controls, with correlation values not exceeding 0.4 (Fig. 2B). On the other 
hand, the profiles of the mutant RET cells grouped together were surprisingly similar, 
with FMTC and MEN2B being the most different from each other (Fig. 2B). Clustering 
analysis of the kinome profiles according to Johnson (Johnson MS, 1967) confirmed 
this trend, with all the mutants clustering together and away from the wild-type 
receptor (Fig. 2C). 
Additionally, for tyrosine phosphorylation we determined patterns of the 
different mutants by Western blotting using a general phosphotyrosine antibody (p­
Y). We observed that, although there are many bands in common between the 
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mutants and the wild-type samples, each mutation has its own specific pattern of 
phosphorylation, supporting the idea that different mutations have different 
signal l ing properties resulting in specific phosphorylation patterns that are 
distinctfrom the wild-type receptor (Fig. 2D). 
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Figure 2 - Kinome profile of RET wild-type and different RET mutants. A) Representative phosphor-imager scans 
of the peptide arrays after incubation with lysates of HEK293-Tet-On RET918 in the presence (+) and absence (·) 
of doxycycline. B) Qualitative comparison of the kinome profiles of the four experimental groups studied showed 
substantial d ifferences between the mutants and wild-type RET, with correlation values not exceeding 0.4. On 
the other hand, the profiles of the different RET mutants were surprisingly similar, with FMTC and MEN2B being 
the most different from each other, and MEN2A and FMTC the most similar. C) Clustering of kinome profiles 
reveals that MEN2A and FMTC mutants are the ones with a higher similarity to each other, while MEN28 
presented a more distinct profile. D) Western blot analysis of the phosphorylation status of the different mutants 
in the presence and absence of doxycycline, using a p-Y antibody showed clear differences in the 
phosphorylation patterns when RET expression is switch on. Furthermore, different RET mutants showed 
different phosphorylation patterns in comparison to other mutants and to the wild-type. 
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Extracellular mutations lead to activation of the Map kinase, Pl3 kinase and RAC 
pathways 
To gain insight into the signalling pathways activated by the RET receptor containing 
extracellular mutations (RET 609, RET620, RET634), we first compared the kinome of 
these mutant cell lines with the wild-type RET kinome in the presence (+) and absence 
(-) of doxycycline. Significant changes in phosphorylation of 37 peptides specific for 
RET609+ were observed after correcting for phosphorylation changes in the RET609-, 
RETWT- and RETWT + (Fig. 3A). Only nine peptides showed changes in phosphorylation 
both in the RETWT+ and RET609+ cells (after correction for changes in RETWT- and 
RET609-). Similarly, the RET620+ showed 39 differentially phosphorylated peptides as 
compared to RETWT-, RETWT+ and RET620- (Fig. 3A). RET620+ and RETWT+ only 
shared eight peptides in common. Finally, RET634+ showed unique phosphorylation 
of 37 peptides with nine peptides shared with the RETWT + (Fig. 3A). 
One of the most prominent effects observed with all MEN2A mutants was the 
consistent phosphorylation changes in MAP kinase, Phosphoinositide 3-kinase (Pl3 
kinase) and Rae pathways. A list of peptides can be found in Supplementary table 1. 
The activity of a number of altered kinases involved in these pathways was verified by 
Western blotting. Consistent with the kinome array data, the Western blot analysis 
showed an increased phosphorylation of p38 and ERK kinases for the RET620 and 
RET634 mutants compared with RETWT (Fig. 3B, 3E). For the RET609 mutant, 
although there was an increase in ERK phosphorylation, no effect was observed on 
p38 kinase, as predicted by the kinome arrays (Fig. 3B, 3E). The kinome arrays also 
indicated a significant change in the Pl3 kinase pathway. By Western blotting we 
observed that the RET609 mutant presented an increase in phosphorylation of 
members of this pathway, namely Akt, PDKl and a slight increase in mTOR. The 
RET620 and the RET634 mutants also showed an increase in the levels of PDKl and 
mTOR phosphorylation and a slight increase on Akt and p70S6 kinase compared to the 
wild-type (Fig. 3C, 3E). Differential activation of the Rae pathway was also observed on 
the kinome arrays and Western blot analysis of its downstream substrate p21 
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activated kinase 2 (PAK2) confirmed these observations. Both RET620 and RET634 
showed an increase in phosphorylation for PAK2, while RET609 showed a decrease in 
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Figure 3 - Signalling pathways associated with MEN2A mutations. A) Venn diagrams showing similarities and 
differences (in numbers of peptides) in the kinome profile of different MEN2A mutations: RET609, RET620 and 
RET634. B) Western blot results confirmed activation of the Map kinase pathway, C) the Pl3 kinase pathway, and 
D) the Rae pathway for all the MEN2A mutants in comparison to RETWT. E) Semi-quantification of the band 
intensity corresponding to individual signalling proteins as determined with lmageJ software. The intensity value 
obtained for each band was divided by the intensity of the �-actin band from the same lysate to obtain a ratio. 
The ratio for each protein was then subtracted from the ratio obtained when no doxycycline stimulation was 
present. This value was compared between the different mutants and the wild-type. The figure shows a trend for 
increased phosphorylation levels for all the mutants compared to the wild-type. HEK-Tet-On cells were used as a 
negative control as they do not express RET. (+) and (-) correspond respectively to the presence or absence of 
doxycycline stimulation. 
MEN2B mutation leads to a specific activation of FAK 
The kinome profile of the most aggressive mutation, RET M918T, is qualitatively 
different from the kinome of the wild-type RET in the presence (+) and in the absence 
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(-) of doxycycline, as expected. Significant changes in phosphorylation of 51 peptides 
were identified for the RET918+ after correction for phosphorylation changes in the 
RET918-, RETWT- and RETWT+. Moreover, only six peptides showed changes in 
phosphorylation in both RETWT+ and RET918+ cells (Fig. 4A). 
Similar to the MEN2A mutants, phosphorylation changes in the MAP kinase, 
the Pl3 kinase and the Rae pathways were consistently observed for the RET918+ 
mutant. Moreover, a change in phosphorylation of the Focal Adhesion Kinase (FAK) 
and Aurora Kinase B were also seen for the MEN2B mutant (Supplementary table 2). 
FAK is involved in cell migration cell adhesion and proliferation (Cai et al., 2008), and 
Aurora Kinase B is a serine/threonine kinase required for chromosome segregation 
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Figure 4 - Signalling pathways associated with MENZB mutations. A) Venn diagrams showing similarities and 
differences (in number of peptides) in the kinome profile of the MEN2B mutant, RET918, compared to the wild­
type. B) Western blot results confirmed activation of the Map kinase pathway, C) the Pl3 kinase pathway, and D) 
the Rae pathway for the MEN2B mutant in comparison to RETWT. E) Specific increases in the levels of 
phosphorylated FAK on tyrosine 397 {Y397) were confirmed by Western blot for RET918. F) Semi-quantification 
of the band intensity corresponding to individual signalling proteins as determined with lmageJ software. The 
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intensity value obtained for each band was divided by the intensity of the 13-actin band from the same lysate to 
obtain a ratio. The ratio for each protein was subtracted from the ratio obtained when no doxycycline 
stimulation was present. This value was compared between the different mutants and the wild-type. The figure 
shows a trend for increased phosphorylation levels for all the mutants compared to the wild-type. HEK-Tet-On 
cells were used as a negative control as they do not express RET. (+) and (-) correspond respectively to the 
presence or absence of doxycycline stimulation. 
By Western blotting we were able to confirm that the phosphorylation levels of the 
MAP kinases p38, ERK and JNK were up-regulated in the RET918 mutant compared to 
the RETWT (Fig. 4B, 4F). An increase in phosphorylation of the kinases involved in the 
Pl3 kinase pathway (Akt, PDKl, mTOR and p7056 kinase) and the Rae pathway (PAK2) 
was also observed (Fig. 4C, 4D, 4F). A change in the levels of phosphorylated FAK was 
exclusively detected for the RET918+ and this change was confirmed by Western 
blotting after comparison to RETWT (Fig. 4E, 4F). 
FMTC mutant RET 891 is more resistant to receptor internalization 
For the FMTC mutants, RET Y791F and RET 5891A, 18 and 26 peptides were 
phosphorylated exclusively for the RET791 + and RET891 + respectively, after 
corrections for phosphorylation changes in the RET791-, RET891-, RETWT- and 
RETWT+. RET791+ and RET891+ shared only six and nine peptides respectively, with 
the RETWT+ (Fig. SA and supplementary table 3). 
As observed for the MEN2A and MEN2B mutants, a marked change in the 
MAP kinase, Pl3 kinase and Rae pathways was detected in the kinome arrays of the 
RET791 and RET891 cell lines. For the MAP kinase pathway, phosphorylation of p38, 
ERK and JNK was analysed by Western blotting. Phosphorylation levels of these three 
kinases were up-regulated for both RET791 and RET891 mutants (Fig. SB, SE). For the 
Pl3 kinase pathway only Akt was altered in the arrays. 
As observed for the MEN2A and MEN2B mutants, a marked change in the 
MAP kinase, Pl3 kinase and Rae pathways was detected in the kinome arrays of the 
RET791 and RET891 cell lines. For the MAP kinase pathway, phosphorylation of p38, 
ERK and JNK was analysed by Western blotting. Phosphorylation levels of these three 
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kinases were up-regulated for both RET791 and RET891 mutants (Fig. SB, SE). For the 
Pl3 kinase pathway only Akt was altered in the arrays. However, since PDKl, mTOR 
and p7056 kinase are also affected by the activation of Akt, the phosphorylation levels 
of all these kinases were analysed. We observed that for both RET791 and RET891 
mutations, there was an increase in phosphorylation of Akt, PDKl  and mTOR 
compared to the wild-type. However, only the RET891 mutant showed an increase in 
phosphorylation of the p7056 kinase (Fig. SC, SE). An alteration of the Rae pathway, 
specifically of PAK2, was also detected in the arrays for both the FMTC mutants. 
However, we were only able to confirm an up-regulation of PAK2 phosphorylation for 
the RET791 mutation (Fig. SD, SE). 
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Figure S - Signalling pathways associated with FMTC mutations. A) Venn diagrams showing similarities and 
differences (in numbers of peptides) in the kinome profile of d ifferent FMTC mutations: RET791 and RET891. B) 
Western blot results confirmed activation of the Map kinase pathway, C) the Pl3 kinase pathway, and D) the Rae 
pathway for the FMTC mutants in comparison to RETWT. E) Semi-quantification of the band intensity 
corresponding to individual signalling proteins as determined with lmageJ software. The intensity value obtained 
for each band was divided by the intensity of the �-actin band from the same lysate to obtain a ratio. The ratio 
for each protein was subtracted from the ratio obtained when no doxycycline stimulation was present. This value 
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was compared between the different mutants and the wild-type. The figure shows a trend for increased 
phosphorylation levels for the all the mutants compared to the wild-type. HEK-Tet-On cells were used as a 
negative control as they do not express RET. (+) and (-) correspond respectively to the presence or absence of 
doxycycline stimulation. 
Previous studies in tyrosine kinase receptors such as EGFR, have shown that 
aminoacids changes from serine to alanine can lead to an abrogation of ligand­
induced internalization of the receptor, while no effect was observed when tyrosine 
residues were mutated (Oskvold et al., 2003). Knowing that one of the FMTC mutants 
has a serine to alanine mutation (RET 5891A), we decided to evaluate the effect of 
alanine changes on RET receptor tyrosine kinase internalization. The recycling 
properties of the RET receptor were measured by flow cytometry. We observed that 
while the wild-type receptor resurfaced twice in one hour, the RET891 mutant only 
recycled once (Fig. GA and 6B). Interestingly, RET791 containing a tyrosine to 
phenylalanine alteration, displayed no changes in its recycling pattern compared to 
the wild-type RET, recycling twice in one hour (Fig. 6A and 6B). This result showed 
that serine to alanine mutations in the RET receptor lead to a decrease in endocytosis 
comparable to what is found in the EGF receptors. Furthermore, we observed that 
RET891 is more resistant to internalization than RET791 and RETWT, and thus stays 
longer in the membrane. 
Discussion 
Several groups have studied how different RET mutations can give rise to a 
constitutive active receptor and which signalling pathways are activated by these 
mutated receptors, in an attempt to find specific signalling pathways that can reveal 
how different RET mutations result in different disease phenotypes (Iwashita et al. , 
1999; Schuringa et al., 2001; Plaza-Menacho et al. , 2005; Plaza-Menacho et al. , 2006). 
However, most of these studies have focussed on one or a specific set of RET 
mutations, and almost no comprehensive comparison between the different mutant 
RET proteins was available. We have therefore compared the most common 
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mutations found in MEN2A (RET609, RET620, RET634), MEN2B (RET918) and FMTC 
(RET791, RET891), using an enzymatic approach that can quantify phosphorylation of 
a wide spectrum of kinase substrates. With this approach, not only activated kinases 
are revealed, but a lso active substrates - we refer to this col lectively as "the kinome" 
(Parikh et al. , 2009; Parikh et al., 2010). 
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Figure 6 - RET891 is more resistant to receptor internalization. A) Mean fluorescence intensity {MFI) values 
showed that RET891 recycles only once (at 30 min) in 1 hour in contrast to RETWT and RET791 (10 min and 30 
min). B) Graphic representation of mean MFI values obtained for RETWT, RET791 and RET891, confirm a 
reduction in receptor internalization for RET891 compared to RET791 and RETWT. 
Analysis of the kinome profile and the phosphorylation levels of each mutant 
showed that different mutations lead to activation of the canonical RET pathways but 
also, as expected, to different activation patterns of specific kinases compared to RET 
wild-type. We observed that the RET918 mutant presented the most distinct profile 
compared to RET wild-type (Fig. 2B, 4A). Interestingly, we a lso observed that the 
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MEN2A and the FMTC mutants were highly similar (Fig. 2B). This result is in 
agreement with the fact that the distinction between MEN2A and FMTC phenotype is 
somewhat disputed and that FMTC should be considered to be a milder form of 
MEN2A (Marx, 2005). 
Previous studies have shown that activation of the RET receptor induces 
downstream signalling via RAS/ERK kinase, the Pl3 kinase/Akt, the p38 kinase, PLC-y, 
JNK and STAT pathways (Santoro et al. , 2004, Arighi et al., 2005, Kodama et al. , 2005). 
For all the mutants studied, the kinome analysis revealed an increased activation of 
this canonical signalling route MAP kinase, Pl3 kinase and Rae pathways. This increase 
was expected, as the MAP kinase pathway is involved in cell proliferation and 
differentiation, the Pl3 kinase pathways is involved in cell survival and proliferation, 
and the Rae pathway is associated with cytoskeletal modifications and cell motility 
(Fukuda et al., 2002; Kodama et al. , 2005). However, not all mutants showed the same 
levels of phosphorylation of these three pathways. It should be noted that activation 
of p38, p70S6kinase and PAK2 was less pronounced for RET609, and PAK2 activation 
was less pronounced for RET891, when compared to the other mutants and to 
RETWT. These results reveal that mutations associated to the same phenotype do 
show variations in activation of downstream signalling pathways. 
The focal adhesion kinase (FAK) is an intracellular tyrosine kinase that has 
been shown to be an important integrator of adhesion-dependent and growth factor­
dependent signalling (Sieg et al. , 2000), and is involved in several cellular responses 
including cell migration, adhesion and proliferation (Cai et al., 2008). Previous studies 
have reported a direct effect of wild-type RET on FAK phosphorylation (Murakami et 
al., 1999, You et al., 2001). Furthermore, RET was reported to signal through FAK in 
medullary thyroid cancer cells (Panta et al. , 2004). In our study, we showed that FAK 
activation at tyrosine 397 is specifically up-regulated in MEN2B. Since FAK is involved 
in cytoskeletal changes that lead to an increase in invasive properties, this result is in 
agreement with our soft agar assays (Fig. lC) and the more severe phenotype 
observed for patients with this mutation. The kinome profile of RET918 also identified 
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a specific up-regulation of the Aurora kinase B, a serine/threonine kinase required for 
chromosome segregation and cytokinesis (Mountzios et al., 2008). Aurora kinase B 
was previously detected to be over-expressed in a variety of human tumour types, 
e.g. endometrial carcinomas (Kurai et al., 2005) and it has been shown to correlate 
with the level of genomic instability within a tumour, suggesting a role for this kinase 
in the acquisition of genetic alterations critical for neoplastic transformation (Smith et 
al., 2005). In addition, Aurora kinase B expression was detected in anaplastic thyroid 
carcinoma (Wiseman et al. ,  2007). Although further studies are necessary to confirm a 
potential effect of Aurora kinase B in the development of MEN2B, the fact that this 
kinase was significantly up-regulated in our arrays for RET918 could also account for 
the more severe phenotype seen in MEN2B. 
Serine to alanine substitutions in EGF tyrosine kinase receptor have been 
reported to result in an abrogation of ligand-induced internalization of the receptor 
(Oskvold et al., 2003). Since the S891A FMTC mutant included in this study had a 
serine to alanine substitution, we investigated the effect of this change on RET 
internalization. We showed that RET891 is more resistant to internalization and 
remains on the membrane longer compared to RETWT and RET791. This result 
showed that serine to alanine mutations in the RET receptor can lead to a decrease in 
endocytosis comparable to the ones found in the EGF receptors. Furthermore, it can 
also explain the slight decrease in activation of the MAP kinases (ERK, p38 and JNK) 
observed for RET891 in comparison with RET791, since receptor internalization was 
reported to be required for MAP kinase activation (Richardson et al., 2006). 
A schematic representation summarizing all the changes detected on the 
kinome arrays for the different mutations included in this study can be seen in Figure 
7. This figure shows the differences in the signalling pathways between RET wild-type 
and different mutants involved in the development of MEN2A, MEN2B and FMTC. 
Identification of specific signalling pathways for the different mutants can be 
used to develop specific therapeutic approaches for treatment of MEN2A, MEN2B 
and FMTC. Our observation that p38 phosphorylation was up-regulated in both 
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MEN2B and FMTC mutants compared to MEN2A and the wild-type receptor, suggests 
that p38 might be a good candidate target for the design of specific therapies for 
treating these subtypes of MEN2. To date, there are no reports of the use of p38 
inhibitors in thyroid cancer. However, they have been used for treating inflammatory 
diseases (Kumar et al. , 2003) as well as cancer (Sun and Sinicrope, 2005), with high 
selectivity, resulting in almost no side-effects for the patients. 
In conclusion, our results showed that differences between RET wild-type and 
different RET mutants do exist that can help explaining the oncogenic phenotypes 
observed in MEN2. Furthermore, we show that, not only RET mutants associated to 
different MEN2 subtypes activate specific signalling pathways, but also different 
mutations responsible for the same phenotype do not necessarily share the same 
signalling pathways, suggesting that different mutations have their own specific 
signalling pathways. Taken together, these results yield new insights into the RET 
protein network that might be helpful in developing specific therapeutic approaches 
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Figure 7 . Provisional signal transduction schemes of the signalling pathways active in MEN2A, MEN2B and 
FMTC compared to wild-type. Signalling pathways observed in: A) MEN2A, B) MEN28, and C} FMTC. Blue circles 
represent specifically activated kinases for each of the MEN2 subgroups and pink circles represent common 
activated pathways between the different subgroups. Peptide numbers provided correspond to the substrate 
location on the peptide array. Unmarked circles correspond to kinases/substrates that were not directly 
identified on the array, but are well known downstream/upstream targets of the respective pathways. 
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Context: Medullary and papillary thyroid carcinoma (MTC and PTC) are two types of 
thyroid cancer that can originate from activating mutations or rearrangements in the 
RET gene. Therapeutic options are limited in recurrent disease but since RET is a 
tyrosine kinase (TK) receptor involved in cellular growth and proliferation, treatment 
with a TK-inhibitor might be promising. Several TK-inhibitors have been tested in 
clinical trials, but it is unknown which inhibitor is most effective and if there is any 
specificity for particular RET mutations. 
Objective: We aimed to compare the effect of four TK-inhibitors (axitinib, sunitinib, 
vandetanib and XL184) on cell proliferation, RET expression and autophosphorylation, 
and ERK activation in cell lines expressing a MEN2A (MTC-TT) mutation, a MEN2B 
(MZ-CRC-1) mutation, and a RET/PTC (TPC-1) rearrangement. 
Design: The three cell lines were cultured and treated with the four TK-inhibitors. 
Effects on cell proliferation, RET and ERK expression and activation were determined. 
Results: XL184 and vandetanib, most effectively inhibited cell proliferation, RET 
autophosphorylation in combination with a reduction of RET expression, and ERK 
phosphorylation in MTC-TT and MZ-CRC-1 respectively. TPC-1 cells showed a decrease 
in RET autophosphorylation after treatment with XL184, but no effect was observed 
on ERK activation. 
Conclusion: There is indeed specificity for different RET mutations, with XL184 being 
the most potent inhibitor in MEN2A and PTC, and vandetanib the most effective in 
MEN2B in vitro. No TK-inhibitor was superior for all the cell lines tested, indicating 
that mutation-specific therapies could be beneficial in treating MTC and PTC. 
Keywords: MTC, PTC, tyrosine kinase inhibitors, XL184, vandetanib. 
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Introduction 
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor which originates 
from the parafollicular calcitonin-producing cells (C-cells) of the thyroid. MTC usually 
occurs sporadically (75% of the cases) or as part of a familial cancer syndrome (25% of 
cases). The familial form occurs as one of the two multiple endocrine neoplasia (MEN) 
type 2 syndromes (MEN2A and MEN2B) or as familial medullary thyroid cancer 
(FMTC). These familial syndromes are caused by a germline mutation in RET, while a 
somatic RET mutation is found in 23-69% of the sporadic MTC patients (de Groot et 
al., 2006; Hofstra et al., 1994; Eng and Mulligan, 1997). 
Papillary thyroid carcinoma (PTC) is the most common cause of thyroid 
cancer, representing approximately 80% of all thyroid cancer cases. PTC occurs in the 
follicular epithelial cells of the thyroid and exposure to radiation is a major risk factor 
for developing PTC. A small percentage of PTCs (5-30%) develops due to RET 
rearrangements, although this percentage is higher - over 60% - in patients exposed 
to radiation and in children (de Groot et al., 2006; Nikoforov, 2008; Greco et al., 
2010). 
Curative treatment for MTC is surgery and consists of a total thyroidectomy 
and extensive lymph node dissection, including a central compartment dissection. 
Patients with sporadic MTC usually present with a palpable solitary thyroid nodule. 
However, when the initial diagnosis is made, cervical and mediastinal node 
metastases are already present in 50% of sporadic MTC patients (Maley and 
Fialkowski, 2007). Recurrent disease is often seen in sporadic patients and until 
recently, re-operation was the only option, because no effective adjuvant therapies 
were available (Kloos et al., 2009). Young MEN2 patients with a known RET mutation 
undergo prophylactic thyroidectomy and have high cure rates. However, when the 
diagnosis is made at a later age, similar to sporadic patients, metastases are 
frequently present and recurrent disease often occurs (Modigliani et al., 1998). 
The main treatment in patients with PTC also consists of a total 
thyroidectomy and, depending on the extent of the disease lymph node dissection, 
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which can be followed by thyroid ablation with radioactive iodine (Cooper et al., 2006; 
Pacini et al., 2006). However, there is no effective adjuvant treatment available for 
PTC patients with radioiodine refractory disease. New systemic therapies are 
therefore needed for both recurrent MTC and PTC. 
With RET being the gene involved in a subset of both MTC and PTC, it is 
logical to consider the RET receptor as an important target for systemic therapy. RET 
is expressed in all tumor cells and is involved in tumor growth (de Groot et al., 2006). 
In MTC patients, RET mutations can affect the extracellular or the intracellular domain 
of this receptor. In both cases, RET is continuously autophosphorylated on tyrosine 
residues, which results in a constant activation of downstream signalling pathways 
that ultimately lead to tumor growth. In PTCs, the intracellular domain of RET (which 
has tyrosine kinase activity) is fused to the N-terminus of an expressed gene. RET/PTC 
does not have a transmembrane domain, and thus is not an integral membrane 
protein, but RET is continuously activated (Plaza-Menacho et al., 2006). Therefore, 
inhibition of RET phosphorylation and its downstream pathways could be of great 
value. 
Small molecule inhibitors that selectively inhibit tyrosine kinases (TK) have 
been proven to be effective in the treatment of several neoplastic diseases (Druker et 
al., 2001; Demetri et al., 2002; McArthur et al., 2005). A number of these clinically 
useful inhibitors target tyrosine kinase receptors that belong to the same family group 
of proteins as RET (Schlumberger et al., 2008; Ye et al., 2010) 
Recently, it has been proven that some of these inhibitors, such as imatinib, 
can inhibit RET activity (Cohen et al., 2002; de Groot et al., 2006). However, high 
concentrations of imatinib are needed to achieve clinically relevant anti-tumor effects 
and resistance may develop. Indeed, the first clinical trials in patients with MTC with 
imatinib showed little effect (de Groot et al., 2007; Frank-Raue et al., 2007). Other TK­
inhibitors such as sorafenib (Nexavar, Bay 43-9006) and vandetanib (ZD6474) have 
already been tested in vitro and have proven to be more effective than imatinib in the 
treatment of MTC (Plaza-Menacho et al., 2007; Carlomagno et al., 2002). Additionally, 
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several TK-inhibitors such as sorafenib, motesanib, gefitinib, vandetanib, axitinib, 
sunitinib, and XL184 have been evaluated in phase II clinical trials (Table 1). In a large 
number of patients (25-81%), a stable disease state can be established and some 
patients even show a partial response (2-33%) (de Groot et al., 2007; Frank-Raue et 
al., 2007; Lam et al., 2010; Schlumberger et al., 2009; Pennell et al., 2008; Wells et 
al., 2010; Robinson et al., 2010; Cohen et al., 2008; Cohen et al., 2008; Kurzrock et al., 
2010). For an extensive review see Sherman SI (Sherman, 2009). 
As most studies have focused on one particular TK-inhibitor and have not 
looked for mutation specificity, it is hard to compare these compounds for the 
different patient groups. We therefore set out to compare the efficiency of four 
recently developed TK-inhibitors - XL184, vandetanib, sunitinib and axitinib - in order 
to determine if there is mutation specificity. We studied the effect of these inhibitors 
on the proliferation of three cell lines: MTC-TT reported to be derived from a sporadic 
MTC expressing a C634W RET mutation; MZ-CRC-1 derived from a patient with 
metastatic sporadic MTC expressing an M918T RET mutation; and TPC-1 derived from 
a patient with PTC expressing a RET/PTC-1 rearrangement. We also determined the 
effect of the most efficient TK-inhibitors on RET expression levels, 
autophosphorylation and activation of the downstream signalling pathways, 
specifically the MAPK/ERK pathway. 
Molecular targets 
lmatinib Bcr-Abl, PDGFR a and 
�. c-Fms, c-Kit, RET 
Sorafenib RAF, VEGFR2 and 3, 
PDGFR, RET 
Motesanib VEGFR 1, 2, and 3, 
PDGFR, c-Kit, RET 
Gefitinib1 EGFR 


















Stable disease Refs 
% (n) 
38% (9) 3,4 




53% ( 16) 8 
53% ( 10) 9 
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Axitinib VEGFR 1, 2, and 3, 11 18% {2) 27% (3)  10 
Sunitinib1 RET, VEGFR, PDGFR 6 D 83% (5) 11  
XL1842 MET, VEGFR-2, RET 37 (35 with 27% (10) 41% (15) 12 
measurable 
disease) 
Table 1. Molecular targets and clinical trials performed with tyrosine kinase inhibitors in medullary thyroid 
carcinoma (MTC) patients.1 Clinical trial performed in advanced thyroid cancer patients, not only those with MTC; 
2 Phase 1 trial. (3. de Groot et al., 2007; 4. Frank-Raue et al., 2007; 5. Lam et al., 2010; 6. Schlumberger et al., 
2009; 7. Pennell et al., 2008; 8. Wells et al., 2010; 9. Robinson et al., 2010; 10. Cohen et al., 2008; 11. Cohen et 
al., 2008; 12. Kurzrock et al., 2010) 
Materials and Methods 
Cell culture 
MTC-TT and TPC-1 cell lines were cultured in RPMI medium (Gibco) supplemented 
with 15% or 10% (for TPC-1) fetal bovine serum ( FBS, BioWhittaker), 1% L-glutamine 
(Gibco) and 1% penicillin/streptomycin (Gibco). MZ-CRC-1 and HEK293 cel l  lines were 
cultured in DMEM high medium containing 4.5 g/L of glucose, L-glutamine and 
pyruvate (Gibco), supplemented with 15% or 10% (for HEK293) FBS and 1% 
penicil lin/streptomycin. Al l cells were maintained at 37
°
C and 5% CO2 atmosphere. 
Tyrosine kinase inhibitors 
XL184 was provided by Exelixis as a stock solution of 10 mM in DMSO. Vandetanib 
was provided by AstraZeneca and made up as a stock solution of 10 mM in DMSO. 
Sunitinib and axitinib were provided by Pfizer and made up as a stock solution of 10 
mM in DMSO. 
Cell proliferation assays 
Cells were seeded in 48-wel l  p lates at different cel l  densities, according to their 
growth rates. MTC-TT and MZ-CRC-1 cells were plated in 200 µI medium at 
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concentrations of 4 x 104 cells/ well. TPC-1 and HEK293 cells were plated at a density 
of 2 x 103 cells/ well. After growing the cells overnight, different concentrations of TK­
inhibitors were added in an extra 100 µI of medium. Proliferation was measured at 
different time points using a cell proliferation kit (MTT assay, Roche) according to the 
manufacturer's instructions. The optical density was determined at 590 nm 
wavelength. To determine the concentration that led to 50% growth inhibition (IC50), 
a concentration range of all the inhibitors tested was added to the wells and ICSO was 
determined using linear interpolation at r = 0.5. All the experiments were performed 
in triplicate. 
Cell lysates and Western blot analysis 
MZ-CRC-1, MTC-TT and TPC-1 cells were seeded in 75 cm2 kimbles (Greiner) and 
grown overnight. Cells were then treated with 0, IC50 and maximal concentrations of 
the different TK-inhibitors. These concentrations were determined based on the 
results of the proliferation assays (Table 2). Cells were grown in the presence of the 
TK-inhibitors for 0, 2 and 5 days and lysates were prepared as follows: cells were 
washed with ice-cold PBS and incubated with lysis buffer (m-PER, Thermo Fisher 
Scientific) containing protease (Thermo Fisher Scientific) and phosphatase (Thermo 
Fisher Scientific) inhibitors, for 30 min on ice. Cell lysates were collected by scraping 
and cleared by centrifugation at 14,000 rpm for 10 min in a pre-cooled (4°C) 
centrifuge. Supernatants were stored at -80°C before they were processed further for 
SOS-PAGE followed by Western blot analysis. The following antibodies were used: RET 
(H-300), RET (C-19), p-RET (Y1062) (Santa Cruz Biotechnology); ERK, p-ERK (Cell 
Signaling) and actin (C4, MP Biomedicals). Secondary antibodies used were goat anti­
rabbit lgG-HRP (Bio-Rad) and goat anti-mouse lgG-HRP (Bio-Rad). All the experiments 




MTC-TT MZ-CRC TPC-1 
Sunitinib 1.56 ± 0.50 µM 1.89 ± 0.46 µM 0.37 ± 0.03 µM 
Vandetanib 0.47 ± 0.33 µM 0.26 ± 0.07 µM 0.41 ± 0.09 µM 
Axitinib 3.43 ± 0.23 µM > S µM 3.49 ± 0.12 µM 
XL184 0.06 µM > S µM 0.06 ± 0.02 µM 
Table 2. ICSO values of the different tyrosine kinase inhibitors in different cell lines. The cell lines express a 
MEN2A (MTC·TT) or a MEN28 (MZ-CRC-1) mutation, or a RET/PTC (TPC-1)  rearrangement. 
RNA extraction and RT-PCR 
MTC-TT and MZ-CRC-1 cells treated with 0, ICS0 and maximal concentrations (Table 2) 
of XL184 and vandetanib respectively, were collected after 0, 2 and 5 days. Cells were 
washed with PBS (Gibco) and RNA extraction was performed using the RNeasy mini 
kit!Cl (Qiagen). First strand cDNA was originated from 2 µg of RNA using the Ready-To­
Go You-Prime First-Strand Beadsc, kit (GE Healthcare) and pdN (6) as first-strand 
primer. First-strand cDNA generated by this method was used directly for RT-PCR. The 
primers used for amplification were: RET forward (S'-CCGTGAAGATGCTGAAAGAG-3'); 





GAP DH forward 
reverse 
The statistical analysis was performed using the software program SPSS 16.0. 
Results 
Effect of different TK-inhibitors on cell proliferation 
(S'­
(5'-
We first evaluated the effect of four different inhibitors (XL184, vandetanib, sunitinib 
and axitinib) on the proliferation of MZ-CRC-1, MTC-TT and PTC-1 cell lines. Cells were 
120 
Effect of TK-inhibitors on MTC and PTC cells 
incubated with increasing concentrations of each TK-inhibitor for 1, 4 and 7 days. 
After these time periods, cell growth was determined using the MTT assay. A dose­
dependent decrease in cell proliferations was seen for all four inhibitors (Fig. lA, 1B 
and lC). In contrast, for a cell line that does not express RET, Human Embryonic 
Kidney cells (HEK293), only minor effects on proliferation were observed at 
concentrations lower than 0.5 µM (Fig. 1D). Concentrations higher than 0.5 µM 
seemed to have a toxic effect on HEK293 cells, except for XL184. Based on the IC50 
values for XL184, vandetanib, sunitinib and axitinib (Table 2), we observed that XL184 
was the most effective inhibitor of MTC-TT (IC50 = 0.06 µM) and TPC-1 (IC50 = 0.06 
µM) proliferation. However, for MZ-CRC-1, treatment with vandetanib inhibited cell 
proliferation at lower concentrations (IC50 = 0.26 µM); it also showed a marked effect 
on TPC-1 (IC50 = 0.41 µM) and MTC-TT (IC50 = 0.47 µM). Sunitinib also seemed to be 
a potent inhibitor for TPC-1 (IC50 = 0.37 µM) but it was less effective in MTC-TT and 
MZ-CRC-1 cells. Axitinib seemed to have hardly any effect on MZ-CRC-1 and TPC-1 
since higher concentrations were needed to achieve 50% cell death (Table 2). Based 
on these results, we concluded that XL184 is the most efficient inhibitor for MTC-TT 
and TPC-1 cells, followed by vandetanib and sunitinib. For MZ-CRC-1, vandetanib is 
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Figure 1 - Effect of XL184, vandetanib, sunitib and axitinib in cell proliferation. Dose response curves of (A) MZ­
CRC-1, (B) MTC-TT, (C) TPC-1 and (D) HEK293 cell lines incubated with different concentrations of XL184, 
vandetanib, sunitinib and axitinib. (E) Overview of the ICS0 values of the four tyrosine kinase inhibitors for MTC­
TT, MZ-CRC-1 and TPC-1 cell lines. Error bars shown correspond to standard deviation. MZ-CRC-1 express a 
MEN2B mutation (RET M918T), MTC-TT express a MEN2A mutation (RET C634R), and TPC-1 express a RET/PTC 
rearrangement. ICS0 = concentration that lead to 50% cell death. 
The effect of XL184 and vandetanib on RET autophosphorylation 
In order to evaluate the effect of the inhibitors with a stronger effect on cell 
proliferation {XL184 and vandetanib) on RET autophosphorylation, cell lysates of MTC­
TT and TPC-1 were prepared after treatment with IC50 and maximal concentrations {5 
µM) of XL184. Cell lysates of MZ-CRC-1 were also analyzed after incubation with IC50 
and maximal concentrations (5 µM) of vandetanib. Inhibition of RET 
autophosphorylation on tyrosine 1062 was observed for the three cell lines tested. 
For MTC-TT and TPC-1, RET activation started decreasing with maximal concentrations 
of XL184 after 2 days of treatment. However, 5 days' exposure to IC50 values of XL184 
were also sufficient to reduce RET autophosphorylation levels (Fig. 2A and 28). For 
MZ-CRC-1, vandetanib led to a decrease in RET activation after 2 days' exposure with 
IC50 levels. Prolonged exposure to IC50 concentrations of vandetanib led to total 
inhibition of RET autophosphorylation. Moreover, maximal concentrations of 
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vandetanib resulted in total inhibition of RET activation after only 2 days' exposure 
(Fig. 2C) . 
To investigate if the observed reduction in RET autophosphorylation was due 
to decreased levels of RET expression, the membranes were stripped and probed for 
RET. The total amount of RET in TPC-1 cells remained relatively unchanged after 5 
days' exposure to maximal concentrations of XL184, although we observed a slight 
increase in RET expression levels after 5 days (Fig. 2B). In contrast, MTC-TT cells 
showed a dose-dependent response to XL184 after 5 days' incubation with the 
inhibitor. At ICSO values, a marked decreased in RET expression was observed and at 
maximal concentrations, RET was no longer detectable (Fig. 2A). For MZ-CRC-1, RET 
expression was markedly affected by ICSO concentrations of vandetanib after 5 days' 
exposure (Fig. 2C}. Maximal concentrations of this inhibitor had an effect on RET 
expression after 2 days' treatment and led to total RET inhibition after prolonged 
exposure (Fig. 2C). Together, these results show that XL184 and vandetanib are 
potent inhibitors of RET activation in MTC-TT, TPC-1, and MZ-CRC-1 cells. 
A) MTC-TT treated with XL184 
2 davs 5 davs 
C O ic-50 max O ic-50 max 
B) TPC-1 treated with XL184 
2 days 5 days 
C O ic-50 max O ic-50 max 
C) MZ-CRC-1 treated with vandetanib 
2 davs 5 davs 




Figure 2 - Effect of Xl184 and vandetanib on RET expression and autophosphorylation. (A) MTC-TT cells treated 
with ICSO concentration and 5 µM of XL184 for 2 and 5 days. (B) TPC-1 cells treated with ICSO concentration and 
5 µM of XL184 for 2 and 5 days. (C) MZ-CRC-1 cells treated with ICSO concentration and 5 µM of vandetanib for 2 
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and 5 days. MTC-TT express a MEN2A mutation (RET C634R), TPC-1 express a RET/PTC rearrangement, and MZ­
CRC-1 express a MEN2B mutation (RET M918T). ICSO " concentration that leads to 50% cell death. 
The effect of XL184 and vandetanib on RET expression 
To determine if the reduction of RET expression seen in MTC-TT and MZ-CRC-1 was 
due to inhibition of RET transcription, RET expression levels were determined by RT­
PCR after treatment with XL184 {MTC-TT) and vandetanib (MZ-CRC-1) for 2 and 5 
days. Treatment of MTC-TT with ICSO and maximal concentration of XL184 had no 
effect on RET transcription levels ( Fig. 3A). However, exposing MZ-CRC-1 for 5 days to 
maximal concentrations of vandetanib led to a decrease in RET expression ( Fig. 3B). 
Semi-quantification of the band intensity, calculated with lmageJ software and 
corrected for the intensity of the GAPDH band for each of the cell lines, confirmed 
that a decrease in RET transcript was observed after prolonged exposure to maximal 
concentrations of vandetanib {Fig. 3C). These results show that although RET protein 
levels were reduced in MTC-TT cells, there was no corresponding reduction of RET 
mRNA. In contrast, in MZ-CRC-1 we showed that maximal concentrations of 
vandetanib led to reduced levels of RET mRNA and corresponding reduced levels of 
RET protein. 
A) MTC-TT treated with XL184 
B) MZ-CRC-1 treated with vandetanib 
2 da'Y! S days 
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Figure 3 - Effects of XL184 and vandetanib on RET mRNA levels. (A) MTC-TT cells treated with ICSO 
concentration and 5 µM of XL184 showed no effect on RET transcription levels. (B) MZ-CRC-1 cells treated with 
vandetanib showed a decrease in RET transcription levels after prolonged exposure (S days) to 5 µM of this 
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inhibitor. (C} Graphical representation of RET bands' intensity after correction for GAPDH levels confirmed that a 
reduction of RET mRNA levels was only seen for MZ-CRC-1 cells after prolonged exposure to 5 µM of vandetanib. 
MTC-TT express a MEN2A mutation (RET C634R) and MZ-CRC-1 express a MEN28 mutation (RET M918T). ICSO = 
concentration that leads to 50% cell death. GAPDH was used as a control. 
The effect of XL184 and vandetanib on RET downstream signalling pathways 
RET is involved in the activation of several signalling pathways, one of which is the 
MAP kinase pathway, which is especially important for cell proliferation, survival and 
transformation (Plaza-Menacho et al., 2007; Wells and Santoro, 2009). To evaluate 
the effect of XL184 and vandetanib in ERK activation, we treated MTC-TT, TPC-1 and 
MZ-CRC-1 cells with ICS0 and maximal concentrations of XL184 (MTC-TT and TPC-1) 
and vandetanib (MZ-CRC-1). XL184 was able to reduce ERK phosphorylation in MTC-TT 
cells at ICS0 concentrations after 2 days' exposure. Prolonged exposure to maximal 
concentrations of XL184 led to total inhibition of ERK activation (Fig. 4A). In contrast, 
no effect was observed for TPC-1, even when maximal concentrations of XL184 were 
used for a period of 5 days (Fig. 4B). For MZ-CRC-1, ERK phosphorylation was 
markedly reduced with ICS0 levels of vandetanib after 5 days' treatment. Maximal 
concentrations of this inhibitor were able to completely block ERK activation after 
only 2 days' exposure (Fig. 4C). Interestingly, total inhibition of ERK activation was 
observed for MTC-TT and MZ-CRC-1 after treatment with XL184 and vandetanib, 
respectively, and was related to a reduction in ERK expression levels (Fig. 4A and 4C). 
A) MTC-TT treated with XL184 B) TPC-1 treated with XL184 
2 days 5 days Z days 5 days 
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Figure 4 - Effects of XL184 and vandetanib on ERK expression and phosphorylation. (A) MTC-TT cells treated 
with ICSO concentration and 5 µM of XL184 for 2 and 5 days. (Bl TPC-1 cells treated with ICSO concentration and 
5 µM of XL184 for 2 and 5 days. (C) MZ-CRC-1 cells treated with ICSO concentration and 5 µM of vandetanib for 2 
and 5 days. MTC-TT express a MEN2A mutation (RET C634R), TPC-1 express a RET/PTC rearrangement, and MZ­
CRC-1 express a MEN2B mutation (RET M918T). ICSO = concentration that lead to 50% cell death. 
Discussion 
Effective systemic treatment for patients with recurrent medullary or papillary thyroid 
carcinoma (MTC, PTC) is still not available, but new therapeutic options are under 
development. In both MTC and PTC, mutations or rearrangements of the RET gene, 
encoding a tyrosine kinase receptor, lead to a constitutive phosphorylated receptor 
that continuously activates its downstream pathways, leading to uncontrolled cell 
growth and proliferation. Therefore, tyrosine kinase (TK) inhibitors that can selectively 
block RET and its intracellular pathways, leading to a decrease in tumor growth and 
invasion, might have potential as new treatment options for recurrent MTC and PTC. 
Several TK-inhibitors have been developed and some have been evaluated in clinical 
trials for the treatment of thyroid cancer with positive results (de Groot et al., 2007; 
Frank-Raue et al., 2007; Lam et al., 2010; Schlumberger et al., 2009; Pennell et al., 
2008; Wells et al., 2010; Robinson et al., 2010; Cohen et al., 2008; Cohen et al., 2008; 
Kurzrock et al., 2010). However, a comparative study of these different inhibitors has 
never been done and therefore the relative effectiveness of the different inhibitors is 
hard to assess. Furthermore, nothing is known about specificity of the different TK­
inhibitors for different types of thyroid cancer and RET mutations. 
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In this paper we, for the first time, compared four different tyrosine kinase 
inhibitors: XL184, vandetanib, sunitinib and axitinib, for their effects on RET inhibition. 
All four TK-inhibitors have been tested in clinical trials and table 1 summarizes the 
molecular targets and therapeutic outcomes (Table 1). It is interesting to see that 
XL184 and vandetanib are the two TK-inhibitors which gave the highest percentage of 
tumor responses in the treatment of MTC (29% and 16-20%, respectively). However, it 
was unknown if these four inhibitors show specificity for MEN2A, MEN2B or PTC 
mutations. 
To evaluate the efficacy and specificity of these inhibitors, we studied their 
effect on the proliferation of cells harboring a MEN2A mutation (MTC-TT), a MEN2B 
mutation (MZ-CRC-1) or a RET/PTC rearrangement (TPC-1). Our results showed that 
all four of the TK-inhibitors investigated are capable of inhibiting cell proliferation to 
some extent. However, the concentrations of inhibitors that were needed to inhibit 
cell growth differed greatly and the ICS0 values for some of them were not within the 
tested concentration range. XL184 was found to be the most potent inhibitor for 
MEN2A {ICS0 = 60 nM) and PTC (ICS0 = 60 nM) derived cell lines. Effects on MZ-CRC-1 
cell proliferation were only seen with higher concentrations of XL184. For the MEN2B 
cell line, vandetanib proved to be the most potent inhibitor (ICS0 = 260 nM). An 
interesting observation was that at the ICS0 values found to have an effect on the 
proliferation of these cell lines, we saw no effect on the proliferation of HEK293, a 
control cell line that does not express RET. Based on the data generated for these 
three cell lines we conclude that XL184 and vandetanib specifically target RET induced 
cell proliferation at concentrations that in vitro have little or no toxic effect. 
We also determined the effect of the two most potent inhibitors, XL184 and 
vandetanib, on RET autophosphorylation levels. For MTC-TT and TPC-1, RET 
phosphorylation on tyrosine 1062 was reduced after exposure to ICS0 concentrations 
of XL184 for 5 days. MZ-CRC-1 cells showed a decrease in RET activation after 2 days' 
exposure to ICS0 values of vandetanib, but prolonged exposure led to a total 
inhibition of RET phosphorylation. Parallel to this effect, we observed that RET 
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expression was also affected by prolonged exposure to these inhibitors in MTC-TT and 
MZ-CRC-1. Both cell lines showed a decrease in RET expression levels after exposure 
for 5 days to ICS0 concentrations of XL184 and vandetanib respectively, but only 
vandetanib exerted this effect by inhibiting RET transcription. For XL184 we were 
unable to detect a change in RET transcript levels even after prolonged exposure to 
maximal concentrations of the inhibitor. It is probable that for XL184 lysosomal or 
proteasomal degradation is involved, as was described for other inhibitors {Plaza­
Menacho et al., 2007). No effect on RET expression levels was detected for TPC-1, 
even after prolonged exposure to maximal concentrations of XL184. This means that 
the effect of XL184 in PTC is only achieved by direct inhibition of RET 
autophosphorylation and that possible lysosomal or proteasomal degradation may 
not be effective due to the presence of the fusion protein. 
Finally, we explored the effect of these drugs in a downstream signalling 
pathway, the MAP kinase pathway, known to be directly activated by RET, and 
specifically at the levels of ERK phosphorylation. Previous studies have reported the 
effect of vandetanib on RET activation and have shown that exposure to this inhibitor 
led to inhibition of ERK phosphorylation (Carlomagno et al., 2002). For MTC-TT and 
MZ-CRC-1, exposure to ICS0 levels of XL184 and vandetanib, respectively, induced a 
marked decrease in ERK phosphorylation. However, prolonged exposure to 
vandetanib was necessary to achieve this effect for MZ-CRC-1. Interestingly we 
observed that there was a reduction on ERK expression in MTC-TT and MZ-CRC-1 after 
treatment with maximal concentrations of XL184 and vandetanib, respectively, 
suggesting that these inhibitors have a possible effect on ERK transcription. 
XL184 demonstrated efficacy and inhibition of RET/PTC in the TPC-1 PTC 
model system. However, no change in ERK phosphorylation was detected, even after 
prolonged exposure to maximal concentrations of XL184. ERK phosphorylation 
through other tyrosine kisase receptors and tyrosine kinase effector molecules 
involved in activation of the MAPK/ERK pathway, e.g. BRAF, are likely to exert a 
stronger effect in ERK phosphorylation than RET. It is possible that for PTC, a 
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combination of different inhibitors targeting RET and e.g. BRAF, could circumvent this 
problem and thus result in an even more effective treatment for this type of cancer. 
In conclusion, our in vitro results are in general agreement with the outcome 
of the clinical trials, supporting the idea that XL184 and vandetanib are two potent 
inhibitors for tumor response in MTC. By studying three cell lines we did observe 
specificity for the treatment of different RET mutations, with XL184 being the most 
potent inhibitor for the cell line expressing a MEN2A mutation and for a cell l ine 
expressing a PTC rearrangement. Vandetanib proved most effective in a cell l ine 
expressing a MEN28 mutation. As no TK-inhibitor was superior for al l  the cell lines we 
tested, our results suggest that mutation-specific therapies could be beneficial in the 
treatment of MTC and PTC. This is an important finding since in clinical trials to date 
no distinction has been made between the different RET related mutational subtypes 
(MEN2A/MEN28/PTC). Making such distinctions might change the outcome, in 
particular in tumor response, and likely improve the outcome of ongoing studies. Our 
data also suggest that a reanalysis of already performed trails, based on mutation 
status is more than worthwhile. 
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RET is a tyrosine kinase receptor which plays a crucial role during embryonic 
development. In the early stages, RET expression is detected in a cranial population of 
neural crest stem cells (NCSCs) and subsequently throughout the central nervous 
system, but specifically in motor and catecholaminergic neurons. During 
development, RET- expressing NCSCs have the ability to migrate caudally via the 
intestinal mesenchyme to form the enteric nervous system, located in the gut wall of 
the gastro-intestinal tract. In addition, another group of RET expressing cells gives rise 
to the development of sensory and autonomic ganglia of the peripheral nervous 
system, adrenal chromaffin cells and c-cells of the thyroid, and the kidney (Manie et 
al., 2001; Arighi et al., 2005; de Groot et al., 2006). 
Specific germline mutations in RET have been reported to lead to an aberrant 
embryonic development of the NCSCs and are consequently are responsible for two 
unrelated neural crest disorders: Hirschsprung disease (HSCR), a congenital absence 
of the enteric neural crest cells in the gastrointestinal tract, and multiple endocrine 
neoplasia type 2 (MEN2), a dominantly inherited cancer syndrome. 
In this last section of the thesis, I summarize the functional and genetic work 
described in this thesis and discuss how it fits into the current body of knowledge on 
the field. I addition, I also present ideas for future work that needs to be carried out in 
the future to improve our current understanding of HSCR and MEN2. 
Part I - HSCR 
HSCR is a complex disorder for which several causative genes have been identified. To 
date, mutations in eleven genes have been described in HSCR patients. Despite the 
relatively large number of associated genes, the precise mechanism of disease 
development is still not fully understood, nor do these genes explain all HSCR cases. 
Since HSCR is frequently associated with other congenital malformations present in 
rare (recessive or dominant) syndromes, studying the genes involved in these 
syndromes may provide greater insights into HSCR development and help identify 
new HSCR candidate genes. 
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In Chapter 2 the protein network associated with KIAA1279/KBP was studied; 
this protein is encoded by a HSCR-associated gene and its function is largely unclear 
(Brooks et al. ,  2005). Homozygous nonsense mutations in KBP are involved in a rare, 
recessive syndrome called Goldberg-Shprintzen syndrome (GOSHS) which is 
characterized by polymicrogyria, microcephaly, facial dysmorphisms, mental 
retardation and, in most cases, with HSCR (Goldberg and Shprintzen, 1981; Brooks et 
al., 2005). 
Based on the clinical phenotype, KBP is required for the normal development 
of both the central and peripheral nervous system, but how this protein is involved in 
this process was largely unclear, in other words, the precise function of KBP was 
unknown. Our results shed some light on its function, by showing that KBP expression 
is up-regulated during neuronal development in mouse cortical neurons. Moreover, 
we showed that KBP is necessary for neuronal differentiation and neurite outgrowth 
of PC12 cells, suggesting that KBP is involved in cell differentiation and neuronal 
development or plasticity. 
Parallel to this, we performed a yeast two-hybrid screen to identify KBP­
interacting proteins, and found several kinesin like proteins, supporting the idea that 
KBP is indeed a kinesin binding protein (Wozniak et al., 2005). In addition, we also 
found that KBP interacts with SCGlO, a stathmin-like protein previously shown to be 
involved in microtubule dynamics (Di Paolo et al., 1997; Grenningloh et al., 2004). 
Additional studies in vitro and in vivo confirmed this interaction and suggested that 
KBP may play a role in microtubule organization or stability. 
Previous characterization of a kbp mutant zebrafish had implicated KBP in the 
regulation of neuronal microtubules organization (Lyons et al., 2008), but we found 
that KBP does not directly interact with microtubules. This raises the question as to 
how KBP affects microtubule dynamics? The answer may lie in its interaction with 
SCGl0 and three possible mechanisms of action are proposed. The first is that KBP 
might be involved in the palmitoylation process that precedes the transport of SCGl0 
to the growth cones. Since SCGl0 needs this post-translational modification to be 
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transported and to exert its microtubule destabilizing action (Lutjens et al. ,  2000), KBP 
depletion would result in an impairment of SCGl0 transport and, consequently, in an 
alteration of its microtubule destabilizing action. The second mechanism could be that 
KBP regulates SCGlO activity. SCGl0 alternates between stages of 
activation/inactivation, triggered by dephosphorylation/phosphorylation of its serine 
residues that are necessary for microtubule dynamics (Antonsson et al. ,  1998). The 
third possible mechanism is that KBP might mediate SCGlO interaction with tubulin. 
Consistent with this, we observed an interaction between KBP and tubulin in our 
yeast two-hybrid screen. Thius, KBP could potentially control the levels of free tubulin 
available for microtubule polymerization. Either way, KBP depletion will affect 
microtubule dynamics and, consequently, neurite extension and axonal growth, which 
is in line with the neuronal development defects seen in the GOSHS clinical 
phenotype. However, the obvious question that arises from our work is what do these 
results tell us about HSCR? 
Impairments in the survival, proliferation and migration of NCSCs have been 
suggested as possible mechanisms for HSCR development (Heanue and Pachnis, 
2007). Our study showed that KBP is involved in neuronal differentiation, suggesting 
that a failure in differentiation of NCSCs into enteric neurons after colonization of the 
intestinal tract could also play a role in HSCR development. Thus, we propose a new 
mechanism based on cell differentiation, in addition to cell survival, proliferation and 
migration. 
Interestingly, our data suggest that SCGlO might be the possible link between 
KBP and the other genes involved in HSCR development. SCGlO activity can be 
controlled by phosphorylation of specific serine residues by the Protein Kinase A (PKA) 
(Togano et al. ,  2005). PKA was previously implicated in HSCR as a possible link 
between the RET and EDNRB signalling pathways (Barlow et al., 2003). Accordingly it 
is tempting to postulate that PKA migth also be the link between KBP, SCGlO, RET and 
EDNRB. A scheme of all the genes involved in HCSR and of their possible interacting 
network is shown in Figure 1. 
134 










Figure 1 - Schematic representation of possible interactions between HSCR related genes (Adapted from Tam 
and Garcia-Barcelo, 2009). 
In Chapter 3, the involvement of SCGlO in HSCR development is evaluated. 
Previous studies have identified SCG10 as a down-regulated gene in a RET mouse 
model for HSCR (Heanue and Pachnis, 2006), and we have shown that SCG10 interacts 
with KBP. In addition, previous studies performed in zebrafish have already shown 
that SCGlO is expressed during the development of the central and enteric nervous 
systems (Burzynski et al., 2009), supporting the idea that SCGlO is involved in HSCR 
development. To determine if SCGlO is expressed in NCSCs during colonization of the 
intestinal tract, E10.5 to E15.5 mouse NCSCs were collected and analysed for SCGlO 
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expression. We detected SCGl0 expression in NCSCs from all embryonic stages, with a 
slight increase in SCG10 levels in the initial stages {El0.S to Ell.S). 
To further evaluate SCG10 involvement in HSCR, 85 sporadic, non-syndromic 
HSCR patients, in whom no mutation in RET had been found, were screened for the 
presence of SCG10 mutations. However, no mutations in SCG10 were found in any of 
these patients. Based on this result, we concluded that SCG10 is not directly involved 
in HSCR development. However, there is still a possibility that SCG10 might play an 
indirect role in HSCR due to a secondary effect caused by disruptions in its protein 
network. SCG10 activity is known to be controlled by two post-translational 
modifications: palmitoylation and phosphorylation (Antonsson et al., 1998; Lutjens et 
al., 2000). As RET is a tyrosine kinase receptor known to be involved in several 
signalling pathways, it is possible that the RET receptor, via one of its downstream 
pathways, controls SCG10 activity, linking this gene directly to HSCR. Further studies 
are required to further elucidate any potential role of SCG10 in HSCR development. 
Complex disorders, such as HSCR, are not caused by mutations in a single 
gene, but rather arise from the combined action of several genes and risk-conferring 
variants. However, the genes contributing to the development of such disorders are 
difficult to find since they normally exert only a small effect on disease risk (Kiberstis 
and Roberts, 2002). Thus, there is now a search for new and more sophisticated 
technologies that might identify these genes/rare variants. In Chapter 4, recent 
approaches that might be helpful in identifying new candidate genes for complex 
disorders are discussed. Using HSCR as an example, we reviewed what is known about 
the disease, what we have learned from genome-wide association studies, and how 
next-generation sequencing in combination with a systems biology approach might 
help us in to unravel the complex inheritance pattern of HSCR. 
Part II - MEN2 
Activating mutations in RET are the main cause of MEN2, a dominantly inherited 
cancer syndrome that can be divided into three subtypess: MEN2A, MEN2B and 
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Familial Medullary Thyroid Carcinoma (FMTC), based on the clinical description and 
tissues affected (Hansford and Mulligan, 2000). The observation that different RET 
mutations result in different disease phenotypes, suggests that specific signalling 
pathways are activated by the mutated RET receptor. Therefore, identifying the 
signalling pathways triggered by the different RET mutations might yield new insights 
into the RET protein network and could be used for the development of specific 
therapeutic approaches for treating MEN2A, MEN2B and FMTC. 
In Chapter 5, we tried to identify the specific downstream signalling pathways 
using a powerful tool called kinome profiling, to generate descriptions of cellular 
signalling networks involved in the different pathogenesis. With this approach, 
phosphorylation patterns specific for the most common mutations found in MEN2A 
(RET609, RET620, RET634), MEN2B (RET918) and FMTC (RET791, RET891) were 
analysed, using a peptide array consisting of 1024 different kinase substrates. 
Based on our results, we confirmed that there are indeed differences 
between RET mutants and RET wild type. But, interestingly, all the mutants we 
analysed showed an enhanced activation of canonical RET signalling pathways: MAP 
kinase, Pl3Kinase/Akt and Rae pathways. This up-regulation was expected since the 
MAP kinase pathway is involved in cell proliferation and differentiation, the Pl3 kinase 
pathways is involved in cell survival and proliferation and the RAC pathway is 
associated with cytoskeletal modifications and cell motility (Fukuda et al., 2002; 
Kodama et al., 2005). Furthermore, it suggests that the differences between RET 
mutants and the wild-type receptor are small and likely to result from exacerbated 
activation of pre-existing signalling pathways. 
Specific alterations in signalling properties were identified in MEN2B- and 
FMTC-associated mutants. For RET918 a specific increase in activation of the focal 
adhesion kinase (FAK) was observed. FAK is an intracellular tyrosine kinase involved in 
several cellular responses including cell migration, adhesion and proliferation (Cai et 
al., 2008). Previous studies have reported a direct effect of wild type RET on FAK 
phosphorylation (Murakami et al., 1999, You et al., 2001). Furthermore, RET was 
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reported to signal through FAK in medullary thyroid cancer cells (Panta et al. , 2004). 
Since FAK is involved in cytoskeletal changes that lead to an increase in invasive 
properties, this increase in FAK phosphorylation levels for RET918 might explain the 
more severe phenotype observed for patients with MEN2B. Besides FAK, we also 
found a specific activation of the Aurora kinase B, a serine/threonine kinase required 
for chromosome segregation and cytokinesis (Mountzios et al., 2008), in the RET918 
mutant. Aurora kinase B was previously reported to be over-expressed in a variety of 
human tumour types, e.g. endometrial carcinomas (Kurai et al., 2005), and it has been 
shown to correlate with the level of genomic instability in a tumour, suggesting that 
Aurora B contributes to the acquisition of genetic alterations critical for neoplastic 
transformation (Smith et al., 2005). Although Aurora kinase B expression was 
detected in anaplastic thyroid carcinoma (Wiseman et al., 2007), this is the first time 
that this kinase has been found to be associated with MEN2. Furthermore, the 
increase in phosphorylation of this kinase observed specifically for the RET918 
mutation can also account for the more severe phenotype seen in MEN2B compared 
to the other mutants and to the wild-type receptor, but further studies are necessary 
to determine the effect of the Aurora kinase B in MEN2B. 
For RET891, one of the FMTC mutants analysed, a specific alteration in 
receptor endocytosis was detected. We observed that while RET wild-type recycles 
twice in one hour after ligand activation, RET891 recycles only once. This difference 
could be explained by the fact that RET891 is not responsive to ligand activation 
(Plaza-Menacho et al. , 2005). Neither was a response to ligand activation observed for 
RET791 (Plaza-Menacho et al. , 2005), but no difference in receptor internalization was 
detected for this mutant when compared to the wild-type. Previous studies have 
shown that a serine to alanine substitution in EGF tyrosine kinase receptors result in 
an abrogation of ligand-induced internalization of the receptor (Oskvold et al., 2003), 
but no effect of similar substitutions has been described for the RET receptor. Given 
that RET891 is the only RET mutant where a serine to alanine substitution occurs, this 
difference might explain the changes observed in the pattern of RET internalization. 
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Accordingly, RET891 is more resistant to internalization than RET791 and RET wild­
type and is retained on the membrane longer after ligand stimulation. 
Together, these data show that there are differences between RET mutants 
and wild-type and provide further evidence of the presence of signalling profiles 
specific for different RET mutations. Our results also yielded new insights into the RET 
protein network, which might be helpful in developing specific therapeutic 
approaches for treating MEN2A, MEN2B and FMTC. 
There is an ongoing search for better and more efficient therapeutic 
approaches for treating recurrent medullary and papillary carcinoma. Since the 
oncogenic activation of the RET receptor plays a major role in the development of 
these carcinomas, the search for efficient tyrosine kinase (TK) inhibitors that could 
inhibit RET and the activation of its downstream signalling pathways is being 
conducted by several pharmaceutical companies. Several TK-inhibitors have been 
developed in order to specifically block the constitutive activation of RET and some of 
them have already been tested in clinical trials. Unfortunately, for the majority of 
these inhibitors, the concentrations needed to suppress RET oncogenic signalling are 
too high to be administered without severe side-effects for the patients. 
In chapter 6, we focus on four new TK-inhibitors: XL184, vandetanib, sunitinib 
and axitinib, and their effects on the treatment of medullary and papillary thyroid 
carcinoma. In order to compare the efficiency of XL184, vandetanib, sunitinib and 
axitinib the effect of these inhibitors on the proliferation of three cell lines: MTC-TT 
(MEN2A, RETC634R); MZ-CRC-1 (MEN2B mutation, RETM918T), and TPC-1 (RET/PTC-1 
rearrangement) was analysed. Furthermore, we evaluated their effect on the levels of 
RET expression, RET phosphorylation and activation of downstream signalling 
pathways, specifically on the MAPK/ERK pathway. 
We observed that the cell lines tested have different sensitivities to the 
various inhibitors. For the cells lines expressing a MEN2A (MTC-TT) and a RET/PTC-1 
rearrangement (TPC-1), XL184 was the most efficient inhibitor, while vandetanib was 
a more potent inhibitor for MZ-CRC-1 cells expressing a MEN2B mutation. In addition, 
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we were able to show that both XL184 and vandetanib led to a decrease in the levels 
of RET and ERK phosphorylation in MTC-TT and MZ-CRC-1 cells, respectively. 
Interestingly, clinical trials for these four TK-inhibitors have been performed and have 
shown that XL184 and vandetanib are the two TK-inhibitors with the highest 
percentage of tumour responses in the treatment of medullary thyroid carcinoma 
(Wells et al. , 2010; Robinson et al., 2010; Cohen et al. , 2008; Cohen et al., 2008; 
Kurzrock et al., 2008). Our results are in agreement with the outcome of the clinical 
trials, reinforcing the idea that XL184 and vandetanib are potent inhibitors for the 
treatment of MTC. However, we also showed that there is specificity for different RET 
mutations, with XL184 being the most potent inhibitor in MEN2A, and vandetanib the 
most effective in MEN2B. For TPC-1 cells, although XL184 demonstrated efficacy and 
inhibition of RET/PTC, no change in ERK phosphorylation was detected. Thus, it is 
likely that other tyrosine kisase receptors and tyrosine kinase effector molecules 
involved in activation of the MAPK/ERK pathway, e.g. BRAF, are likely to exert a 
stronger effect in ERK phosphorylation than RET. It is possible that for PTC, a 
combination of different inhibitors targeting RET and e.g. BRAF, could circumvent this 
problem and thus result in an even more effective treatment for this type of cancer. 
The most important finding of this study was the mutation specificity of the 
different inhibitors. It has a direct bearing on the RET-related clinical trials since, so 
far, no distinction has been made between the different RET-related mutational 
subtypes (MEN2A/MEN2B/TPC) in the trails performed. 
Future Perspectives 
The work described in this thesis provides a better understanding of the development 
of two neural crest-related disorders, HSCR and MEN2. It has, however, raised five 
important questions that should be addressed in future studies to fully evaluate the 
effect of these findings. 
The first question arose from the functional studies performed for KBP. 
Although, we were able to associate KBP to microtubule dynamics based on its 
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interaction with SCGlO, the mechanism by which KBP exerts this effect is still 
unknown. We reported that KBP does not directly interact with microtubules, which 
suggests that KBP might be able to control the microtubule destabilizing activity of 
SCGl0. As described, this could happen in three possible ways: 1) KBP might be 
involved in the palmitoylation process that regulates SCGlO transport to the growth 
cones; 2) KBP could play a role in SCGlO dephosphorylation/phosphorylation that 
controls SCGlO activation; 3) KBP might mediate SCGl0 interaction with tubulin. To 
test these hypotheses, KBP expression should be knocked down in neuronal cells and 
1) SCGlO localization should be determined; 2) SCGl0 phosphorylation levels should 
be checked; 3) SCGl0 microtubule destabilizing effects should be analysed. If, in one 
of these situations, KBP depletion results in a deregulation of SCGlO activity, a 
microtubule defect is to be expected, linking KBP to microtubule dynamics. 
A second question concerns the involvement of KBP in HSCR development. 
Our results showed that KBP is necessary for neuronal differentiation. However, we 
still cannot exclude KBP being incolved in the survival, proliferation and migration of 
NCSCs. To further investigate these effects, it would be of tremendous value to 
generate a KBP-/- mouse in which the process of gut colonization by NCSCs could be 
followed and analysed for the presence of abnormalities. 
A third question is related to the mechanism by which SCGl0 is involved in 
HSCR. Although SCGlO had been proposed as a candidate HSCR gene, and we found a 
direct interaction between SCGlO and KBP, the exact mechanism by which SCGlO 
plays a role in HSCR still remains to be elucidated. One possible option is that RET 
controls SCGlO activity via direct interaction. To investigate this hypothesis, co­
immunoprecipitation assays to detect RET-SCGlO interaction, and analysis of SCGlO 
phosphorylation levels in the presence of specific RET TK-inhibitors, might help clarify 
the role of SCGlO in HSCR. Another possible mechanism is that RET controls SCGlO 
activity indirectly, via activation of one of its downstream signalling pathways. Since 
SCGlO activity is known to be controlled by PKA, and serine 696 (in mice 697) of RET is 
known to be the docking site for PKA, we suggest that SCGlO activity could be 
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affected by an alteration of PKA activation due to a mutation of RET serine 696. To 
investigate this hypothesis, SCGlO and PKA activation should be analysed in the 
presence of this RET mutation. Since there is already a mouse model containing a 
homozygous RET697 mutation available, it could be used to study the precise effect of 
RET in SCGlO activation. 
A fourth question comes from the study of different RET mutations. Although 
we found activation of specific pathways for different mutations, these changes were 
studied using cell lines and thus in an in vitro setting. Ideally, these pathways should 
be validated in patient material. This would further allow us to identify true targets, 
since it is possible that some of these pathways are not replicated in the three­
dimensional setting of a tissue. Identifying these true targets could then lead to 
creating animal models that would provide further mechanistic insights into the 
development of the different subtypes of MEN2. In addition, this could lead to the 
development of specific therapeutic strategies for treating MEN2A, MEN2B and 
FMTC. 
The final question is related to the use of TK-inhibitors in the clinic. We 
showed that different RET mutations have different sensitivities to the TK-inhibitors 
tested, suggesting that mutation-specific therapies could be beneficial in treating MTC 
and PTC. Thus, future treatment strategies should take into consideration patients' 
genetic make-up along with any functional data available for the different TK­
inhibitors, in order to provide patients with the most efficient treatment available. 
Furthermore, our data suggest that re-analysing earlier trials based on their mutation 
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Hirschsprung disease (HSCR) and Multiple Endocrine Neoplasia type 2 (MEN2) are two 
seemingly unrelated neural crest-associated disorders that can be caused by germ line 
mutations in RET. HSCR and MEN2 have distinct characteristics and different tissues 
are affected in each disease. However, in both diseases the basic problem is the 
disruption of signal transduction pathways required for normal physiological 
functions. This thesis presents a functional and genetic study on HSCR and MEN2, and 
aimed at unravelling the protein networks involved in the development of these 
disorders. 
Part I of this thesis focuses on HSCR, which is an inherited disorder 
characterized by the absence of enteric neurons in the distal part of the colon. It can 
occur as an isolated trait, but is frequently associated with other congenital 
malformations present in rare, recessive syndromes. The study of the genes involved 
in these syndromes can yield new insights into the HSCR-related protein network and 
may help identify new HSCR candidate genes. One of these rare, recessive syndromes 
is called Goldberg-Shprintzen syndrome, for which mutations in KBP/KIAA1279 were 
found to be the causal entity. In Chapter 2 the function of the protein encoded by 
KBP/KIAA1279, the Kinesin-Binding Protein (KBP) was studied. Since the KBP function 
was largely unclear, we performed expression studies in zebrafish and found that KBP 
is expressed in the central and enteric nervous system. In addition, we showed that 
KBP is involved in neuronal differentiation and neurite outgrowth. In order to 
determine the KBP protein network, a yeast two-hybrid screen was performed. 
Several kinesin-like proteins were found to interact with KBP, as expected. KBP was 
also found to interact with SCGlO, a microtubule-destabilizing protein. This 
interaction was further confirmed by co-immunoprecipitation, co-localization and by 
epistasis experiments in zebrafih, thus linking KBP to microtubule dynamics. Since a 
direct interaction between KBP and microtubules could not be found, it is likely that 
KBP exerts its effect via SCG10 interaction. 
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In Chapter 3 we evaluated the involvement of SCGlO in HSCR development. 
Since SCGlO was reported to be a down-regulated gene in a mouse model for HSCR, 
and we found a direct interaction between SCGlO and KBP in vitro and in vivo, we 
considered SCGlO to be a good candidate gene for HSCR. To determine if SCGlO is 
involved in the aethiology of HSCR, we performed expression studies in mouse enteric 
neural crest stem cells. In addition, 85 patients diagnosed with isolated, non­
syndromic HSCR were screened for the presence of SCGlO mutations. We found that 
SCGO expression can be detected from the early stages of gut colonization, but there 
were no germline mutations found in the patients analysed. These results suggest 
that SCGlO is not directly implicated in HSCR development. However, an indirect 
involvement of SCGlO in HSCR cannot be ruled out as this could be due to a secondary 
effect in SCGlO regulation. 
In chapter 4 we focus on HSCR as a complex disorder. Using HSCR as an 
example, we reviewed what is known about this disorder, what we learned from the 
genome-wide association studies, and discussed how next-generation sequencing in 
combination with a systems biology approach can help in unravelling the complex 
inheritance of HSCR. 
Part II of this thesis focused on MEN2, which is a dominantly inherited cancer 
syndrome that can be divided into three subtypes: MEN2A, MEN2B and Familial 
Medullary Thyroid Carcinoma ( FMTC), based on the clinical description and tissues 
affected. As different RET mutations result in different disease phenotypes, it is logical 
to assume that different mutations have different effects on downstream signalling 
pathways. 
In chapter 5, the kinome profile of MEN2 mutants was determined. For this, 
protein phosphorylation profiles specific for the most common mutations found in 
MEN2A (RET609, RET620, RET634), MEN2B (RET918), and FMTC (RET791, RET891) 
were determined using a peptide array consisting of 1024 different kinase substrates. 
All the mutants showed activation of the canonical RET signalling pathways via MAP 
kinase, Pl3 Kinase/ Akt and Rae pathways. Specific alterations were also identified for 
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some of these mutants. For the RET918 mutant, an increase in FAK phosphorylation 
levels was seen, and for RET891, a decrease in receptor internalization was detected. 
We also observed that mutations associated to the same phenotype do not always 
behave in the same way, as small differences in activation levels of the shared 
pathways were detected. We concluded that there are indeed differences in the 
signalling pathways between RET wild-type and different types of MEN2, confirming 
the hypothesis that different RET mutations have specific effects on downstream 
signalling pathways. Furthermore, different mutations associated to the same 
phenotype do not necessarily share the same signalling pathways, which supports the 
idea that different mutations act through their own specific signalling pathways. 
In chapter 6, four tyrosine kinase inhibitors were analysed for the treatment 
of MEN2 and papillary thyroid carcinoma (PTC). For this, the effects of XL184, 
vandetanib, sorafenib and axitinib on cell proliferation, RET expression and 
autophosphorylation, and activation of the MAP kinase pathway, namely ERK, were 
compared in cell lines expressing a MEN2A (MTC-TT) mutation, a MEN2B (MZ-CRC-1) 
mutation, and a RET/PTC (TPC-1) rearrangement. Our results showed that the most 
effective inhibitors in vitro are XL184 and vandetanib, in reducing cell proliferation, 
RET autophosphorylation in combination with a reduction of RET expression, and ERK 
phosphorylation, in MEN2A and MEN2B, respectively. For PTC, XL184 was the most 
efficient inhibitor in reducing cell proliferation and RET autophosphorylation. 
However, no effect on RET expression and ERK activation was observed for PTC after 
exposure to XL184. To conclude, there is TK-inh ibitor specificity for the different RET 
mutants and, mutation-specific therapies could therefore be beneficial in treating 
MEN2 and PTC. 
Together, our results yielded new insights into HSCR and MEN2 as we 




De ziekte van Hirschsprung (afgekort als HSCR) en Multipele Endocriene Neoplasieen 
type 2 (afgekort als MEN2) zijn twee schijnbaar ongerelateerde aandoeningen. Ze 
kunnen echter warden veroorzaakt door mutaties in een en hetzelfde gen, het RET 
gen. In beide gevallen gaat het om mutaties die leiden tot een verstoring van de 
signaaltransductie routes die door RET warden geactiveerd, routes die nodig zijn voor 
de normale fysiologische functies van de aangedane weefsels. In dit proefschrift 
beschrijven we functionele en genetische studies over zowel HSCR als MEN2. De 
meeste studies hebben als doel het ontrafelen van de eiwitnetwerken die betrokken 
zijn bij de ontwikkeling van deze aandoeningen. 
Deel I van dit proefschrift richt zich op HSCR. HSCR is een erfelijke aandoening 
die wordt gekenmerkt door de afwezigheid van neuronen in het laatste deel van de 
dikke darm. De ziekte kan voorkomen als een geTsoleerde eigenschap (een patient 
heeft alleen HSCR), maar in ongeveer 20% van de patienten komt de ziekte voor in 
combinatie met andere aangeboren afwijkingen of is het een onderdeel van een 
syndroom. In deel 1 richten we ans op een dergelijk zeldzaam syndroom, genaamd 
Goldberg-Shprintzen. Dit syndroom wordt veroorzaakt door mutaties in KBP. In 
hoofdstuk 2 wordt de functie van het eiwit waar het gen voor codeert beschreven. Dit 
omdat de functie grotendeels onbekend is. Wat we wel weten is dat het een 
interactie kan aangaan met een eiwit uit de kinesine eiwit familie. We hebben 
gekeken naar expressie van KBP in zebravis embryo's en vonden dat KBP wordt 
aangemaakt in zowel het centrale als het perifere (enteric) zenuwstelsel. Bovendien 
konden we laten zien dat KBP betrokken is bij de neuronale differentiatie en neuriet 
uitgroei. Met het oog op het KBP-eiwit netwerk, hebben we naar eiwit-eiwit 
interacties gezocht door middel van een 'yeast two-hybride screen'. Verschillende 
kinesines werden gevonden, zeals verwacht. Daarnaast werd echter oak een 
interactie van KBP met SCGlO gevonden. SCGl0 is een microtubuli destabiliserend 
eiwit. Deze interactie werd bevestigd door middel van co-immunoprecipitatie. Oak 
werden co-localisatie studies en een epistase experiment in zebravissen uitgevoerd. 
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Alie data koppelen KBP aan microtubuli. Een directe interactie tussen KBP en 
microtubuli werd niet gevonden. 
In hoofdstuk 3 evalueerden we de mogelijke betrokkenheid van SCGlO in 
HSCR. Dit omdat we een eiwit-eiwit interactie vonden tussen SCGl0 en KBP, maar ook 
omdat SCGlO al eerder aangemerkt was als goede kandidaat voor de ziekte door 
anderen. Om te bepalen of SCGl0 betrokken is bij het ontstaan van HSCR, werd 
gekeken of het gen tot expressie komt in de voorloper cellen van het zenuwstelsel in 
de darm. Deze studie werd gedaan op cellen ge'isoleerd uit muizenembryo darmen. 
Bovendien werden 85 patienten met ge'isoleerde HSCR gescreend op de aanwezigheid 
van SCGlO mutaties. We vonden dat SCGl0 inderdaad tot expressie komt in deze 
voorloper cellen, maar we konden geen (kiembaan)mutatie vinden bij de patienten. 
Deze resultaten suggereren dat SCGlO niet rechtstreeks betrokken is bij de 
ontwikkeling van de ziekte. Een indirecte betrokkenheid van SCGlO in HSCR kan 
echter niet warden uitgesloten. 
Hoofdstuk 4 is een review waarin wordt beschreven hoe complexe 
aandoeningen, genetisch gezien, wordt aangepakt. We gebruiken HSCR als voorbeeld. 
In dit hoofdstuk geven we een overzicht van wat er bekend is over deze aandoening, 
wat we hebben geleerd uit het verleden en vooral uit de genoom wijde associatie 
studies, en we bespreken wat een vervolgstrategie zou kunnen zijn voor het verder 
ontrafelen van deze en andere genetisch complexe aandoeningen. 
Deel II van dit proefschrift richt zich op MEN2. MEN2 is een dominant 
erfelijke kanker syndroom. Op basis van de klinische beschrijving (en de weefsels die 
zijn aangedaan) kan MEN2 in drie subtypen warden ingedeeld: MEN2A, MEN2B en 
familiale medullaire schildkliercarcinoom (afgekort als FMTC). Omdat verschillende 
RET mutaties resulteren in verschillende subtypen, is het logisch om te 
veronderstellen dat verschillende mutaties verschillende effecten op downstream­
signaalroutes hebben. 
In hoofdstuk 5 beschrijven we de 'kinome' profielen die gevonden zijn voor 
de verschillende MEN2 mutaties. Een kinome profiel is in feite een verzameling van 
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eiwitten die door RET kunnen warden geactiveerd. Deze bepaling doen we door 
actieve RET moleculen te hybridiseren met peptides (stukjes eiwitten) die mogelijk 
door RET (een tyrosine kinase) kunnen warden geactiveerd. Deze eiwitten zijn 
zogeheten tyrosine kinase substraten. Dit werd gedaan voor de meest voorkomende 
mutaties die gevonden zijn in MEN2A (RET609, RET620, RET634), MEN2B (RET918) en 
FMTC (RET791, RET891). We hebben gekeken naar 1024 verschillende kinase 
substraten. Alie mutanten vertoonden activering van bekende RET signaalroutes zoals 
de MAP-kinase, Pl3 kinase/Akt en Rae signaalroutes. Daarnaast werd voor een aantal 
mutaties specifieke veranderingen gevonden. Zo werd voor de RET918 mutant een 
toename van FAK phosphorylatie gezien, terwijl voor de RET891 mutant een daling 
van de receptor internalisatie werd gedetecteerd. We vonden ook dat mutaties die 
geassocieerd zijn met hetzelfde fenotype niet altijd hetzelfde resultaat gaven. Tot slot, 
bespreken we de gevonden verschillen in de signaalroutes tussen de RET wild-type en 
de verschillende soorten MEN2 mutaties. Dit alles bevestigt onze hypothese dat 
verschillende RET mutaties specifieke effecten hebben op de downstream 
signaleringsroutes. 
Hoofdstuk 6 laat de analyse zien van vier tyrosine kinase remmers die 
mogelijk bruikbaar zijn voor de behandeling van MEN2 en papillair 
schildkliercarcinoom (PTC). Gekeken is naar de effecten van XL184, vandetanib, 
sorafenib en axitinib op eel proliferatie, RET expressie, RET autophophorylatie, en 
activering van de MAP-kinase route. Dit werd gedaan in eel lijnen waarin een MEN2A 
(MTC-TT), een MEN2B (MZ-CRC-1) mutatie, en een RET/PTC (TPC-1) rearrangement 
aanwezig zijn. Onze resultaten toonden aan dat de meest effectieve inhibitoren XL184 
en vandetanib zijn voor respectievelijk MEN2A en MEN2B. Voor PTC bleek XL184 de 
meest efficiente remmer. Er werd echter geen effect op de RET expressie en op 
activering van de MAP-kinase route waargenomen voor PTC na blootstelling aan 
XL184. Ons onderzoek laat zien dat de TK remmers mutatie specifiek lijken te zijn en 
dus zouden mutatie-specifieke therapieen gunstig kunnen zijn voor de behandeling 
van MEN2 en PTC. 
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Onze resultaten hebben geleid tot nieuwe inzichten in de ontwikkeling van 




A doenc;a de Hirschsprung (HSCR) e a Neoplasia End6crina Multipla tipo 2 (NEM2) sao 
duas doenc;as aparentemente diferentes que podem ser causadas par mutac;oes no 
proto-oncogene RET. A HSCR e a NEM2 tern caracterfsticas distintas e em cada uma 
destas doenc;as sao afectados 6rgaos diferentes. No entanto, em ambos os casos a 
disrupc;ao das vias de sinalizac;ao necessarias para o normal funcionamento fisiol6gico 
constitui o maior problema. Nesta tese, sao apresentados estudos funcionais e 
geneticos sabre HSCR e NEM2 desenvolvidos com o objectivo de decifrar a rede 
proteica, "the protein network", envolvida no aparecimento destas duas doenc;as. 
A primeira parte desta tese focaliza-se na HSCR. A HSCR e uma doenc;a 
genetica caracterizada pela ausencia de nervos entericos na parte distal do colon. A 
HSCR pode ocorrer de forma isolada, mas esta frequentemente associada a outras 
malformac;oes congenitas presentes em sfndromes recessives raros. 0 estudo dos 
genes envolvidos nestes sfndromes pode trazer novas pistas sabre a rede proteica 
envolvida no desenvolvimento da HSCR, e pode ajudar a identificar novas genes 
candidates. Um exemplo destes sfndromes recessives e o sf ndrome de Goldberg­
Shprintzen (GOSHS), em que se descobriu que a principal causa desta patologia sao 
mutac;oes no gene KIAA12 79/KBP. 
No capftulo 2 e estudada a func;ao da protef na envolvida em GOSHS, a Kinesin 
Binding Protein (KBP). Tenda em conta que a func;ao da KBP e praticamente 
desconhecida, a expressao desta proteina foi determinada em zebrafish e descobriu­
se que a KBP e expressa no sistema nervoso central e no sistema nervoso enterico. 
Adicionalmente, mostrou-se que a KBP esta envolvida na diferenciac;ao neuronal e no 
crescimento de neurites. Com o objective de determinar a rede proteica da KBP, 
realizou-se um "yeast two-hybrid screen". Foram identificadas varias cinesinas que 
interactuam com KBP. Paralelamente, identificou-se que a KBP interactua com a 
SCGl0, uma protefna envolvida no processo de destabilizac;ao dos microtubulos. Esta 
interacc;ao foi confirmada par co-imunoprecipitac;ao, co-localizac;ao e determinac;ao 
de epistase em zebrafish entre KBP e SCGlO. Desta forma, a KBP foi implicada no 
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processo de estabilizac;ao/destabilizac;ao (dinamica) dos microtubulos. No entanto, 
nao foi possfvel detectar uma interacc;ao directa da KBP com os microtubulos, o que 
sugere um envolvimento indirecto da KBP na dinamica dos microtubulos, 
possivelmente exercido via SCGlO. 
No capftulo 3, foi determinado o envolvimento de SCGl0 na HSCR. Tenda em 
conta que a reduc;ao de expressao de SCGl0 foi previamente detectada num modelo 
animal para HSCR, e que n6s descobrimos que a KBP interactua com a SCGl0 in vitro e 
in vivo, o SCG10 foi considerado um 6ptimo gene candidate para a HSCR. Com o 
objective de determinar o envolvimento de SCGl0 na HSCR, a expressao deste gene 
foi determinada em celulas da crista neural derivadas de rato. Adicionalmente, 85 
pacientes diagnosticados com HSCR, foram testados para a presenc;a de mutac;oes no 
SCG10. Os nossos resultados mostraram que o SCG10 e expresso desde o perfodo 
inicial de colonizac;ao do intestine, mas nao foi detectada nenhuma mutac;ao neste 
gene nos pacientes analisados. Estes resultados sugerem que SCGlO nao estara 
directamente envolvido no desenvolvimento da HSCR. No entanto, o envolvimento 
indirecto deste gene na HSCR nao pode ser exclufdo, ja que pode ocorrer devido a um 
efeito secundario desencadeado na regulac;ao da actividade de SCGl0. 
No capftulo 4, sao analisados os problemas associados ao estudo de doenc;as 
complexas. Usando a HSCR coma exemplo, realizamos uma revisao da literatura, na 
qual descrevemos a etiologia desta doeni;:a, o que aprendemos dos estudos de 
associac;ao gen6mica, e discutimos de que forma a sequenciac;ao de pr6xima gerac;ao 
em combinac;ao com a biologia de sistemas nos pode ajudar a desvendar a complexa 
rede genetica envolvida no desenvolvimento da HSCR. 
A segunda pa rte desta tese incide na NEM2. A NEM2 e uma forma sindr6mica 
de cancro da tir6ide que pode ser dividida em 3 subtipos: NEM2A, NEM2B e 
Carcinoma Medular da Tir6ide Familiar (CMTF), dependendo das caracterfsticas 
clfnicas e dos tecidos afectados. Como diferentes mutac;oes no proto-oncogene RET 
resultam em diferentes tipos de NEM2, e 16gico prever-se que diferentes mutac;oes 
desencadeiam diferentes vias de sinalizac;ao. 
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No capftulo 5 foi determinado o "kinome profile" das diferentes mutac;oes 
associadas a NEM2. Para isso, foram determinados os padroes de fosforilac;ao 
especfficos para as mutac;oes mais comuns encontradas em NEM2A (RET609, RET620, 
RET634), NEM2B (RET918) e CMTF (RET791, RET891), recorrendo a um "array" 
contendo 1024 substratos diferentes para cinases. Em todas as mutac;oes analisadas 
foi detectada uma activac;ao das vias can6nicas de sinalizac;ao associadas a RET: MAP 
cinase, Pl3 cinase/ Akt e Rae. 
Adicionalmente, foram identificadas alterac;oes especfficas associadas a 
algumas mutac;oes. Para o RET918 foi identificado um aumento de fosforilac;ao da 
cinase FAK, e para o RET891 foi detectada uma diminuic;ao de internalizac;ao do 
receptor. Pode-se tambem observar que as mutac;oes associadas ao mesmo tipo de 
NEM2 nem sempre se comportam da mesma forma, ja que foram detectados nfveis 
diferentes de activac;ao das vias de sinalizac;ao comuns. Em conclusao, as vias de 
sinalizac;ao associadas ao RET "wild-type" e as diferentes mutac;oes sao distintas, o 
que esta de acordo com a hip6tese inicialmente proposta: diferentes mutac;oes em 
RET tern diferentes efeitos na activac;ao das vias de sinalizac;ao. Para alem disso, 
mutac;oes associadas ao mesmo tipo de NEM2 nem sempre se apresentam da mesma 
forma, o que reforc;a a ideia de que mutac;oes diferentes activam vias de sinalizac;ao 
especfficas. 
0 capftulo 6 descreve a analise de quatro inibidores de tirosina-cinases 
(XL184, vandetanib, sunitinib e axitinb) para o tratamento da NEM2 e do Carcinoma 
Papilar da Tiroide (CPT). Para isso, os efeitos de XL184, vandetanib, sunitinib e axitinb 
foram avaliados em termos de proliferac;ao celular, expressao e fosforizac;ao do RET, e 
activac;ao da via de sinalizac;ao da MAP cinase, nomeadamente da ERK, entre as 
diferentes linhas celulares expressando mutac;oes caracteristicas de NEM2A (MTC-TT), 
NEM2B (MZ-CRC) e de um rearranjo do RET, RET/PTCl (TPC-1). Os nossos resultados 
mostraram que os inibidores mais eficazes in vitro foram o XL184 e o vandetanib, uma 
vez que promoveram a reduc;ao da proliferac;ao celular, dos nfveis de fosforizac;ao do 
RET em combinac;ao com uma diminuic;ao da expressao deste receptor, e a activac;ao 
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da ERK, em NEM2A e NEM2B respectivamente. Para o CPT, o inibidor mais eficaz foi o 
XL184 que provocou uma diminui�ao da prolifera�ao celular e dos nfveis de 
fosforila�ao do RET. No entanto, nenhum efeito foi detectado nos nfveis de expressao 
do RET e na activa�ao da ERK no CPT ap6s exposi�ao a XL184. Deste estudo pode-se 
concluir que os inibidores de tirosina cinase apresentam especificidade para as 
diferentes muta�oes em RET, e par isso, uma interven�ao terapeutica espedfica para 
as diferentes muta�oes podera ser benefica no tratamento da NEM2 e do CPT. 
Em conclusao, os resultados apresentados nesta tese trazem novas 
perspectivas para o estudo da HSCR e da NEM2, uma vez que contribuem para a 




To accomplish great things, we must not only act, but also dream; not only plan, but 
also believe." 
William Bragg 
With this sentence I reach the last section of my thesis ! When I look back to where 
everything started, it is hard to believe it was such a long time ago ... Everyone tells 
you that it goes very fast. But I guess you have to experience it to understand what 
that means ... During this time, so many things have happened and so many other 
things have changed ... But as I look back and remember everything I've learned, all 
the people I've met, and all the places I've seen, it is hard not to smile ! So now it is 
time acknowledge everyone who was part of my journey and express my deep 
gratitude. 
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thank you all for making up the reading committee for my thesis. I am very grateful 
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always being so nice to me. You were my first roommate and I enjoyed your company 
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taking care of my cells and for doing all my sequences. Thank you also for being my 
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it was great to meet you and to work with you! Thank you for all your help, your 
optimism and supporting words whenever I needed it. I wish you all the best for your 
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possible, but in the end I think we did a very good job ! Thank you for dropping by in 
the lab, even after your clinical work, to help me every time you could, and for being 
such a nice guy. It was really great to meet you and I wish you all the best for your 
internship and for your PhD. 
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